

## PRESIDENT'S COLUMN

### ***ACCP's PRNs: A Culture Where Everyone Can Thrive***



**Jimmi Hatton Kolpek, Pharm.D.,  
FCCP, FCCM, FNAP**

The Practice and Research Networks (PRNs) are a unique structure within ACCP that allow committed professionals to share interests, build alliances, and exchange ideas about practice, research, and education. The camaraderie exhibited during the live PRN meetings creates opportunities for new collaborations, mentoring activities, and lasting friendships. The significance of these interactions became even more evident when, in 2020, PRN members were required to connect remotely. Much of the content of the 2020 PRN meetings was unaffected by the new format. However, the vitality, encouragement, and support typically enjoyed during these informal, face-to-face interactions were affected. This experience is another “lesson learned” from the collective pandemic transitions – power is derived from a PRN culture in which each person feels understood and accepted.

Long before the term *inclusive leadership* was introduced, the College's founding members recognized the value of individuals with common interests and goals sharing time in a more casual setting, an important driving factor behind the creation of ACCP's PRNs. Today, the PRNs provide a safe platform where member voices can be heard and shared with ACCP leadership. This input is essential to maintaining a member-driven organization. PRN members' leadership, interests, and concerns are priorities for ACCP's officers, regents, trustees, and staff.

Moving forward post-pandemic, there will be opportunities to expand each PRN's reach as inclusive leaders. The PRN “culture of belonging” is critical to the successful expansion of equity across practice, within research, and throughout education/training. Inviting those with different life experiences to participate in

leadership, committee activities, and programming will help demonstrate the College's determination to embrace organizational diversity.

As leaders, we are committed to supporting less experienced members and encouraging them to pursue meaningful career opportunities. This approach can enhance the visibility of talented, underrepresented professionals within the profession. Our students, residents, fellows, and colleagues will be able to pursue opportunities within ACCP, independent of their color, creed, gender identity, age, or disability. The PRNs serve as a launch pad for career advancement – let's commit to building examples of visible transformation into this legacy.

The 2020–2021 presidential theme introduced the prospect of “developing inclusive leadership skills, embracing diversity, and building health equity.” The Board of Regents is leading this journey. Through our board development activities, we are reading and discussing *How to Be an Inclusive Leader: Your Role in Creating Cultures of Belonging Where Everyone Can Thrive*.<sup>1</sup> In February, we examined the Inclusive Leader Continuum, a multi-stage model allowing us to identify our individual progress in this continuum (see [https://jenniferbrownspeaks.com/inclusive-leader-book/assessment/#jump\\_trgt](https://jenniferbrownspeaks.com/inclusive-leader-book/assessment/#jump_trgt)).

Understanding the impact of inclusive leadership and the necessary individual journey each of us must undertake is crucial to creating meaningful change. This is a very personal experience. I encourage you to visit the link above to gain insight into the incremental steps necessary to strengthen our presence as leaders. A culture of authentic, respectful exchange of ideas permits us to learn from voices, life experiences, and perspectives that differ from our own. The cooperative spirit within our PRNs provides a fertile environment for expanding the conversation of belonging, inclusion, diversity, and equity. Our PRNs can transform the fabric of our organization by integrating inclusion and diversity into programs, publications, presentations, membership activities, leadership, and policy positions.

Let's decide today that our PRNs will provide a safe space for critical conversations, actions that build equity, and expanded representation for all clinical pharmacy

professionals. When planning for the 2021 ACCP Annual Meeting, consider how your PRN will reflect inclusive leadership principles. Will fresh paradigms be needed? Will your business meeting items consider how inclusivity, diversity, and equity are visible in your ACCP activities? How will your PRN be different because of your decision to courageously engage in critical conversations probing the gaps and needed changes to build a culture of belonging for all clinical pharmacists?

PRN input and participation will allow ACCP to build health equity in an authentic and sustainable manner for tomorrow's clinical pharmacists. Hopefully, ACCP's PRNs will participate in inclusive leadership assessment and determine where they will be a year from now.

On behalf of the Board of Regents, thank you for your important voice in shaping our future.

1. Brown J. How to Be an Inclusive Leader: Your Role in Creating Cultures of Belonging Where Everyone Can Thrive. Oakland, CA: Berrett-Koehler, 2019.

## PRNs Prepare for Elections

This spring, the PRNs begin the election process to determine who will serve as officers in the coming year. If you are interested in running for office in your PRN or in nominating a PRN member colleague for office, please contact your PRN's chair.

2021 PRN Election Timetable	
PRNs issue call for nominations	Spring
PRNs submit slate of candidates to ACCP	June 4, 2021
Electronic balloting opens; PRN members notified by e-mail	July 12, 2021
Electronic balloting closes	August 9, 2021
ACCP notifies PRNs of election results	August 13, 2021
PRNs notify candidates within 10 days after balloting closes	August 19, 2021

## Voting

As in previous years, PRN elections will be held online. PRN members will receive an e-mail announcing the opening of balloting. Members will use their log-in and password to access the ACCP website. Each member will then be able to access and cast a ballot for each PRN of which he or she is a current member.

As the election nears, members should review their e-mail and the ACCP website for further news about online voting.

## ACCP Career Center

The College is excited to announce the launch of the new [ACCP Career Center](#)!

ACCP has been committed to excellence in clinical pharmacy practice, research, and education for more than 40 years and continues to extend the frontiers of clinical pharmacy. The College has an outstanding reputation for providing premier resources to advance clinical pharmacists. Now, ACCP is providing access to all of its career advancement resources in one place: the ACCP Career Center is **the place** for clinical pharmacy career advancement. Whether you're thinking about taking the next step in your career or recruiting for your own clinical pharmacy team, the ACCP Career Center is ready to meet your needs.

The ACCP Career Center, powered by Madgex Job Board Technology, provides an intuitive searching experience on desktop and mobile devices. The center hosts searchable employer profiles and offers candidates relevant job search results and customizable job alerts.

Employers will find [diverse recruitment packages](#) to choose from that include publicizing their open positions on the ACCP webpage and within the *ACCP Report* and ACCP journal space. Position listings can also be advertised to specific Practice and Research Networks (PRNs) and on ACCP's social media platforms. ACCP members will receive a 50% discount on all position listing packages and upgrades. Moreover, employers will want to create an employer profile to attract potential candidates.

Job seekers will find an [easily searchable list of open positions](#) and can sign up for job alerts that meet their specifications. They can also create a profile and upload a curriculum vitae, allowing them to apply to open positions directly within the ACCP Career Center platform.

[The ACCP Career Center](#) also hosts a variety of career development resources: news, meetings, articles, and study materials. The ACCP Career Center is **the place** for clinical pharmacy career advancement.

## Clinical Practice Forum to Feature CMM and Preceptor Development Programming

The 2021 Clinical Practice Forum will be held virtually April 28–30 in conjunction with the ACCP Spring Forum. This year's program, designed to enhance your expertise in implementing or expanding comprehensive medication management (CMM) services and add to your skills as a preceptor, will offer 14.0 hours of continuing pharmacy education credit.

In the opening session, participants will get a first look at the updated CMM implementation platform. Mary Roth McClurg, Pharm.D., MHS, FCCP, and Lori Armistead, Pharm.D., part of the CMM in Primary Care study team, will demonstrate the open-access web-based platform, which will provide users with a wide range of CMM resources, including tools developed as part of the Primary Care study. Jon Easter, BSPHarm, RPh, will address the key elements needed to develop a metric-based business case for CMM implementation, and Amanda Brummel, Pharm.D., BCACP, and Todd Sorenson, Pharm.D., FCCP, FAPhA, will guide participants through the process of creating a business plan for implementing or scaling CMM services. Shawn McFarland, Pharm.D., FCCP, BCACP, will share work currently being done by the Veterans Health Administration in establishing CMM metrics and developing assessment tools. This work has the potential to significantly affect our ability to assess the value of CMM in improving all aspects of the Quadruple Aim of health care.

The CMM implementation consultancy – the first of three workshops during the Clinical Practice Forum – will build on the previous presentations and assist participants in inventorying their current practices to prioritize implementation needs and apply these results to develop customized action plans. The workshop will also allow time for networking and sharing examples with program faculty and other participants. After the workshop, Randy McDonough, Pharm.D., BCPS; Ryan Jacobsen, Pharm.D., BCPS; and Jamie Benken, Pharm.D., BCPS, will discuss their experiences in developing successful collaborations between clinical pharmacists in clinic-based, community

pharmacy-based, and hospital-based or specialty care practice settings. Christine Schumacher, Pharm.D., FCCP, BCPS, BCACP, will speak about her transition from a disease-focused practice to providing CMM services and will lead a workshop to help participants make or consider a similar transition. In addition, Kylee Funk, Pharm.D., BCPS, will share her research into the impact of CMM on provider well-being.

The 2021 Clinical Practice Forum will also introduce a new series focused on preceptor development. Jean Moon, Pharm.D., BCACP, will share her experiences in incorporating students and residents into her CMM practice. She will follow her presentation with a workshop to help participants identify the steps to introduce learners to a CMM practice and select methods to enhance each learner's CMM skills. Participants will have the opportunity to take their skills in writing recommendation letters to a new level with David Dixon, Pharm.D., FCCP, FACC, FNLA, BCPS, BCACP, CDCES, CLS – whether the letter is for a resident applying for a first clinical or faculty position or for a colleague applying for promotion or being considered for an award.

Rounding out the program, Alicia Forinash, Pharm.D., FCCP, BCPS, BCACP, will provide guidance for one of the most challenging aspects of precepting: helping learners to accurately self-assess.

Registration for the 2021 ACCP Spring Forum is now open at [www.accp.com/meetings/sf](http://www.accp.com/meetings/sf). Take a break from your routine and join your ACCP colleagues virtually at the Clinical Practice Forum to be introduced to new ideas, learn new techniques, and create new strategies for expanding your practice and precepting expertise.



The banner features the ACCP logo in the top left corner. The main text is centered and reads: "2021 ACCP SPRING FORUM" in large, bold, yellow and white letters. Below this, it says "REGISTER NOW" in large, bold, blue letters, followed by "April 26–30, 2021" in large, bold, black letters, and "Virtual Event" in large, bold, blue letters. The background is dark blue with abstract light blue and yellow geometric shapes and lines.

Preparatory Review and Recertification Course	Availability for Preparatory Review (2021)	Available for BPS Recertification Credit (2021)	Anticipated Credit (hours)
Pharmacotherapy	May 17	May 17	25.25
Ambulatory Care Pharmacy*	April 14	June 16	25.0
Cardiology Pharmacy*	June 23	June 23	24.0
Critical Care Pharmacy	May 17	May 17	21.0
Geriatric Pharmacy*	March 17	April 28	23.0
Infectious Diseases Pharmacy*	June 23	June 23	25.0
Oncology Pharmacy	March 17	April 28	25.75
Pediatric Pharmacy	July 15	July 15	21.0
Solid Organ Transplantation Pharmacy*	July 14	N/A	25.0

For more information, visit <https://www.accp.com/store/index.aspx>.

\*ACCP collaborates with ASHP on ambulatory care pharmacy, cardiology pharmacy, geriatric pharmacy, infectious diseases pharmacy, oncology pharmacy, and solid organ transplantation pharmacy activities.

## 2021 Board Preparatory and Recertification Products for Home Study

ACCP will offer home study review and recertification courses in the following nine specialties in 2021:

- Pharmacotherapy
- Ambulatory Care Pharmacy\*
- Cardiology Pharmacy\*
- Critical Care Pharmacy
- Geriatric Pharmacy\*
- Infectious Diseases Pharmacy\*
- Oncology Pharmacy\*
- Pediatric Pharmacy
- Solid Organ Transplantation Pharmacy\*  
(not available for recertification credit)

Developed by leading board-certified pharmacists and therapeutic specialists, each course delivers a comprehensive review of the domains outlined in the relevant specialty certification examination content outline developed by BPS. All courses use a case-based approach, covering all key content areas, with strong emphasis on the thought processes needed to solve patient care problems in each therapeutic area. Except for the review course for Solid Organ Transplantation Pharmacy (which was only recently approved as a new specialty), each course is BPS approved as one component in a professional development program that can be used as an

alternative to the written recertification examination. Board Certified Oncology Pharmacists are required to complete the review course for recertification at least once but no more than three times, in nonconsecutive years, during a 7-year recertification cycle. For all other specialties listed above, the respective course can only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

The 2021 home study review and recertification courses will be released according to the schedule above.

## PRN NEWS BRIEFS

### Adult Medicine PRN

#### Promotions

- **Alexandra Whiddon Tartara:** Advanced Clinical Pharmacist at Massachusetts General Hospital.

#### Awards

- **Sarah L. Anderson:** ACCP AMED PRN Mentoring Award.
- **Paul P. Dobesh:** Distinguished Teaching Award – University of Nebraska College of Pharmacy. South Dakota State University College of Pharmacy and Allied Health Professions Distinguished Alumnus Award.

- **Donald Moore:** 40 Under 40 in Cancer 2020 National Community Oncology Dispensing Association.
- **Mate Soric:** Editor's Choice Award, *Journal of the American College of Clinical Pharmacy*.
- **Asha Tata:** Society of Hospital Medicine Maryland Chapter, Non-Physician Clinician of the Year Award 2020.

#### Grants

- **Metzger NL,** Tilton CS, King H, Nave J: Adult Medicine PRN Seed Grant from ACCP for: Impact of Inpatient Pharmacy-Driven Transitions of Care Services on Clinical Outcomes. Amount: \$5000.

#### Publications

- **Anderson SL,** Bassetti M, Mangoni AA. Drugs in context editorial: review of 2020 and what lies ahead in therapeutic interventions. *Drugs Context* 2021;10:2020-12-10.
- **Anderson SL,** Bianco J, DeRemer CE. Adapting ambulatory care learning environments in response to the COVID-19 pandemic. *Am J Health Syst Pharm* 2021;78:467-71.
- White BM, **Anderson SL,** **Marrs JC.** Antihypertensive prescribing patterns and hypertension control in females of childbearing age. *Am J Health System Pharm* 2021. [In press]
- **Clements JN,** Emmons RP, **Anderson SL,** et al. Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. *J Am Coll Clin Pharm* 2021 Feb 1.
- **Dobesh PP.** Anticoagulation. In: 2020 Cardiology Pharmacy Preparatory Review and Recertification Course. Lenexa, KS: American College of Clinical Pharmacy, 2020.
- **Dobesh PP.** Anticoagulation. In: 2020 Updates in Therapeutics®: Pharmacotherapy Preparatory Review and Recertification Course. Lenexa, KS: American College of Clinical Pharmacy, 2020.
- **Dobesh PP,** DiDomenico RJ, Rogers KC. Chapter 32: Stable ischemic heart disease. In: DiPiro JT, Yee GC, Posey LM, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. New York: McGraw-Hill, 2020.
- **Dobesh PP,** Finks SW, Trujillo TC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. *Clin Ther* 2020;42:2084-97.
- **Dobesh PP,** Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. *Pharmacotherapy* 2020;40:1130-51.

- Cochran GL, Foster JA, Klepser DG, **Dobesh PP,** et al. The impact of eliminating backward navigation on computerized exam scores and completion time. *Am J Pharm Educ* 2020;84:1620-6 (Article 8034).
- Coleman CI, **Dobesh PP,** Danese S, et al. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. *Future Cardiol* 2021;17:127-35.
- DiDomenico RJ, **Dobesh PP,** Finks SW. Chapter 33: Acute coronary syndrome. In: DiPiro JT, Yee GC, Posey LM, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. New York: McGraw-Hill, 2020.
- Tomaselli GT, Mahaffey KW, Cuker A, **Dobesh PP,** et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2020;76:594-622.
- Belk M, **Epperson T,** **Niemi S.** Overview of 2019 ATS/IDSA CAP guidelines. *ACCP AMED PRN Fall News* 2020;15:12-6.
- **Flurie RW.** Disorders of potassium and magnesium homeostasis. In: DiPiro JT, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. New York: McGraw-Hill, 2020.
- **Flurie RW,** Brophy GM, Kirkwood CK. Active learning strategies. In: Schwinghammer TL, et al., eds. *Pharmacotherapy Casebook: A Patient-Focused Approach*, 11th ed. New York: McGraw-Hill, 2020.
- **Gibson CM.** Updates on the use of direct oral anticoagulants for the management of chronic conditions. *Pharmacy Today* 2020;12:44-58.
- **Gibson CM,** Hall C, Davis S, et al. Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. *J Thromb Thrombolysis* 2021 Jan 5. [Epub ahead of print]
- **Guirguis E,** Grace Y, Bolson A, et al. Emerging therapies for the treatment of non-alcoholic steatohepatitis: a systematic review. *Pharmacotherapy* 2021;41:315-28.
- **Guirguis E,** Strachan D, Danielson J, et al. Clinical subject exams during advanced pharmacy practice experiences. *J Am Coll Clin Pharm* 2021;4:133-6.
- **Ilcewicz HN,** **Martello JL,** Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. *Eur J Gastroenterol Hepatol* 2020 Oct 16. [Epub ahead of print]

- **Marrs JC, Anderson SL.** Bempedoic acid for the treatment of dyslipidemia. *Drugs Context* 2020;9:2020-6-5.
- **Marrs JC, Anderson SL.** Ertugliflozin in the treatment of type 2 diabetes mellitus. *Drugs Context* 2020;9:2020-7-4.
- Cornelison P, **Marrs JC, Anderson SL.** Clinical pharmacist outreach to increase statin use for patients with cardiovascular disease in a safety net healthcare system. *Am Health Drug Benefits* 2020. [In press]
- Tilton CS, Sexton ME, Johnson S, Gu C, Chen Z, Robichaux C, **Metzger NL.** Evaluation of a risk assessment model to predict infection with healthcare facility-onset *Clostridioides difficile*. *Am J Health Syst Pharm* 2021. [In press]
- **Moore DC,** Gebru T, Plesca D. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. *J Oncol Pharm Pract* 2020 Dec 9. [Epub ahead of print]
- **Moore DC,** Nelson V, Muslimani A. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of *IDH2*-positive acute myeloid leukemia and multiple myeloma. *Ann Hematol* 2020 Oct 1. [Epub ahead of print]
- **Moore DC,** Thompson D. A review of the Bruton tyrosine kinase inhibitors in B-cell malignancies. *J Adv Pract Oncol.* [In press]
- Arnall JR, Tran T, Elmes J, Downing L, DiSogra K, **Moore DC.** Comparative utilization and efficacy of thrombopoietin receptor agonists in relapsed/refractory immune thrombocytopenia. *Am J Ther* 2020 Jan 8. [Epub ahead of print]
- DiSogra K, Thuy T, Arnall JR, Janes A, **Moore DC,** et al. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. *J Oncol Pharm Pract* 2020 Oct 27. [Epub ahead of print]
- Lee A, Larck C, **Moore DC.** Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. *J Oncol Pharm Pract* 2020 Dec 26. [Epub ahead of print]
- **Nisly SA,** Nifong E, Coble EB, et al. Longitudinal pharmacy student presentations mentored by pharmacy residents: a pilot study. *Curr Pharm Teach Learn* 2021;13:63-7.
- Skrupky L, Dy-Boarman E, Gurgle H, Isaacs A, McCreary E, **Nisly SA,** et al. Letters of reference for PGY1 pharmacy residency candidates: a survey of residency program directors and opinion statement. *J Am Coll Clin Pharm* 2021;4:379-89.
- Burch A, **Owens R, Nisly SA,** et al. Wellbeing during COVID-19: a social media takeover. *Pharm Educ* 2020;20:272-5.
- Paulsen MR, **Patel NR,** Sulis C, et al. Human papillomavirus, herpes zoster, and hepatitis B vaccinations in immunocompromised patients: an update for pharmacists. *J Pharm Pract* 2020 Sep 17. [Epub ahead of print]
- Ferguson PJ, Lynton J, **Resman-Targoff BH.** Advantages of imbedding a specialty pharmacist in a rheumatology clinic. *Rheumatologist* 2020 Nov 12.
- **Sebaaly J, Nisly SA.** Student perceptions of COVID-19 impact on experiential learning. *Education in the health professions.* *Educ Health Prof* 2020;3:101-4.
- Walkerly A, Neugebauer RE, Misko B, Shively D, Singh S, Chahda B, Dhanireddy S, King K, Lloyd M, Fosnight S, Costello M, Palladino C, **Soric MM.** Prevalence, predictors, and trends of opioid prescribing for lower back pain in United States emergency departments. *J Clin Pharm Ther* 2020 Dec 11. [Epub ahead of print]
- **Steuber TD,** Butler L, Sawyer A, Chappell R, Edwards J. Comparison of blood cultures versus T2Candida panel in management of candidemia at a large community hospital. *Eur J Clin Microbiol Infect Dis* 2021 Jan 2. [Epub ahead of print]
- Muklewicz J, **Steuber TD,** Edwards J. Evaluation of area underneath the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury. *Int J Antimicrob Agents* 2021;57:106234.
- Moore PQ, Cheema N, Celmins LE, Patel A, Follman S, Soni H, **Szwak JA,** et al. Point-of-care naloxone distribution in the emergency department: a pilot study. *Am J Health Syst Pharm* 2021;78:360-6.
- Cheung F, Doherty S, **Tatara A.** Ketamine in refractory cyclic vomiting syndrome: a case report and review of literature. *J Pharm Pract.* [In press]
- **Valanejad SM, Davis KA, Nisly SA.** Outcomes associated with resuming direct oral anticoagulant therapy following admission for a gastrointestinal bleed. *Ann Pharmacother* 2020;54:975-80.
- Falconer EA, Harris DA, **Van Prooyen A,** et al. Pharmacy-led initiative for improving peri-operative medication reconciliation among bariatric surgical patients: what is the role? *Surg Endosc* 2021 Feb 12. [Epub ahead of print]

#### New ACCP Fellows

- Jon P. Wietholter

#### Other Notable Achievements

- **Jennifer Austin Szwak:** Chair of the Vizient Pharmacy Network Research Committee.
- **Ashley Otto:** American Academy of HIV Medicine – HIV Pharmacist (AAHIVP) Certification.

## Ambulatory Care PRN

### Promotions

- **Ashley Meredith:** Master's Degree in Public Health, Purdue University Global.
- **Roda Plakogiannis:** Professor of Pharmacy Practice, LIU Pharmacy, Arnold and Marie Schwartz College of Pharmacy.
- **Anjoli Punjabi:** Director of Diversity, Equity, and Inclusion, MOBE, LLC.
- **Paul Stranges:** Assistant Director, Opioid Stewardship/Drug Diversion at University of Illinois Hospital & Health Sciences System.

### Awards

- **Henry I. Bussey:** 19th recipient of the Paul F. Parker Medal from the American College of Clinical Pharmacy.
- **Gregory Castelli:** 2020 UPMC Pharmacy Residency Programs Preceptor of the Year, University of Pittsburgh Medical Center.
- **Christine Schumacher:** Association of Diabetes Care and Education Specialists (ADCES) Diabetes Education Specialist of the Year from the Illinois Coordinating Body of ADCES.
- **Mate Soric:** Editor's Choice Award, *Journal of the American College of Clinical Pharmacy*.

### Publications

- Ford CR, **Astle KN**, Garza KB, **Kleppinger EK**. Exploring standardized persons' expectations for practice-readiness among student pharmacists. *Curr Pharm Teach Learn* 2021 Jan 25. [Epub ahead of print]
- **Benjamin T, Schumacher C**. Characterization of risk factors for genitourinary infections with sodium glucose cotransporter-2 inhibitors. *Pharmacotherapy* 2020;40:1002-11.
- **Bussey HI**. Ode to Paul Parker, Charlie Walton, Dawn Mitchell, my family and other wonderful people. *J Am Coll Clin Pharm* 2021;4:4-7.
- **Bussey HI**, Beavers CJ. Evaluation of an interactive online information service to improve patient care in the field of anticoagulation and antithrombotic therapy. *J Am Coll Clin Pharm* 2021. [In press]
- **Cardinal RM**, D'Amico F, D'Addezio A, Dakers K, **Castelli G**. Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design. *J Thromb Thrombolysis* 2021 Jan 2. [Epub ahead of print]
- **Castelli G**, Desai KM, Cantone RE. Peripheral neuropathy: evaluation and differential diagnosis. *Am Fam Physician* 2020;102:732-9.

- **Choi D, Martin MT**, Chacra W, et al. Practical considerations when treating chronic hepatitis E in solid organ transplant recipients. *Int J Clin Pharm* 2020 Nov 9. [Epub ahead of print]
- **Clements JN, Castelli G**, Meade LT, et al. A guide for the pharmacist's role in insulin pump management during transitions of care. *J Am Coll Clin Pharm* 2021;4:352-63.
- **Clements JN, Emmons RP, Anderson SL**, Chow M, **Coon S, Irwin AN, Mukherjee SM, Sease JM, Thrasher K**, et al. Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. *J Am Coll Clin Pharm* 2021;4:390-405.
- **Clements JN, Isaacs D**, Hartman RE, **Gambill K**. Pharmacokinetics and clinical implications of oral semaglutide for type 2 diabetes mellitus. *Clin Pharmacokinet* 2021;60:153-63.
- **Coon SA, Hill LG, Hutchison RW**, Arnold LM, **Jarrett JB**, Ottney AR, **Oung AB, Painter NA**, Smith MA, **Stranges PM, Tran TH**, et al. Mobilizing pharmacists to address the opioid crisis, a joint opinion of the Ambulatory Care and Adult Medicine Practice and Research Networks for the American College of Clinical Pharmacy. *J Am Coll Clin Pharm* 2020;3:1493-513.
- **Evoy KE, Hill LG**, Davis CS. Considering the potential benefits of over-the-counter naloxone. *Integr Pharm Res Pract* 2021;10:13-21.
- **Hill LG**, Loera LJ, **Evoy KE**, et al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. *Addiction* 2020 Nov 3. [Epub ahead of print]
- Peckham AM, Ball J, Colvard MD, Dadiomov D, **Hill LG**, Nichols SD, **Tallian K**, Ventricelli DJ, **Tran TH**. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19. *Am J Health Syst Pharm* 2021 Jan 7. [Epub ahead of print]
- Renfro ML, Loera LJ, Tirado CF, **Hill LG**. Lofexidine for acute opioid withdrawal: a clinical case series. *Ment Health Clin* 2020;10:259-63.
- Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, **Hill LG**. Type and extent of opioid-related education provided by U.S. college of pharmacy continuing education divisions. *Am J Pharm Educ* 2020;84:ajpe8001.
- Zagorski CM, Myslinski JM, **Hill LG**. Isotonitazene as a contaminant of concern in the illegal opioid supply: a practical synthesis and cost perspective. *Int J Drug Policy* 2020;86:102939.

- **Isaacs DM**, Kruger DF, Spollett GR. Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. *Diabetes Spectr* 2021;34:7-19.
- **Litten K, Hill LG, Garza A, Srinivasa M**. Increasing naloxone knowledge and use through direct-to-patient education. *J Pharm Technol* 2020;36:237-42.
- **Martin MT, Patel S**, Kulik L, et al. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. *J Hepatol* 2021 Feb 27. [Epub ahead of print]
- Lin J, Mauntel-Medici C, Maheswaran AB, Baghikar S, Pugach O, Stein EM, **Martin MT**, et al. Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor. *J Public Health* 2021 Feb 5. [Epub ahead of print]
- Nabulsi N, **Martin MT**, Sharp LK, Koren DE, Teply R, **Zuckerman A**, et al. Predicting treatment failure for initiators of hepatitis C virus treatment in the era of direct-acting antiviral therapy. *Front Pharmacol* 2020;11:551500.
- **Meredith AH**, Buatois EM, Krenz JM, et al. Assessment of clinical inertia in people with diabetes within primary care. *J Eval Clin Pract* 2021;27:365-70.
- **Meredith AH**, Howell C. Using shared decision-making tools: are they worth it? *iForumRx* 2020 Nov 13.
- **Meredith AH, Schmelz AN**, Dawkins E, et al. Group education program for hypertension control. *J Clin Hypertens* 2020;22:2146-51.
- Howell C, **Meredith AH**. CGM-101: how to identify appropriate use. *ADCES Pract* 2020;8:22-32.
- Alberston S, **Murray T**, Triboletti J, Pence L, Gonzalvo J, **Meredith A**, et al. Implementation of primary care clinical pharmacy services for adults experiencing homelessness. *J Am Pharm Assoc* 2021;61:e80-e84.
- **Nguyen Q**, Duval C. The utility of FreeStyle® Libre flash glucose monitoring in identifying nocturnal hypoglycemia. *ACCP Ambulatory Care PRN Fall 2020 Newsletter*, October 2020.
- **Plakogiannis R, Saseen J**, Stefanidis A. Pharmacists' utilization of non-HDL-C levels in managing patients with lipid disorders. *Hosp Pharm* 2020 Mar 6. [Epub ahead of print]
- **Plakogiannis R**, Stefanidis A, **Hernandez N**, et al. A heart failure themed escape room approach to enhance pharmacy student learning. *Curr Pharm Teach Learn* 2020;12:940-4.
- Chen M, Vider E, **Plakogiannis R**. Insulin dosage adjustments after initiation of GLP-1 RA with type 2 diabetes. *J Pharm Pract* 2021. [In press]
- Furer J, Popova O, **Plakogiannis R**. A newly approved cholesterol drug joins the lipid-lowering arsenal: bempedoic acid. *J Nurse Pract* 2020;16:722-5.
- Gonzalvo J, Kenneally A, Pence L, Walroth T, **Schmelz A**, Nace N, Chang J, **Meredith A**. Reimbursement outcomes of a pharmacist-physician co-visit model in a federally qualified health center. *J Am Coll Clin Pharm*. [In press]
- **Schumacher C, Van Dril E, Shealy K, Goldman J**. Optimizing management of type 2 diabetes and its complications in patients with heart failure. *Clin Diabetes* 2021;39:105-16.
- **Sobeski LM, Schumacher CA**, Alvarez NA, Anderson KC, **Bradley B**, Crowe SJ, **Merlo JR**, Nyame A, **Shapiro NL**, Rivera KS, Spencer D, **Van Dril E**. Medication access: policy and practice opportunities for pharmacists. *J Am Coll Clin Pharm* 2021;4:113-25.
- Walkerly A, Neugebauer RE, Misko B, Shively D, Singh S, Chahda B, Dhanireddy S, King K, Lloyd M, Fosnight S, Costello M, Palladino C, **Soric MM**. Prevalence, predictors, and trends of opioid prescribing for lower back pain in United States emergency departments. *J Clin Pharm Ther* 2020 Dec 11. [Epub ahead of print]
- **Tran T**, Ball J, Bratberg JP, DeSimone EM, Franko TS, **Hill LG**, et al. Report of the 2020 Special Committee on Substance Use and Pharmacy Education. *Am J Pharm Educ* 2020;84:8421.
- **Westerhof LR**, Dumkow LE, Hanrahan TL, et al. Outcomes of an ambulatory care pharmacist-led antimicrobial stewardship program within a family medicine resident clinic. *Infect Control Hosp Epidemiol* 2020 Nov 13. [Epub ahead of print]
- **Wheeler SE**, Struebing T, Drury RLC, et al. Glycemic relapse in a collaborative primary care-based type 2 diabetes management program. *J Am Pharm Assoc* 2021. [In press]

#### New ACCP Fellows

- Nancy Borja-Hart
- Erica F. Crannage
- Holly E. Gurgle
- Diana Isaacs
- James C. Lee
- Tracy E. Macaulay
- Jean Y. Moon
- Rebecca H. Stone



## Other Notable Achievements

- **Sarah Anderson** (University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences) and **Brian Irons** (Texas Tech University Health Sciences Center): Named Series Editors for the 2022–2024 ACSAP Series.
- **Hedva Barenholtz Levy**: Named President-Elect of the American Society of Consultant Pharmacists.
- **Lucas Hill**: Appointed to the *JACCP* Editorial Board.
- **Diana Isaacs**: Appointed to the American Diabetes Association (ADA) Professional Practice Committee (committee that updates the ADA Standards of Care).

## Cardiology PRN

### Promotions

- **Kristen Pogue**: Clinical Associate Professor, University of Michigan.

### Awards

- **Lindsay Davis**: Exemplary Patient Care Award, Arizona Pharmacy Association.
- **Christie Schumacher**: Diabetes Education Specialist of the Year, Association of Diabetes Care and Education Specialists (ADCES) Illinois Coordinating Body.

### Grants

- **Larisa Cavallari, Craig Lee**: Precision Antiplatelet Therapy After Percutaneous Coronary Intervention. NIH/NHLBI. Amount: \$3.5 million.
- **Rob DiDomenico**: Program to Educate & Vaccinate Underserved Members of the Public (PREVENT) Pilot. Otho S.A. Sprague Memorial Institute. Amount: \$81,635.
- **Dave Dixon**: The Association of Ambulatory Blood Pressure Phenotypes with Cognition in Community-Dwelling Older Adults: A Pilot Study. VCU Center for Clinical and Translational Research (CCTR) Endowment Fund. Amount: \$50,000.
- **James E. Tisdale**: Risk of Drug-Induced QT Interval Prolongation and Associated Proarrhythmia in Patients with Heart Failure with Preserved Ejection Fraction. Indiana CTSI Pilot Funding for Research Use of Core Facilities. Amount: \$10,000.

### Publications

- **Atallah B, AlMahmeed W**. The Emirates Cardiac Society Congress 2020. *Eur Heart J* 2021;42:807-9.
- **Atallah B, El Lababidi R, Jesse W, et al**. Adapting to the COVID19 pandemic at a quaternary care hospital in the Middle East Gulf Region. *Heart Views* 2020;21:133-40.

- **Atallah B, Hamour I, Mallah SI, et al**. Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East. *Drugs Ther Perspect* 2020 Oct 31. [Epub ahead of print]
- **Atallah B, Sadik ZG, Salem N, et al**. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. *Anaesthesia* 2021;76:327-35.
- Anouassi Z, **Atallah B, Alsoud LO, et al**. Appropriateness of the direct oral anticoagulants dosing in the Middle East Gulf Region. *J Cardiovasc Pharmacol* 2021;77:182-8.
- Göbölös L, Rácz I, Hogan M, Ramsey-Semmelweis E, **Atallah B, et al**. The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection. *J Vasc Surg* 2020 Dec 18. [Epub ahead of print]
- Salem N, **Atallah B, El Nekidy WS, et al**. Thromboelastography findings in critically ill COVID-19 patients. *J Thromb Thrombolysis* 2020 Oct 4. [Epub ahead of print]
- **Baker WL, Sobieraj DM, DiDomenico RJ**. Influence of digoxin on mortality in patients with atrial fibrillation: overview of systematic reviews. *Pharmacotherapy* 2021 Feb 5. [Epub ahead of print]
- Bascetta T, Bolton L, Kurtzman E, Hantzios W, Standish H, Margarido P, Race K, Spencer J, **Baker WL, et al**. Air medical transport of patients diagnosed with confirmed COVID-19 infection undergoing extracorporeal membrane oxygenation (ECMO). A case review and lessons learned. *Air Med J* 2021;40:130-4.
- Costa OS, **Baker WL, Roman-Morillo Y, McNeil-Posey K, Lovelace B, White CM, Coleman CI**. Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review. *BMJ Open* 2020;10:e040499.
- Gluck JA, Kaiser T, Considine B, Zantah M, Kurtzman E, Drake C, Underhill D, Radojevic J, Jaiswal A, **Baker WL**. Predicting survival with mobile extracorporeal membrane oxygenation: a single-center evaluation. *Conn Med*. [In press]
- An J, Derington CG, Luong T, Olson KL, King JB, **Bress AP, Jackevicius CA**. Fixed-dose combination medications for treating hypertension: a review of effectiveness, safety, and challenges. *Curr Hypertens Rep* 2020;22:95.
- McGrath PR, Kersten B, **Chilbert MR, et al**. Evaluation of metoprolol versus diltiazem for rate control of atrial fibrillation in the emergency department. *Am J Emerg Med* 2020 Nov 22. [Epub ahead of print]

- Kenny M, **Clarke MM, Pogue KT**. Overview of riociguat and its role in the treatment of pulmonary hypertension. *J Pharm Pract* 2020 Oct 21. [Epub ahead of print]
- **Davis LE**, Pogge E. A retrospective chart review evaluating efficacy, tolerability, and cost of pro-protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in older adults. *High Blood Press Cardiovasc Prev* 2020;27:331-8.
- Patel H, Calip GS, **DiDomenico RJ**, Schumock GT, Suda KJ, Lee TA. Comparison of cardiac events associated with azithromycin vs amoxicillin. *JAMA Network Open* 2020;3:e2016864.
- Patel H, **DiDomenico RJ**, Suda KJ, Schumock GT, Calip GS, Lee TA. Risk of cardiac events with azithromycin: a prediction model. *PLoS One* 2020;15:e0240379.
- **Dixon DL**. Introducing emerging concepts in pharmacotherapeutics. *J Cardiovasc Pharmacol* 2020;76:372-3.
- **Dixon DL, Saseen JJ**. Pharmacist-administered long-acting injectable PCSK9 service: a solution to improve patient access and adherence. *J Am Pharm Assoc (2003)* 2020 Dec 28. [Epub ahead of print]
- Khaddage SJ, Patterson JA, Sargent LJ, Price ET, **Dixon DL**. Sex and age differences in ambulatory blood pressure monitoring tolerability. *Am J Hypertens* 2020 Nov 12. [Epub ahead of print]
- Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig RA, Van Tassell BW, Abbate A, Biondi-Zoccai G, **Dixon DL**. Impact of different doses of omega-3 fatty acids on cardiovascular outcomes: a pairwise and network meta-analysis. *Curr Atheroscler Rep* 2020;22:45.
- Sargent LJ, Mackiewicz M, Roman Y, Diallo A, Russell S, Falls K, Zimmerman KM, **Dixon DL**, et al. The translational approaches to personalized health collaborative: pharmacogenomics for African American older adults. *Clin Transl Sci* 2020 Oct 7. [Epub ahead of print]
- **Hendricks AK, Zieminski JJ**, Yao X, et al. Safety and efficacy of oral anticoagulants for atrial fibrillation in patients after bariatric surgery. *Am J Cardiol* 2020;136:76-80.
- **Jackevicius C**. Evidence-based medicine in the COVID-19 era. *Can J Hosp Pharm* 2021;74:3-4.
- **Jackevicius CA**, Krumholz HM, Ross JS, et al. Clinical outcomes with beta-blocker use in patients with prior history of myocardial infarction. *Can J Cardiol* 2020;36:1633-40.
- Lauffenburger JC, Fontanet CP, Isaac T, Gopalakrishnan C, Sequist TD, Gagne JJ, **Jackevicius CA**, et al. Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardio-metabolic disease. *Am Heart J* 2020;228:36-43.
- Moon J, Cohen Sedgh R, **Jackevicius C**. Examining the nocebo effect of statins through statin adverse events reported in the FDA Adverse Event Reporting System (FAERS). *Circ Cardiovasc Qual Outcomes* 2021;14:e007480.
- **Kido K**, Bianco C, Caccamo M, Fang W, Sokos G. Evaluating sacubitril/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction. *Ann Pharmacother* 2020 Dec. 31. [Epub ahead of print]
- **Kido K**, Shimizu M, Shiga T, et al. Network meta-analysis comparing apixaban versus rivaroxaban in morbidly obese patients with atrial fibrillation. *Am J Cardiol* 2020;134:160-1.
- Brokmeier H, **Kido K**. Off-label use for direct oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension – a systematic review. *Ann Pharmacother* 2020 Nov 4. [Epub ahead of print]
- **Kulig CE, Roberts JR**, Rowe AR, **Kim H, Dager WE**. INR response to low-dose vitamin K in warfarin patients. *Ann Pharmacother* 2021 Feb 5. [Epub ahead of print]
- **Kulig CE**, Schomer KJ, Blacker HB, **Dager WE**. Activated partial thromboplastin time versus anti-factor Xa monitoring of heparin anticoagulation in adult venoarterial extracorporeal membrane oxygenation patients. *ASAIO J* 2021;67:411-5.
- **Lee CR**, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, **Lee JC**, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, **Coons JC**, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, **Stevenson JM**, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, **Cavallari LH**, et al. Impact of the *CYP2C19\*17* allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Clin Pharmacol Ther* 2021;109:705-15.
- Khatri R, Kulick N, Rementer RJB, Fallon JK, Sykes C, Schauer AP, Malinen MM, Mosedale M, Watkins PB, Kashuba ADM, Boggess KA, Smith PC, Brouwer KLR, **Lee CR**. Pregnancy-related hormones increase nifedipine metabolism in human hepatocytes by inducing CYP3A4 expression. *J Pharm Sci* 2021;110:412-21.
- **Levito MN, Coons JC**, Verrico MM, Kane-Gill S, **Szymkowiak A**, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. *Ann Pharmacother* 2021;55:618-23.

- **Macaulay TE, Sheridan E, Ward S.** Reconsidering the polypill for management of cardiovascular risk factors in underserved patients. *Curr Cardiol Rep* 2021;23:19.
- **Moreland-Head LN, Coons JC,** Seybert AL, et al. Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the food and drug administration adverse event reporting system (FAERS) database. *J Cardiovasc Pharmacol Ther* 2021 Jan 6. [Epub ahead of print]
- **Patil T,** Hobson J. Risk of new-onset osteoporosis in single-center veteran population receiving direct oral anticoagulants versus warfarin. *Thromb Res* 2021;200:56-63.
- **Patil T,** Murphy K, Woodard L, Lebrecht M. Proton pump inhibitor utilization in veteran patients on combined antithrombotic therapy and validation of simplified bleeding risk score. *Pharmacotherapy* 2020;40:1219-27.
- **Rodino AM,** Henderson JB, Dobbins KF, Rubin DT, **Hollis IB.** Impact of thrombocytopenia on post-operative bleeding incidence in patients receiving aspirin following coronary artery bypass grafting. *J Pharm Pract* 2020 Oct 21. [Epub ahead of print]
- Kline TM, **Rodino AM,** Dorszynski A, et al. Ultrasound-assisted catheter-directed thrombolysis versus systemic anticoagulation alone for submassive pulmonary embolism. *J Thromb Thrombolysis* 2020 Sep 29. [Epub ahead of print]
- **Schumacher C,** Van Dril E, Shealy K, et al. Optimizing management of type 2 diabetes and its complications in patients with heart failure. *Clin Diabetes* 2021;39:105-16.
- Benjamin T, **Schumacher C.** Characterization of risk factors for genitourinary infections with sodium glucose cotransporter-2 inhibitors. *Pharmacotherapy* 2020;40:1002-11.
- Sobeski LM, **Schumacher CA,** Alvarez NA, Anderson KC, Bradley B, Crowe SJ, Merlo JR, Nyame A, Rivera KS, Shapiro NL, **Spencer DD,** et al. Medication access: policy and practice opportunities for pharmacists. *J Am Coll Clin Pharm* 2021;4:113-25.
- Doyno C, **Sobieraj DM, Baker WL.** Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. *Clin Toxicol* 2021;59:12-23.
- **Tisdale JE,** Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. *Circulation* 2020;142:e214-e233.
- **Tisdale JE,** Jaynes HA, **Overholser BR, Sowinski KM,** Fisch MD, **Rodgers JE, Aldemerdash A,** et al. Enhanced response to drug-induced QT

lengthening in patients with heart failure with preserved ejection fraction. *J Card Fail* 2020;26:781-5.

- Farhan HA, **Yaseen IF.** Chapter 9: Setting up a clinical service for PPCM in Iraq. In: Sliwa K, ed. *Peripartum Cardiomyopathy: From Pathophysiology to Management.* London: Elsevier, 2021:93-114.

### Board-Certified Cardiology Pharmacists (BCCPs)

- Lindsay Davis
- Emily McElhaney
- Anne Rodino
- Nick Servati
- Erica Sheridan
- Ju-Chieh Wung
- Israa Yaseen

### Other Notable Achievements

- **Ahmed Aldemerdash:** Appointed as Director of Postgraduate Pharmacy Education Center (PGPE) in College of Pharmacy KSU.
- **William Baker:** Appointed as Chair of the ACCP Foundation Board of Trustees starting October 26, 2020.
- **Rob DiDomenico:** Appointed as Co-Chair of HFSA Annual Scientific Meeting Programming Committee.
- **Dave Dixon:** Appointed to ACC Prevention Council.
- **Ian Hollis:** Appointed as Chair of BCPS Cardiology Specialty Council.
- **Kristen Pogue:** Appointed as Vice Chair of BCPS Cardiology Specialty Council.
- **Joe Saseen:** President, National Lipid Association.
- **Christie Schumacher:** Appointed as Vice Chair of BPS Ambulatory Care Pharmacy Specialty Council.
- **James Tisdale:** Chair, Board of Directors, Pharmacotherapy Publications, Inc.

## Central Nervous System PRN

### Promotions/New Positions

- **Alyssa Peckham:** Neuroscience Medical Science Liaison for MA/VT/NH/ME for Otsuka Pharmaceuticals.
- **Richard Silvia:** Full Professor of Pharmacy Practice, MCPHS University School of Pharmacy-Boston.

### Awards

- **Mark E. Schneiderhan:** Membership in the 2020 Academy for Excellence in Clinical Practice by the University of Minnesota.

### Grants

- **Zach Krauss:** Received a \$1500 Defining the Future Grant from the College of Psychiatric and Neurologic Pharmacists (CPNP) for: Analyzing the

Effect of Art Therapy Interventions and Wellness Programs on Graduate Pharmacy Students' Mental Health.

- **Alyssa Peckham:** Co-PI on a \$21,642.39 grant from RIZE Massachusetts for project titled "Evaluating and Minimizing the Negative Impact of COVID-19 on People Who Inhale and Inject Drugs" that sought applications regarding SUD harm reduction amid COVID-19.

## Publications

- **Peckham AM**, Ball J, Colvard MD, et al. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. *Am J Health Syst Pharm* 2021 Jan 7. [Epub ahead of print]
- **Peckham AM**, Young EH. Opportunities to offer harm reduction to people who inject drugs during infectious disease encounters: narrative review. *Open Forum Infect Dis* 2020;7:ofaa503.
- Bernstein SN, **Peckham AM**, Schiff DM, et al. Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. *Obstet Gynecol* 2021;137:377-8.
- Evoy KE, Covvey JR, **Peckham AM**, et al. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. *Int J Clin Pharm* 2021 Jan 2. [Epub ahead of print]
- Evoy KE, Roccograndi L, Le S, Leonard CE, Covvey JR, Ochs L, **Peckham AM**, et al. National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. *J Subst Abuse Treat* 2020;119:108141.
- Evoy KE, Sadrameli S, Contreras J, Covvey JR, **Peckham AM**, et al. Abuse and misuse of pregabalin and gabapentin: a systematic review update. *Drugs* 2021;81:125-56.
- **Reed RC**, Rosenfeld WE, Lippmann SM, et al. Creative use of the conventional "human photosensitivity model in epilepsy." In: Kasteleijn-Nolst Trenite D, ed. *The Importance of Photosensitivity for Epilepsy*. Springer Nature, 2021:305-21.
- **Reed RC**, Rosenfeld WE, Lippmann SM, et al. Rapidity of CNS effect on photoparoxysmal response for brivaracetam vs. levetiracetam: a randomized, double-blind, crossover trial in photosensitive epilepsy patients. *CNS Drugs* 2020;34:1075-86.
- Kasteleijn-Nolst Trenite DG, **Reed RC**. Summary of current knowledge and the path forward for new research into photosensitivity and epilepsy. In: Kasteleijn-Nolst Trenite D, ed. *The Importance of Photosensitivity for Epilepsy*. Springer Nature, 2021:413-27.

- Singh B, Nuñez NA, Schock L, Joseph B, Kohoute B, **Roerig JL**. Lithium continuation for a patient with bipolar disorder and chronic kidney disease. *Bipolar Disord* 2020;22:316-8.
- Steffen KJ, Mohammad AS, **Roerig JL**, et al. Lisdexamfetamine pharmacokinetic comparison between patients who underwent Roux-en-Y gastric bypass and nonsurgical controls. *Obes Surg* 2020. [In press]
- **Silvia RJ**, **Lee KC**, Bostwick JR, et al. Assessment of the current practice of psychiatric pharmacists in the United States. *Ment Health Clin* 2020;10:346-53.
- **Walkerly A**, King M. Evaluation of initial atypical antipsychotic monitoring parameters in children and adolescents. *Ment Health Clin* 2020;10:354-7.
- **Walkerly A**, Neugebauer RE, Misko B, et al. Prevalence, predictors, and trends of opioid prescribing for lower back pain in United States emergency departments. *J Clin Pharm Ther* 2020 Dec 11. [Epub ahead of print]

## Presentations

- **Peckham AM**, Covvey JR, Vogel SM, et al. Characteristics and prevalence of self-reported kratom use in a representative US general population sample. Poster presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.
- Acquisto NM, **Peckham AM**, Melton ST. Team-based management of opioid misuse across the care continuum. Presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.
- Evoy KE, Covvey JR, **Peckham AM**, et al. Quetiapine and olanzapine misuse and abuse in a US general population sample. Poster presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.
- Karavolis Z, Mills K, **Peckham AM**. Evaluation of provider knowledge and attitudes toward implementing safer psychostimulant smoking kits at a large academic medical center before and after education. Poster presented at: ASHP Midyear Clinical Meeting; December 2020; virtual.

## Other Notable Achievements

- **Alyssa Peckham:**  
Interviewed by Pharmacy Practice News in October 2020 for an article titled "Bridge Clinics Address Opioid Treatment Gap After Discharge."  
Interviewed by Psycrom Pro in December 2020 for an article titled "Assessing Alcohol Abuse and Alcohol-Related Dementia."

Interviewed by Pharmacy Practice News in January 2021 for an article titled "Health Systems Tackle Addiction in Varied Settings."

- **Autumn Walkerly:** Became a Board Certified Pharmacotherapy Specialist (BCPS).
- **James Roerig:** Completed the ACCP Certificate in Precision Medicine: Applied Pharmacogenomics.

## Clinical Administration PRN

### Promotions

- **Paul Stranges:** Assistant Director, Opioid Stewardship/Drug Diversion at University of Illinois Hospital & Health Sciences System.
- **Tyler Vest:** Pharmacy Manager, Automation, Medication Distribution, and Controlled Substances, Duke University Hospital.

### Grants

- **Vest TA, Gazda NP, Schenkat DH, et al.:** Development of an Efficient Process to Identify Practice-Enhancing Publications About the Medication Use Process and Evaluate Use by Pharmacy Leaders. ASHP Research and Education Foundation New Practitioner Pharmacist Leadership Development Grant Program Award. Amount: \$5000.

### Publications

- **Lattos AK, Hartkopf K, Langley J.** The consideration of at-home administration of omalizumab. *J Pharm Soc Wis* 2021;24:40-1.
- **Vest TA, Amerine LB, Savage SW, et al.** Effectiveness and impact of a structured research approach for health-system pharmacy administration and leadership residents. *Am J Health Syst Pharm* 2021;78:229-34.
- **Vest TA, DeAngelis JT.** Steps to ensure emergency preparedness. *PP&P* 2020;17:16-8.
- **Vest TA, Gazda NP, Schenkat DH, et al.** Practice-enhancing publications about the medication use process in 2019. *Am J Health Syst Pharm* 2021;78:141-53.
- **Vest TA, Kelm MJ.** Utility of health system based pharmacy technician training programs. *J Am Pharm Assoc* 2020;60:e125-e128.
- **Vest TA, Tiry KM, Dapaah-Afriyie R, et al.** Redeploy pharmacy technicians to advanced roles. *PP&P* 2020;17:8-11.
- **Barta BT, Vest TA.** Drug diversion identification and prevention strategies. *PP&P* 2021;18:2-6.

## Critical Care PRN

### Promotions

- **Md Jahidul Hasan:** Lead, Clinical Pharmacy Services, Corona Unit, Square Hospitals Ltd.
- **Judi Jacobi:** Editorial Board, *Critical Care Explorations*.
- **Kristin Kooda:** Critical Care Pharmacist/Antimicrobial Stewardship, Mayo Clinic.
- **Lisa Smart-Langerud:** Lead OR Pharmacist, Inova Health System.

### Awards

- **Paul Dobesh:** Distinguished Teaching Award, University of Nebraska College of Pharmacy. Distinguished Alumnus Award, South Dakota State University College of Pharmacy and Allied Health Professions.
- **Alex Flannery:** Pharmacy Mentor of the Year, Kentucky Society of Health-System Pharmacists.
- **Lana Gettman:** Award for Excellence in Assessment, American Association of Colleges of Pharmacy.
- **Christine Groth:** Presidential Citation Award, Society of Critical Care Medicine.
- **Leslie Hamilton:** UT Knoxville Alumni Volunteer 40 Under 40 Award, University of Tennessee, Knoxville Alumnus.
- **Md Jahidul Hasan:** Trainer Award, Ministry of Health and Family Affairs, Bangladesh.
- **Alison Novak:** Star Research Award, Society of Critical Care Medicine. In-Training Award, Society of Critical Care Medicine.
- **Kaitlin Pruskowski:** Who's Who in America, Critical Care Providers, Texas.
- **Andrea Sikora Newsome:** Junior Investigator Award, American College of Clinical Pharmacy Critical Care PRN.
- **Susan Smith:** Star Research Award, Society of Critical Care Medicine.

### Grants

- **Christopher Droege and Sarah Schuman Harlan:** American College of Clinical Pharmacy, Critical Care Pharmacy Practice and Research Network, UC Health-University of Cincinnati Medical Center, Cincinnati, Ohio, Co-PIs. A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients with Severe Traumatic Brain Injury. Amount: \$7500.
- **Alison Novak:** Department of Clinical Pharmacy Seed Grant, Associate Dean of Research Core Seed Grant, University of Colorado Skaggs School of Pharmacy.

- **Susan Smith:** Clinical Pharmacy and Pharmacology Travel Grant, Society of Critical Care Medicine.

## Publications

- Alkofide H, **Alhammad AM**, Alruwaili A, et al. Multidrug-resistant and extensively drug-resistant Enterobacteriaceae: prevalence, treatments, and outcomes – a retrospective cohort study. *Infect Drug Resist* 2020;13:4653-62.
- **Berger K**, Kaplan AS. Advocacy during crisis: maintaining a legislative presence during the COVID-19 pandemic. *Am J Health Syst Pharm* 2020;77:1830-3.
- Bastin MT, **Berger K**, Adams C, Altshuler J, **Dixit D**, Effendi M, **Johnston J**, **Lemieux D**, Lemieux S, Littlefield A, Owusu K, Rose C, Rouse G, **Heavner MS**. Adapting clinical pharmacy staffing models during the COVID-19 pandemic: lessons learned and considerations for future disaster planning. *J Am Coll Clin Pharm* 2020;4:10-9.
- Carothers C, **Birrer KL**, Vo M. Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: a case series. *Pharmacotherapy* 2020;40:1166-71.
- Stuart MK, **Blackwell SB**, Holder HB, et al. Efficacy and safety of nonvitamin K oral anticoagulants following cardiac valve replacement. *South Med J* 2021;114:46-50.
- Domecq JP, Amos L, Sheldrick CR, Kumar VK, Boman K, **Bolesta S**, et al. Outcomes of patients with coronavirus disease 2019 receiving organ support therapies. *Crit Care Med* 2021;49:437-48.
- Walkey AJ, Sheldrick RC, Kashyap R, Kumar VK, Boman K, **Bolesta S**, et al. Guiding principles for the conduct of observational critical care research for the coronavirus disease 2019 pandemics and beyond: the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study Registry. *Crit Care Med* 2020;48:e1038.
- **Buckley MS**, Agarwal SK, **MacLaren R**, **Kane-Gill SL**. Adverse hemodynamic events associated with concomitant dexmedetomidine and propofol for sedation in mechanically ventilated ICU patients. *J Intensive Care Med* 2020;35:1536-45.
- **Condeni MS**, Basting A, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Magee CA, McLean B, Reichert M, **Santibañez M**, Wieruszewski PM, **Newsome AS**. Major publications in the critical care pharmacotherapy literature: 2019. *J Crit Care* 2021;62:197-205.
- Deloney LP, **Condeni MS**, Carter C, et al. Efficacy of methocarbamol for acute pain management in young adults with traumatic rib fractures. *Ann Pharmacother* 2020 Oct 12. [Epub ahead of print]
- **Dobesh PP**, DiDomenico RJ, Rogers KC. Chapter 32: Stable ischemic heart disease. In: DiPiro JT, Yee GC, Posey LM, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. New York: McGraw-Hill, 2020.
- **Dobesh PP**, Finks SW, Trujillo TC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. *Clin Ther* 2020;42:2084-97.
- **Dobesh PP**, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. *Pharmacotherapy* 2020;40:1130-51.
- Cochran GL, Foster JA, Klepser DG, **Dobesh PP**, et al. The impact of eliminating backward navigation on computerized exam scores and completion time. *Am J Pharm Educ* 2020;84:1620-6.
- Coleman CI, **Dobesh PP**, Danese S, et al. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. *Future Cardiol* 2021;17:127-35.
- DiDomenico RJ, **Dobesh PP**, Finks SW. Chapter 33: Acute coronary syndrome. In: DiPiro JT, Yee GC, Posey LM, et al., eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. New York: McGraw-Hill, 2020.
- Tomaselli GT, Mahaffey KW, Cuker A, **Dobesh PP**, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2020;76:594-622.
- **Droege CA**, Mueller EW. Practicing evidence-based medicine and clinical pathway development. In: Boucher BA, Haas CE, eds. *Critical Care Self-Assessment Program, 2020 Book 2. Issues in Critical Care Practice*. Lenexa, KS: American College of Clinical Pharmacy, 2020:85-115.
- Adams CD, Altshuler J, Barlow BL, Dixit D, **Droege CA**, Effendi MK, **Heavner MS**, Johnston JP, Kiskaddon AL, Lemieux D, Lemieux SM, Littlefield AJ, Owusu KA, Rouse GE, Thompson Bastin ML, **Berger K**. Analgesia and sedation strategies in mechanically ventilated adults with COVID-19. *Pharmacotherapy* 2020;40:1180-91.
- McMullan JT, **Droege CA**, Strilka RJ, et al. Food and Drug Administration and Institutional Review Board approval of a novel prehospital informed consent process for emergency research. *Prehosp Emerg Care* 2020 Sep 9. [Epub ahead of print]

- McMullan JT, **Droege CA**, Strilka RJ, et al. Intranasal ketamine as an adjunct to fentanyl for the prehospital treatment of acute traumatic pain: design and rationale of a randomized controlled trial. *Prehosp Emerg Care* 2020 Oct 15. [Epub ahead of print]
- Peters DM, Winter JB, **Droege CA**, et al. Comparison of ceftriaxone and antipseudomonal  $\beta$ -lactam antibiotics utilized for potential AmpC  $\beta$ -lactamase-producing organisms. *Hosp Pharm* 2020 Jun 4. [Epub ahead of print]
- **Dzierba AL**, Pedone T, Patel MK, Ciolek A, Mehta M, **Berger K**, et al. Rethinking the drug distribution and medication management model: how a New York City hospital pharmacy department responded to COVID-19. *J Am Coll Clin Pharm* 2020 Aug 12. [Epub ahead of print]
- **Flannery AH**, Bosler K, Ortiz-Soriano VM, et al. Kidney biomarkers and major adverse kidney events in critically ill patients. *Kidney360* 2021;2:26-32.
- **Flannery AH**, Delozier NL, Effoe SA, et al. First-dose vancomycin pharmacokinetics versus empiric dosing on area-under-the-curve target attainment in critically ill patients. *Pharmacotherapy* 2020;40:1210-8.
- **Flannery AH**, Hammond DA, Oyler DR, et al. Vancomycin dosing practices among critical care pharmacists: a survey of Society of Critical Care Medicine Pharmacists. *Infect Dis (Auckl)* 2020;13:1178633720952078.
- **Flannery AH**, Owen GD, Coz A, et al. Impact of hyperoncotic albumin on duration of vasopressor support in septic shock: a propensity score-matched analysis. *Ann Pharmacother* 2021;55:584-91.
- Noel ZR, See VY, **Flannery AH**. Walk the line – the importance of well-informed interpretation of QT prolongation. *Ann Pharmacother* 2021;55:123-6.
- **Gettman L**. 10-second active learning exercise in a pharmacotherapy course [blog]. *Pulses* 2020 Oct 13.
- Boston B, Petty B, Shipp M, **Gettman L**. Crash diets: what a wreck! *Searcy Living Magazine* 2020;20:14.
- **Groth CM**, **Droege C**, Connor KA, Kaukeinen K, **Acquisto NM**, Chui SH, Cucci M, **Dixit D**, **Flannery A**, Gustafson K, Glass N, Horng H, **Heavner M**, Kinney J, **Kruer R**, Peppard W, Sarangarm P, **Newsome A**, **Viswesh V**, **Erstad B**. Multicenter retrospective review of ketamine use in pediatric ICU patients (Ketamine-PICU Study) [abstract]. *Crit Care Med* 2021;49(suppl 11):427.
- Attin M, Abiola S, Magu R, Rosero S, Apostolakos M, **Groth CM**, et al. Polypharmacy prior to in-hospital cardiac arrest among patients with cardiopulmonary diseases: a pilot study. *Resuscitation Plus* 2020;4:1-8.
- Rappaport SH, Clark JM, Delibert S, Maynard KM, Prasad P, Kaufman DC, Pietropaoli AP, Quill CM, **Groth CM**. Anti-FXa activity with intermediate-dose thromboprophylaxis in COVID-19. *Am J Respir Crit Care Med* 2020;202:1731-3.
- **Hamilton LA**, Darby SH, Rowe AS. A retrospective cohort analysis of the use of enteral nutrition plus pharmacologic prophylaxis or enteral nutrition alone. *Hosp Pharm* 2020 Sep 10. [Epub ahead of print]
- Abraham MP, Hinds M, Tayidi I, Jeffcoach DR, Corder JM, **Hamilton LA**, et al. Quetiapine for delirium prophylaxis in high-risk critically ill patients. *Surgeon* 2021;19:65-71.
- Livesay SL, Severson AJ, **Hamilton LA**, et al. Clinical Q&A: translating therapeutic temperature management from theory to practice. *Ther Hypothermia Temp Manag* 2020;10:248-53.
- Rowe AS, Dietrich S, **Hamilton LA**. Analysis of anticoagulation reversal survey (ARES). *Hosp Pract* 2020;48:123-7.
- Tatro HA, McMillen JC, **Hamilton LA**, et al. 23.4% sodium chloride versus mannitol for the reduction of intracranial pressure in patients with traumatic brain injury; a single-center retrospective cohort study. *Ann Pharmacother* 2020 Dec 21. [Epub ahead of print]
- **Hasan MJ**, Rabbani R, Anam AM, et al. Additional baricitinib loading dose improves clinical outcome in COVID-19. *Open Med* 2020;16:41-6.
- **Hasan MJ**, Kumar Das S. Early hospitalization reduces the length-of-hospital stay and antibiotic use in children with moderate diarrhea: a study in Bangladesh. *J Pediatr Rev* 2021;9:71-80.
- **Hasan MJ**, Rabbani R, Anam AM, et al. The susceptibility of MDR-*K. pneumoniae* to polymyxin B plus its nebulised form versus polymyxin B alone in critically ill South Asian patients. *J Crit Care Med* 2020;7:28-36.
- **Hasan MJ**, Rabbani R, Nessa SS. Comparative evaluation of linezolid and teicoplanin in the treatment of ventilator-associated MRSA pneumonia: a single center experience. *Int J Infect* 2020;7:e104447.
- Blanco N, Robinson GL, Heil EL, Perlmutter R, Wilson LE, Brown CH, **Heavner MS**, et al. Impact of a *C. difficile* infection (CDI) reduction bundle and its components on CDI diagnosis and prevention. *Am J Infect Control* 2020;49:319-26.
- Kalaria S, Williford S, Guo D, Shu Y, Medlin C, Li M, Yeung SYA, Ali F, Jean W, Gopalakrishnan M, **Heavner MS**. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. *Pharmacotherapy* 2021;41:205-11.

- **Jacobi J.** Another stepping stone toward personalized glycemic control [invited editorial]. *Crit Care Med* 2020;48:1893-6.
- **Jacobi J.** How the pandemic impacted evidence-based medicine. *SCCM Critical Connections* 2020;19:12-3.
- **Jacobi J.** Call for pharmacists to join vascular safety teams. *Am J Health Syst Pharm* 2020;77:1347-53.
- McFarland MS, Buck M, Armistead L, **Jacobi J**, et al. The outcomes of implementing and integrating comprehensive medication management in team-based care: a review of the evidence on quality, access and costs, October 2020. Tysons Corner, VA: Get the Medications Right Institute, 2020.
- **Kooda KJ**, Rudis MR, Mara K, et al. Critically ill health care-associated urinary tract infection: broad vs narrow antibiotics in the emergency department have similar outcomes. *J Emerg Med* 2021;60:8-16.
- Bova SE, **Kruer RM**, Nesbit SA, et al. Perioperative methadone prescribing and association with respiratory depression. *J Opioid Manag* 2020;16:443-9.
- Gruz TM, **Kruer RM**, Bernice F, et al. Aminoglycoside dosing and volume of distribution in critically ill surgery patients. *Surg Infect (Larchmt)* 2020;21:859-64.
- **Lat I, Paciullo C**, Daley MJ, **MacLaren R, Bolesta S, McCann J, Stollings JL**, Gross K, **Foos SA, Roberts RJ, Acquisto N, Taylor S, Bentley M, Jacobi J**, et al. Position paper on critical care pharmacy services: 2020 update. *J Am Coll Clin Pharm* 2020;3:1380-9.
- **MacLaren R, Roberts RJ, Dzierba AL, Buckley MS, Lat I, Lam SW.** Characterizing critical care pharmacy services across the United States. *Crit Care Explor* 2021;3:e0323.
- **Mo Y**, Adarkwah O, Zeibeq J, et al. Treatment with tocilizumab for patients with COVID-19 infections: a case-series study. *J Clin Pharm* 2021;61:406-11.
- **Mo Y**, Shcherbakova N, Zeibeq J, et al. Clinical and economic impact of the use of dexmedetomidine for sedation in the intensive care unit compared to propofol. *Int J Clin Pharm* 2020;44:1419-24.
- **Novak AR**, Bradley ME, Kiser TH, et al. Azole-resistant *Aspergillus* and *Echinocandin* resistant *Candida* – what are the treatment options? *Curr Fungal Infect Rep* 2020;14:141-52.
- **Poyant JO**, Kanderi T, DiCecco SR, et al. Poor interrater reliability of retrospectively applied subjective global assessment for malnutrition in the critically ill. *Top Clin Nutr* 2020;36:13-22.
- **Pruskowski KA.** Pharmacokinetics and pharmacodynamics of antimicrobial agents in burn patients. *Surg Infect* 2021 Jan 12. [Epub ahead of print]
- **Pruskowski KA**, Akers KS, Chung KK. Chapter 23: Diagnosis and treatment of infections in burns. In: Jeschke MG, Kamolz LP, Sjöberg F, et al., eds. *Handbook of Burns*, 2nd ed. New York: Springer, 2020:299-308.
- **Pruskowski KA**, Britton GW, Cancio LC. Outcomes after the use of hydroxocobalamin. *Int J Burns Trauma* 2020;10:231-6.
- **Pruskowski KA**, Gurney JM, Cancio LC. Impact of a therapy dog program on burn center patients and staff. *Burns* 2020;46:293-7.
- **Pruskowski KA**, Shields BA, Ainsworth CR, et al. Evaluation of the use of sitagliptin for insulin resistance in burn patients. *Int J Burns Trauma* 2020;10:237-45.
- Dewey WS, Cunningham KB, Shingleton SK, **Pruskowski KA**, et al. Safety of early post-operative range of motion in burn patients with newly placed hand autografts: a pilot study. *J Burn Care Res* 2020;41:809-83.
- Suresh M, **Pruskowski KA**, Rizzo JA, et al. Characteristics and outcomes of patients with inhalation injury treated at a military burn center during US combat operations. *Burns* 2020;46:454-8.
- **Salman G**, Boullata J, Sacks GS, et al. Call to action: the need for enhanced nutrition support education and training in pharmacy schools and postgraduate programs. *J Am Coll Clin Pharm* 2021 Feb 4. [Epub ahead of print]
- **Salman G**, Moussavi K, Hua H, et al. 1059: a survey of intravenous phenytoin administration and monitoring practices in adult patients. *Crit Care Med* 2021;49(suppl 11):530.
- **Salman G**, Vo K. Medication reconciliation: an integral component of transitions of care for ICU patients. *Crit Care Med* 2020;48:e1362-e1363.
- **Schmidt LE**, Patel S, **Stollings JL.** The pharmacist's role in the implementation of the ABCDEF bundle into clinical practice. *Am J Health Syst Pharm* 2020;77:1751-62.
- **Sikora Newsome A, Smith SE**, Bland CM, et al. Scholastic synergy: a team prototype for pharmacist engagement in education, research, and service. *Curr Pharm Teach Learn* 2021;13:238-44.
- Branan TN, Hawkins WA, **Sikora Newsome**, Bland CM, **Smith SE.** Twelve tips for synergistic delivery of remote advanced pharmacy practice experience rotations. *MedEdPublish* 2020 Nov 18. [Epub ahead of print]
- Carr J, Hawkins AW, **Sikora Newsome A, Smith SE**, et al. Fluid stewardship of maintenance intravenous fluids. *J Pharm Pract* 2020. [In press]
- Moon P, **Sikora Newsome A**, Hawkins WA, Patel MY, **Smith SE.** Exploration of body habitus and fluid overload in critically ill patients [letter]. *J Pharm Technol* 2020;36:270-1.



- **Skrupky LP**, Dy-Boarman EA, Gurgle HE, et al. Letters of reference for PGY1 pharmacy residency candidates: a survey of residency program directors and opinion statement. *J Am Coll Clin Pharm* 2021;4:379-89.
- **Skrupky LP**, West CP, Shanafelt T, et al. Ability of the well-being index to identify pharmacists in distress. *J Am Pharm Assoc* 2020;60:906-914.e2.
- Paulson CM, Handley JH, Dilworth TJ, Persells D, Prusi RY, Brummitt CF, Torres KM, **Skrupky LP**. Impact of a systematic pharmacist-initiated antibiotic time-out intervention for hospitalized adults. *J Pharm Pract* 2020 Dec 23. [Epub ahead of print]
- **Smith SE**, Ayers P, **Sikora Newsome A**, et al. Pharmacy perceptions of CliftonStrengths® themes important for success in advanced cardiovascular life support. *J Clin Pharm Ther* 2021;46:143-8.
- **Smith SE**, Finder S, **Sikora Newsome A**, et al. Effect of formal advanced cardiovascular life support training with high-fidelity mannequins on knowledge and confidence of third-year PharmD students. *MedEdPublish* 2020 Nov 19. [Epub ahead of print]
- **Smith SE**, Fuchs M, **Sikora Newsome A**, et al. Clinical controversy over vasopressin in septic shock: a survey of critical care pharmacists [letter]. *Hosp Pharm* 2020 Jul 27. [Epub ahead of print]
- **Smith SE**, **Sikora Newsome A**, Guo Y, et al. A multicenter observational cohort study of angiotensin II in shock. *J Intensive Care Med* 2020 Nov 24. [Epub ahead of print]
- **Smith SE**, Slaughter A, Butler S, **Buckley M**, MacLaren R, **Sikora Newsome A**. Examination of critical care pharmacist work activities and burnout. *J Am Coll Clin Pharm* 2021 Feb 5. [Epub ahead of print]
- Branan TN, **Smith SE**, Phan R, **Sikora Newsome A**, et al. Association of hidden fluid administration with development of fluid overload reveals opportunities for targeted fluid minimization. *Sage Open Med* 2020 Dec 9. [Epub ahead of print]
- Olney WJ, Chase AM, Hannah SA, **Smith SE**, **Sikora Newsome A**. Medication regimen complexity score (MRC-ICU) as an indicator of fluid balance in critically ill patients. *J Pharm Pract* 2021 Mar 9. [Epub ahead of print]
- Schoen RR, **Smith SE**, Ball J, et al. Insight into development of a mentorship program in a professional pharmacy organization. *Curr Pharm Teach Learn* 2020. [In press]
- **Viswesh V**. New antimicrobial agents. In: Murphy JE, Lee MW, eds. *Pharmacotherapy Self-Assessment Program, 2021 Book 1. Infectious Diseases*. Lenexa, KS: American College of Clinical Pharmacy, 2021:7-29.

- **Viswesh V**, Hassell K, Coyne L, et al. Ten tips for successful navigation of promotion and tenure. *Am J Pharm Educ* 2021;85:Article 8414.
- Luu Q, Vitale K, Shan G, Keel-Jayakumar R, **Viswesh V**. Evaluation of guideline recommendations for dual antipseudomonal therapy in hospitalized adults with pneumonia using combination antibiograms. *Pharmacotherapy* 2020;40:1089-98.

#### Presentations

- Scott C, Jayakumar R, Zhu E, **Viswesh V**. Eravacycline versus best previously available therapy in adults with pneumonia due to drug-resistant *Acinetobacter baumannii*. Presented at: ASHP Midyear Clinical Meeting; December 2020; virtual.

#### New Fellows

- **Gretchen Brophy**: MCCM – Master of Critical Care Medicine, American College of Critical Care Medicine.
- **Rachel Krueer**: FCCM – American College of Critical Care Medicine.
- **Andrea Sikora Newsome**: FCCM – American College of Critical Care Medicine.
- **Lee Skrupky**: FCCM – American College of Critical Care Medicine.
- **Lisa Smart-Langerud**: FASHP – American Society of Health-System Pharmacists; FCCP – American College of Chest Physicians.

#### Other Notable Achievements

- **Abdullah Alhammad**: Member, Critical Care and Emergency Medicine Pharmacy Specialty Network, Saudi Society of Clinical Pharmacy. PGY2 Critical Care Residency Program Director, College of Pharmacy-King Saud University Medical City.
- **Kristen Bamberg**: Chair, Board of Pharmacy Specialties, Critical Care Pharmacy Board.
- **Kayla Bardzel**: BCCCP.
- **Aeryana Beaudrie-Nunn**: Secretary, ACCP National Student Network Advisory Committee.
- **Karen Berger**: Member-at-Large, SCCM CPP Section.
- **Chris Droege**: Advisory Board, Subject Matter Expert, National Emergency Telecritical Care Network (NETCCN) for COVID-19, Deloitte Consulting LLP.
- **Christine Groth**: Chair, SCCM CPP Practice Advancement Committee; Past-Chair, ACCP Critical Care PRN Recognition Committee.

- **Leslie Hamilton:**  
Chair-Elect, ACCP Critical Care PRN.  
Vice Chair, ACCP Credentials FCCP Committee.  
Chair, Tennessee Pharmacists Association Awards Committee.
- **Md Jahidul Hasan:**  
Trainer of the national “Facility Management and Leadership Program” (UNFAO, UNFPA, Ministry of Health and Family Affairs, Bangladesh).  
Nominated as Program Coordinator, Infection Prevention and Control Program, Square Hospitals Ltd., Bangladesh.  
Team Leader, Critical Care Pharmacotherapy Research Group, Square Hospitals Ltd.  
Critical Care Clinical Pharmacy Training of Professional Students, Department of Pharmacy, North-South University, Bangladesh.
- **Judi Jacobi:**  
Pharmacy-Based Immunization Delivery certificate, APhA.  
Local county volunteer COVID vaccinator.
- **Christian Kressin:** BCCCP.
- **Yoonsun Mo:** BCCCP, BCPS.
- **Janelle O. Poyant:** CE Presentation with Brianne M. Ritchie: COVID-19: challenges and considerations for pain and sedation management in mechanically ventilated patients with COVID-19. Presented at: ASHP Midyear Clinical Meeting; December 2020.
- **Kaitlin Pruskowski:** BCCCP, BCPS.
- **Melissa Santibañez:**  
Amato M, Benavides S, Gross B, Santibañez M.  
Student perspectives – etiquette tips for virtual interviews and networking during residency season. Invited panelist for ASHP Student Perspectives podcast. October 2020.  
Chair, SCCM Florida Chapter Membership Committee.  
Chair, ACCP Pulmonary PRN Education, Programming, and Communications Committee.
- **Hanady Sharabash:** BCCCP.
- **Lisa Smart-Langerud:** USAF Representative, ASHP.
- **Velliyur Viswesh:** BCCCP, BCIDP.

## Drug Information PRN

### Publications

- **Afanasjeva J**, Burk M, Cunningham F, Fanikos J, **Gabay M**, Hayes G, Masters PL, **Rodriguez R**, et al. ASHP guidelines on medication-use evaluation. *Am J Health Syst Pharm* 2021;78:168-75.
- Bailey AG, **Brown JN**, Hammond JM. Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review. *Support Care Cancer* 2021;27:156-64.

- Compton ALP, Pepin MJ, Katzenberger DR, Kemp DW, **Brown JN**. Vitamin D supplementation during statin rechallenge in patients with a history of intolerance [letter]. *Ann Pharmacother* 2020 Oct 15. [Epub ahead of print]
- **Johnson S, Gosser R, Kier K, Anderson KC, Douglas JS, Heindel GA, Majerczyk D, Manian R, Thornby K**. Formulary management challenges and opportunities: 2020 and beyond – an opinion paper of the Drug Information Practice and Research Network of the American College of Clinical Pharmacy. *J Am Coll Clin Pharm* 2021;4:81-91.
- Hitner H, Nagel B, **Kaufman MB**, et al., eds. *Pharmacology: An Introduction*, 8th ed. New York: McGraw-Hill, 2021.
- **Rodriguez R**, Touchette DR. Part II: Statistics in practice: statistics overview. *J Am Coll Clin Pharm* 2021;3:554-9.
- Miles KE, **Rodriguez R**, Gross AE, et al. Strength of recommendation and quality of evidence for recommendations in current Infectious Diseases Society of America guidelines. *Open Forum Infect Dis* 2021;8:ofab033.
- **Thornby K**, Maksutovic N. A systematic review on the use of sacubitril/valsartan initiated prior to discharge in hospitalized patients with heart failure. *Ann Pharmacother* 2021;55:378-89.
- Dougherty J, Guirguis E, **Thornby K**. A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. *Ann Pharmacother* 2021;55:65-79.

### Presentations

- **Erin Fox:** Management of high-cost drugs – case studies in formulary management. Presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.
- **Mandy Leonard:** Pharmacoeconomic evaluation strategies to support rational formulary decision-making. Presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.
- **Ryan Rodriguez:** Do evidence-based clinical guidelines get a grade? Presented at: American College of Clinical Pharmacy Annual Meeting; October 2020; virtual.

### Other Notable Achievements

- **Amy Howard:** Elected to 4-year term as Representative of the Americas for the Health and Medicines Information Section for the International Pharmaceutical Federation (FIP).

## Education and Training PRN

### Awards

- **Alex Isaacs:** ACCP New Educator Award
- **Mate Soric:** JACCP Editor's Choice Award

### Grants

- **Alex Isaacs:** Purdue Resume Enhancement Program (PREP) for Career Success; Purdue University Office of the Provost Instructional Equipment Grant. Amount: \$55,000.

### Publications

- Al-Haqan A, Al-Taweel D, Kosy S, **Alghanem S.** Evolving to objective structured clinical exams (OSCE): transitional experience in an undergraduate pharmacy program in Kuwait. *Saudi Pharm J* 2021;29:104-13.
- Al Saeedy D, Gillani SW, **Al-Salloum J**, et al. Comparative efficacy of beta-lactams and macrolides in the treatment of pediatric pneumonia: a systematic review. *Curr Pediatr Rev* 2020;16:307-13.
- Gillani SW, Gulam SM, Thomas D, Gebreigziabher FB, **Al-Salloum J**, et al. Role and services of pharmacist in the prevention of medication errors: a systematic review. *Curr Drug Saf* 2020 Oct 2. [Epub ahead of print]
- **Asias-Dinh BD, Garey KW.** Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. *J Am Pharm Assoc* 2021;62:174-80.
- Ford CR, **Astle KN**, Garza KB, et al. Exploring standardized persons' expectations for practice-ready pharmacists. *Curr Pharm Teach Learn* 2021;13:492-9.
- Gonzalez LE, **Boylan PM.** Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review. *Ann Pharmacother* 2020 Nov 4. [Epub ahead of print]
- **Bzowyckyj A.** Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. *J Clin Pharm Ther* 2020;45(suppl 1):7-16.
- **Bzowyckyj AS**, Crabtree B, Franson K, Klepser D, Okere AN, Poirier T, Welch A, Gandhi N, **Ragucci K.** Developing the pharmacist workforce for society's medication use needs in 2030: report of the 2019-2020 AACP Academic Affairs Committee. *Am J Pharm Educ* 2021;84:Article 8203.
- **Dy-Boarman EA, Bryant GA**, Herring MS. Faculty preceptors' strategies for teaching clinical reasoning skills in the advanced pharmacy practice experience (APPE) setting. *Curr Pharm Teach Learn* 2021 Feb 3. [Epub ahead of print]

- **Farland MZ, Childs-Kean LM.** Stop tempting your students to cheat. *Curr Pharm Teach Learn Online* 2021 Feb 3. [Epub ahead of print]
- **Higbea A, Bald E, Isaacs AN, Richter SK, Stamm PL, Kassel LE.** Forging ahead from adaptations of teaching during the COVID-19 pandemic: perspectives from multiple pharmacy programs. *J Am Coll Clin Pharm* 2021;4:101-12.
- **Isaacs AN**, Scott SA, **Nisly SA.** Move out of "Z" way millennials. *Curr Pharm Teach Learn* 2020;12:1387-9.
- Beal JL, Weber ZA, **Isaacs AN**, Plake KS, **Zillich A**, et al. Pharmacy student preferences and perceptions of in-person versus video evaluations in pharmacy skills-based laboratory courses. *Am J Pharm Educ* 2020;85:Article 7976.
- Beckett RD, **Isaacs AN**, Montagano KJ, et al. Perceived value of teaching and learning curriculum programs among pharmacy practice department chairs. *Am J Pharm Educ* 2020;84:Article 7981.
- Kawaguchi-Suzuki M, **Merlo J, White S**, Gibbard R, Ly L, **Bzowyckyj A**, Bojorquez D, **Begert J**, Saito E, **Marcus K.** Health-system introductory pharmacy practice experience as an online course in the United States. *Pharm Educ* 2020;20:11-2.
- Burch A, Owens R, **Nisly SA**, Taylor S. Wellbeing during COVID-19: a social media takeover. *Pharm Educ* 2020;20:272-5.
- Valanejad SM, Davis KA, **Nisly SA.** Outcomes associated with resuming direct oral anticoagulant therapy following admission for a gastrointestinal bleed. *Ann Pharmacother* 2020;54:975-80.
- Ferguson PJ, Lynton J, **Resman-Targoff BH.** Advantages of embedding a specialty pharmacist in a rheumatology clinic. *Rheumatologist* 2020 Nov 12.
- **Skrupky LP, Dy-Boarman EA, Gurgle HE, Isaacs AN**, McCreary EK, **Nisly SA, Paloucek F**, Peterson DM, **Smith A, Schramm GE.** Letters of reference for PGY1 pharmacy residency candidates: a survey of residency program directors and opinion statement. *J Am Coll Clin Pharm* 2020;4:379-89.
- Walkerly A, Neugebauer RE, Misko B, Shively D, Singh S, Chahda B, Dhanireddy S, King K, Lloyd M, Fosnight S, Costello M, Palladino C, **Soric MM.** Prevalence, predictors, and trends of opioid prescribing for lower back pain in United States emergency departments. *J Clin Pharm Ther* 2020 Dec 11. [Epub ahead of print]
- **Steuber TD**, Butler L, Sawyer A, et al. Comparison of blood cultures versus T2Candida panel in management of candidemia at a large community hospital. *Eur J Clin Microbiol Infect Dis* 2021 Jan 2. [Epub ahead of print]

- Muklewicz JD, **Steuber TD**, Edwards JD. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury. *Int J Antimicrob Agents* 2021;57:106234.
- Cho J, Dunn R, **Wallace-Gay T**. Global initiatives to combat antimicrobial resistance. In: Ghazi IM, Cawley MJ, eds. *21st Century Challenges in Antimicrobial Therapy and Stewardship*, *Frontiers in Anti-Infective Agents*, vol 3. Sharjah, United Arab Emirates: Bentham Books, 2020:342-66.

#### Other Notable Achievements

- **Jumana Al-Salloum**: Granted MOHAP Clinical Pharmacist license (first Pharm.D. graduate of Gulf Medical University to be granted the license in UAE).
- **Eliza Dy-Boarman**: Named to *Currents in Pharmacy Teaching and Learning* Editorial Board.

### Emergency Medicine PRN

EMED PRN members have won several prestigious awards and been involved in many publications. The PRN has continued to host journal club webinars from pharmacy residents and students across the country. The monthly journal clubs have continued to host two presenters each month, and attendance has continued to increase. In addition, the Twitter account has remained active with daily tweets and achieved over 3500 followers.

#### Promotions

- **Craig Cocchio**: Associate Editor and Director of Continuing Education, High-Yield Med Reviews.
- **Henry Lederer**: Clinical Pharmacy Coordinator – Emergency Medicine, University of Maryland Baltimore Washington Medical Center.
- **Lance Ray**: Emergency Medicine Residency Program Director and Clinical Specialist, Denver Health.
- **Alicia Sanchez**: Clinical Assistant Professor, University of Georgia College of Pharmacy.

#### Awards

- **Nicole Acquisto**: *Rochester Business Journal's* 40 Under 40. Fellow, American College of Critical Care Medicine.
- **Jimmy Pruitt**: Excellence in Diversity Award, MUSC College of Pharmacy. 2020 SAEM Got Talent 1st Place Winner for Best FOAM Ed Project for Pharmacy Friday Pearls, Society of Academic Emergency Medicine.

- **Megan Rech**: Research Section Congress Scholarship – Pharmacist Avoidance or Reductions in Medical Costs in Critically and Emergently Ill: Pediatrics. Society of Critical Care Medicine. Gold Snapshot Award – Pharmacist Avoidance or Reductions in Medical Costs in Critically and Emergently Ill: Pediatrics. Society of Critical Care Medicine.

#### Grants

- **Faisal Minhaj**: American Academy of Clinical Toxicology Trainee Grant. Amount: \$4000.

#### Publications

- **Acquisto NM**, Coralic Z. In the midst of an opioid epidemic: pharmacists on the frontline of substance use disorder treatment [guest editorial]. *Am J Health Syst Pharm* 2021;78:277-8.
- Lat I, Paciullo C, Daley MJ, MacLaren R, Bolesta S, McCann J, Stollings JL, Gross K, Foos SA, Roberts RJ, **Acquisto NM**, et al. Position paper on critical care pharmacy services: 2020 update. Executive summary. *J Am Coll Clin Pharm* 2020;3:1380-9.
- Morgan MM, Perina DG, **Acquisto NM**, et al. Ketamine use in prehospital and hospital treatment of the acute trauma patient: a joint position statement of the American College of Surgeons Committee on Trauma (ACS-COT), ACEP, National Associate of State EMS Officials (NASEMSO), National Association of EMS Physicians (NAEMSP), and the National Association of EMTs (NAEMT). *Prehosp Emerg Care* 2020 Aug 27. [Epub ahead of print]
- Train MK, Patel N, Thapa K, Pasho M, **Acquisto NM**. Unit-based interdisciplinary team approach to implementing a naloxone prescription upon hospital discharge. *Am J Nurs* 2020;120:48-52.
- **Awad NI**. Disparities in gender distribution within editorial boards of pharmacy journals. *J Am Coll Clin Pharm* 2021 Jan 10. [Epub ahead of print]
- **Awad NI**, Geib AJ, Roy A, **Cocchio C**, et al. Protocol deviations in intravenous acetylcysteine therapy for acetaminophen toxicity. *Am J Emerg Med* 2020;38:830-3.
- Fay L, Rechner-Neven G, Hammond DA, **DeMott JM**, et al. Evaluating the risk of developing thrombocytopenia within five days of continuous renal replacement therapy initiation in septic patients. *J Pharm Pract* 2020 Sept 21. [Epub ahead of print]
- **Gilbert BW**, Bissel BD, Santiago RD, **Rech MA**. Tracing the lines: a review of viscoelastography for emergency medicine clinicians. *J Emerg Med* 2020;59:201-15.

- **Gilbert BW, Rech MA.** An alternative perspective to just halting tranexamic acid utilization in gastrointestinal bleeding. *Am J Emerg Med* 2020. Sep 7. [Epub ahead of print]
- **Gregory H,** Cantley M, Calhoun C, Hall GA, Matuskowitz AJ, **Weant KA.** Incidence of prescription errors in patients discharged from the emergency department. *Am J Emerg Med* 2020 Jul 25. [Epub ahead of print]
- **Kelly GF, Makhoul T,** Zammit CG, Jones CMC, **Acquisto NM.** The accuracy of ICD-CM codes to identify thromboembolic events for clinical outcomes research. *J Am Coll Clin Pharm* 2021;4:40-6.
- Griebe K, Jiang C, To L, Peters M, **MacDonald NC.** Pharmacy emergency preparedness training as a PGY2 longitudinal rotation. *Am J Health Syst Pharm* 2021 Feb 17. [Epub ahead of print]
- **Minhaj FS,** Leonard JB. Dangers of the TikTok Benadryl challenge. *Contemp Pediatr J* 2021;38.
- Leonard JB, **Minhaj FS,** Klein-Schwartz W. An analysis of fatal iatrogenic therapeutic errors reported to United States poison centers. *J Clin Toxicol* 2021;59:53-60.
- **Núñez Cruz S, DeMott JM, Peksa GD, Slocum GW.** Evaluation of blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. *Am J Emerg Med* 2020 Oct 3. [Epub ahead of print]
- Khan AA, Gurnani PK, **Peksa GD,** Whittier WL, **DeMott JM.** Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy. *Ann Pharmacother* 2021;55:277-85.
- **Rech MA,** Horng M, Holzhausen JM, et al. International survey of thrombolytic use for treatment of cardiac arrest due to massive pulmonary embolism. *Crit Care Explor* 2020;2:e0132.
- Adeleye A, Sharp L, **Rech MA.** Neurotoxicity secondary to local tetracaine use. *Am J Emerg Med* 2020;38:1984.e1-1984.e3.
- Bonderski VA, Portillo J, Sharp L, **Rech MA.** Thromboelastometry-guided anticoagulation reversal in a patient with ventricular assist device with intracranial hemorrhage. *Am J Emerg Med* 2021;41:265.e5-265.e8.
- DiCesare MA, **Rech MA, DeMott JM.** Predictors of a response to dexmedetomidine in intubated, critically ill adult patients. *Pharmacotherapy* 2021 Jan 9. [Epub ahead of print]
- Garg R, Knox N, Prasad S, Zinzuwadia S, **Rech MA.** The atherogenic index of plasma is independently associated with symptomatic carotid artery stenosis. *J Stroke Cerebrovasc Dis* 2020;29:105351.
- Hidalgo DC, Amin V, Hukku A, Kutlu K, **Rech MA.** Etomidate use for rapid sequence intubation is not associated with nosocomial infection. *J Pharm Pract* 2020 Dec 11. [Epub ahead of print]
- Lovett S, Reed T, Riggs R, Lew G, Koch E, Durazo-Arvizu RA, **Rech MA.** A randomized, non-inferiority, controlled trial of two doses of intravenous sub-dissociative ketamine for analgesia in the emergency department. *Acad Emerg Med* 2020 Dec 22. [Epub ahead of print]
- Masic D, Kwon O, **Rech MA.** Desmopressin with four-factor prothrombin complex concentrate for life-threatening bleeding: a case series. *Am J Emerg Med* 2020;38:2634-6.
- Sterk E, Hyun BY, **Rech MA.** Comparison of an ED triage sepsis screening tool and qSOFA in identifying CMS SEP-1 patients. *Am J Emerg Med* 2020;38:1995-9.
- Yurukov Y, Boykin T, **Rech MA.** Tranexamic acid for the treatment of acute gastrointestinal bleeding in a Jehovah's Witness patient on apixaban and dual antiplatelet therapy. A case report. *J Emerg Nurs* 2020. [In press]
- **Renzoni AJ, Peksa GD, DeMott JM.** Emergency department methicillin-resistant *Staphylococcus aureus* naive screen effect on pneumonia treatment duration. *Am J Emerg Med* 2021;44:68-71.
- **Schult RF,** Omar D, Gorodetsky RM, Wiegand TJ, **Acquisto NM.** Experience with lower dose flumazenil at an academic medical center. *Am J Emerg Med* 2021 Feb 5. [Epub ahead of print]
- Lowy R, Bodkin RP, **Schult RF,** McCann M, Jones CMC, **Acquisto NM.** Emergency medicine intern education for best practices in opioid prescribing. *West J Emerg Med.* [In press]
- Eswaran V, Allen KC, Bottari DC, **Splawski JA,** et al. Take-home naloxone program implementation: lessons learned from seven Chicago-area hospitals. *Ann Emerg Med* 2020;76:318-27.
- **Weant KA,** Barre SL, Bruner S, et al. Assessment of benzodiazepine dosing strategies for the management of status epilepticus in the emergency department. *Am J Emerg Med* 2021;44:106-11.
- Frederickson JJ, Monroe AK, Hall GA, **Weant KA.** Characterization of emergency department rabies post-exposure prophylaxis procedures with an infectious diseases clinic referral process. *Hosp Pharm* 2020 Nov 24. [Epub ahead of print]
- LaScala EC, Monroe AK, Hall GA, **Weant KA.** Antibiotic prescribing errors in patients discharged from the pediatric emergency department. *Pediatr Emerg Care* 2020 Dec 15. [Epub ahead of print]

## Other Notable Achievements

- **Jennifer Splawski:** Completed an M.S. degree in pharmacy – emphasis in toxicology from the University of Florida.
- **Michael Thomas:** Appointed to BPS Emergency Medicine Pharmacy Specialty Council.

## Endocrine and Metabolism PRN

The Endocrine and Metabolism PRN has had a successful year and is excited to acknowledge members' contributions to the profession of pharmacy through their work!

### Promotions

- **Nicole Albanese:** Assistant Director of Experiential Education, University at Buffalo School of Pharmacy and Pharmaceutical Sciences.
- **Heather Whitley:** Full Clinical Professor, Auburn University Harrison School of Pharmacy.

### Awards

- **Sarah Anderson:** 2020 ACCP Adult Medicine PRN Mentoring Award.
- **Laura Challen:** 2020 Excellence in Innovation, Missouri Pharmacy Association.
- **Lalita Prasad-Reddy:** 2020 Educator of the Year, Illinois Pharmacists Association.
- **Christie Schumacher:** 2020 Diabetes Education Specialist of the Year, Illinois Coordinating Body of ADCES. 2020 Outstanding Faculty of the Year, Midwestern University College of Pharmacy.

### Publications

- **Anderson SL,** Bassetti M, Mangoni AA. Drugs in context editorial: review of 2020 and what lies ahead in therapeutic interventions. *Drugs Context* 2021;10:2020-12-10.
- **Anderson SL,** Bianco J, DeRemer CE. Adapting ambulatory care learning environments in response to the COVID-19 pandemic. *Am J Health Syst Pharm* 2021 Jan 23. [Epub ahead of print]
- **Benjamin T, Schumacher C.** Characterization of risk factors for genitourinary infections with sodium glucose cotransporter-2 inhibitors. *Pharmacotherapy* 2020;40:1002-11.
- **Clements JN,** Emmons RP, **Anderson SL,** Chow M, Coon S, Irwin AN, **Mukherjee M,** et al. Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. *J Am Coll Clin Pharm* 2021;4:390-405.
- **Goldman JD.** Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. *J Clin Pharm Ther* 2020;45:61-72.

- Pass A, Bialonczyk D, Chiquette E, **Goldman JD.** Oral superabsorbent hydrogel (Plenity) for weight management. *Ann Pharmacother* 2020 Dec 21. [Epub ahead of print]
- **Marrs JC, Anderson SL.** Ertugliflozin in the treatment of type 2 diabetes mellitus. *Drugs Context* 2020;9:2020-7-4.
- **Schumacher C, Van Dril E, Shealy K, Goldman JD.** Optimizing management of type 2 diabetes and its complications in patients with heart failure. *Clin Diabetes* 2021;39:105-16.
- Sobeski LM, **Schumacher CA,** Alvarez NA, Anderson KC, Bradley B, Crowe SJ, Merlo JR, Nyame A, Shapiro NL, Rivera KS, Spencer D, **Van Dril E.** Medication access: policy and practice opportunities for pharmacists. *J Am Coll Clin Pharm* 2021;4:113-25.
- **Stauffer R, Pitlick J, Challen L.** Impact of an electronic-based assessment on student pharmacist performance in a required therapeutics course. *Curr Pharm Teach Learn* 2020;12:287-90.
- **Whitley HP,** Smith WD, Hanson C, et al. Interdisciplinary speed dating augments diabetes self-management education and support to improve health outcomes. *Patient Educ Couns* 2020;103:2305-11.
- Gamston CE, Kirby AN, Hansen RA, Redden DT, **Whitley HP,** et al. Comparison of 3 risk factor-based screening tools for the identification of pre-diabetes. *J Am Pharm Assoc (2003)* 2020;60:481-4.

## Geriatrics PRN

### Awards

- **Jeannie Lee:** 2020 University of Arizona Health Sciences Faculty Leadership Award, University of Arizona Health Sciences Office of Equity, Diversity and Inclusion, LGBTQ+ Interest Group.

### Grants

- **Sharon See, Judy Beizer, Sum Lam,** John Conry: Neuropsychiatric Disorders in Older Adults Symposium at St. John's University. Biogen Multinational Biotechnology. Amount: \$20,642.60.

### Publications

- **Clark CM,** Hejna M, Shao E, et al. Knowledge and attitudes of student pharmacists regarding polypharmacy and deprescribing: a cross-sectional study. *Pharmacy (Basel)* 2020;8:220.
- **Clark CM,** Monte SV, Hejna M, et al. Student pharmacist perceptions of the utility of a medication therapy management-based medication related falls risk assessment tool. *Sr Care Pharm* 2020;35:439-45.

- Shaver AL, **Clark CM**, Hejna M, et al. Trends in falls risk increasing drugs (FRIDs) and rate of fatal falls in older adults, 1999-2017. *Pharmacoepidemiol Drug Saf* 2021 Feb 3. [Epub ahead of print]
- Mueller A, **Fixen DR**. Use of cannabis for agitation in patients with dementia. *Sr Care Pharm* 2020;35:312-7.
- Pearson SM, Tandon A, **Fixen DR**, et al. Pharmacist-led transition of care pilot targeting older people after emergency department discharge. *Sr Care Pharm* 2020;35:273-82.
- Snellings MS, Linnebur SA, Pearson SM, Wallace JI, Saseen JJ, **Fixen DR**. Effectiveness of methenamine for UTI prevention in older adults. *Ann Pharmacother* 2020;54:359-63.
- **Jacob E**. Understanding the neurological manifestations of COVID-19. *US Pharm* 2021;46:33-41.
- Hitner H, Nagel B, **Kaufman MB**, et al. *Pharmacology: An Introduction*, 8th ed. New York: McGraw-Hill, 2022. [Available February 2021]
- **Lisi DM**. Population health and social determinants of health in diabetes management. *US Pharm* 2020;45(11):34-44.
- **Lisi DM**. Epigenetics and pharmacoepigenetics – fine tuning precision medicine. *US Pharm* 2020;45(10):34-44.
- **Lisi DM**. Assessing anticholinergic effects in older adults. In: *Geriatrics*. London: IntechOpen, 2020.
- Bhattacharjee B, Naeem S, Knapp S, **Lee J**, et al. Health outcomes associated with adherence to antidepressant use during acute and continuation phases of depression treatment among older adults with dementia and major depressive disorder. *J Clin Med* 2020;9:3358.
- Nakanishi M, Mizuno T, Mizokami F, Koseki T, Takahashi K, Tsuboi N, Katz M, **Lee J**, et al. Impact of pharmacist intervention for blood pressure control in patients with chronic kidney disease: a meta-analysis of randomized clinical trials. *J Clin Pharm Ther* 2021;46:114-20.
- **Lee JK**, Davis S. Gastroesophageal reflux disease. In: Katz MD, Matthias KR, eds. *Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach*, 5th ed. New York: McGraw-Hill, 2020.
- **Lee JK**, McCutcheon LRM, Fazel MT, et al. Assessment of interprofessional collaborative practices and outcomes in adults with diabetes and hypertension in primary care: a systematic review and meta-analysis. *JAMA Netw Open* 2021;4:e2036725.
- **Lee JK**, Quelland D. Dyslipidemia. In: Katz MD, Matthias KR, eds. *Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach*, 5th ed. New York: McGraw-Hill, 2020.

- Brooks A, Chen MK, Goldblatt E, Klatt M, Kligler B, Koithan M, Kreitzer MJ, **Lee JK**, et al. Introducing integrative primary health care to an interprofessional audience: feasibility and impact of an asynchronous online course. *Explore (NY)* 2020;16:392-400.
- Vadie N, Howe C, Zerr B, Ladziak N, Fain M, **Lee JK**. Psychotropic medication use patterns in home-based primary care: a scoping review. *Ment Health Clin* 2020;10:282-90.

## GI/Liver/Nutrition PRN

The GI/Liver/Nutrition PRN would like to congratulate its members for their inspiring accomplishments this past year! We are continuing to explore new ways to engage members on our social media platforms, including Twitter (@accpGILNprn) and Facebook ([ACCP GI/Liver/Nutrition PRN](#)). Please contact us if you have new ideas for how the PRN can serve your professional interests!

### Promotions

- **Kevin Wissman**: Ambulatory Care GI Pharmacist, University of Kansas School of Medicine.

### Publications

- **Martin MT**, Patel S, Kulik L, et al. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. *J Hepatol* 2021 Feb 27. [Epub ahead of print]
- Choi D, **Martin MT**, Chacra W, et al. Practical considerations when treating chronic hepatitis E in solid organ transplant recipients. *Int J Clin Pharm* 2020 Nov 9. [Epub ahead of print]
- Lin J, Mauntel-Medici C, Maheswaran AB, Baghikar S, Pugach O, Stein EM, **Martin MT**, et al. Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor. *J Public Health* 2021 Feb 5. [Epub ahead of print]
- Nabulsi N, **Martin MT**, Sharp LK, et al. Predicting treatment failure for initiators of hepatitis C virus treatment in the era of direct-acting antiviral therapy. *Front Pharmacol* 2020;11:551500.

## Global Health PRN

### Promotions

- **Clarissa-Cecile Wu**:  
Incoming PGY1 Resident at Crow/Northern Cheyenne Hospital (Indian Health Service).  
Pending Lieutenant at USPHS Commissioned Corps.

## Awards

- **Ellen Schellhase, Rakhi Karwa, Sonak Pastakia**, et al. Purdue Kenya Partnership. 2020 AACP Global Education SIG Outstanding Program Award.

## Grants

- **Sonak Pastakia**: (Co-PI) Peers and Technology for Adherence (PT4A). Source: National Heart, Lung, and Blood Institute (NHLBI) r56. Amount: \$500,000.

## Publications

- **Drame I**, Seo S, **Connor S**, Kahaleh A, **Jonkman L**, **Schellhase E**, et al. Ethical approaches to funding global health research projects. *Res Social Adm Pharm* 2020;16:1588-96.
- van den Bergh D, Messina A, **Goff DA**, et al. A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa. *Int J Antimicrob Agents* 2020;56:106189.
- **Karwa R**, Miller ML, **Schellhase E**, **Tran DN**, Manji I, Njuguna B, Fletcher S, Kanyi J, Maina M, Jakait B, Kigen G, Kipyegon V, Aruasa W, **Crowe S**, **Pastakia SD**, et al. Evaluating the impact of a 15-year academic partnership to promote sustainable engagement, education, and scholarship in global health. *J Am Coll Clin Pharm* 2020;3:885-96.
- Chang AY, Mungai M, Coates SJ, Chao T, Odhiambo HP, Were PM, Fletcher SL, Maurer T, **Karwa R**, **Pastakia SD**. Implementing a locally made low-cost intervention for wound and lymphedema care in western Kenya. *Dermatol Clin* 2021;39:91-100.
- Seo SW, Ombengi D, Sultan D, Kahaleh A, Nonyel N, **Karwa R**, Abrons J, Lukas S, Singhal M, Miller ML, **Truong HA**. An ethics-based approach to global health research part 1: building ethical partnerships in global health. *Res Social Adm Pharm* 2020;16:1574-9.
- Genberg B, Gallaraga O, Wachira J, **Pastakia SD**, et al. Integrated community-based HIV and non-communicable disease care within microfinance groups in Kenya: study protocol for the Harambee randomized controlled trial. *BMJ Open*. [In press]
- Njuguna BN, Fletcher SL, Akwanalo C, Asante KP, Baumann A, Brown A, Davila-Roman VG, Dickhaus J, Fort M, Iwelunmor J, Irazola V, Mohan S, Mutabazi V, Newsome B, Ogedegbe O, **Pastakia SD**, et al. Proactive prevention: act now to disrupt the impending non-communicable disease crisis in low-burden populations. *PLoS One* 2020;15:e0243004.
- **Schellhase EM**, Hendricks S, Hasan I, et al. Integration of intercultural learning into an

international advanced pharmacy practice experience in London, England. *Pharmacy* 2021;9:37.

- **Schellhase EM**, Miller ML, Malhotra JV, et al. Development of a Global Health Learning Progression (GHELP) model. *Pharmacy* 2020;9:E2.
- Miller ML, **Schellhase EM**, **Karwa R**, **Kimani S**, **Pastakia SD**, et al. Global service learning: a unique educational pathway for community engagement and student scholarship development. *J Am Coll Clin Pharm* 2021;4:203-10.
- Welles C, Steeb D, Miller M, **Schellhase E**. Creating global health leaders in pharmacy by evolving postgraduate training. *Res Social Adm Pharm* 2020;16:1622-5.
- **Tran DN**, Manji I, Njuguna B, Amisi J, Kibet P, **Pastakia SD**, et al. Preserving the supply of essential medicines in rural western Kenya during COVID-19: adjusting supply chain strategies to meet the challenges. *Bull WHO* 2021:BLT.20.271593.
- **Tran DN**, Manji I, Njuguna B, Kamano J, Laktabai J, Tonui E, Vedanthan R, **Pastakia SD**. Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. *BMJ Global Health* 2020;5:e003116.
- **Tran DN**, Manji I, **Schellhase E**, **Karwa R**, Miller ML, Aruasa W, Khan Z, **Pastakia SD**. Framework and case study for establishing impactful global health programs through academia-biopharmaceutical industry partnerships. *Res Social Adm Pharm* 2020;16:1519-25.

## Other Notable Achievements

- **Debra Goff**: Invited expert to the World Health Organization (WHO) Policy Guidance on Integrated Antimicrobial Stewardship Activities in Human Health, working group.

## Health Outcomes PRN

### Publications

- **Adeoye-Olatunde OA**, Lake LM, Strohmier CA, Gourley AK, Ray AR, Zillich AJ, **Snyder ME**. Positive deviants for medication therapy management: a mixed-methods comparative case study of community pharmacy practices. *Res Social Adm Pharm* 2020 Oct 28. [Epub ahead of print]
- **Snyder ME**, **Adeoye-Olatunde OA**, Gernant SA, et al. A user-centered evaluation of medication therapy management alerts for community pharmacists: recommendations to improve usability and usefulness. *Res Social Adm Pharm* 2020 Nov 4. [Epub ahead of print]



## Hematology/Oncology PRN

### Promotions

- **Eve Carciofi:** ACCP-SCCP Chapter President at Western New England University College of Pharmacy and Health Sciences.
- **Onyebuchi (Onye) Ononogbu:** Research Assistant Professor at the University of Houston College of Pharmacy.

### Awards

- **Katie S. Gatwood:** New Practitioner Award, Pharmacy Special Interest Group of the American Society for Transplantation and Cellular Therapy.
- **Donald C. Moore:** 40 Under 40 in Cancer Award 2020 from the National Community Oncology Dispensing Association.

### Publications

- Muz B, **Abdelghafer A**, Markovic M, et al. Targeting E-selectin to tackle cancer using uproleselan. *Cancers (Basel)* 2021;13:335.
- **Arnall JR**, Tran T, Elmes J, Downing L, DiSogra K, **Moore DC**. Comparative utilization and efficacy of thrombopoietin receptor agonists in relapsed/refractory immune thrombocytopenia. *Am J Ther* 2021 Jan 8. [Epub ahead of print]
- DiSogra K, Thuy T, **Arnall JR**, Janes A, **Moore DC**, et al. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. *J Oncol Pharm Pract* 2020 Oct 27. [Epub ahead of print]
- May HP, **Bartoo GT**, Wolf RC, et al. Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: a pilot study. *J Oncol Pharm Pract* 2021 Feb 16. [Epub ahead of print]
- Behbahany K, **Bubalo J**. Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules – a report of two cases and a solution. *J Oncol Pharm Pract* 2020 Oct 25. [Epub ahead of print]
- Hanna KS, **Campbell M**, Kolling A, et al. Updates in the management and future landscape of urothelial carcinoma. *J Oncol Pharm Pract* 2021;27:435-44.
- **Carciofi EE**, Kinney S, Whitman A. Student and faculty perception of an integrated therapeutics course in a doctor of pharmacy program. *Curr Pharm Teach Learn* 2021. [In press]
- Chan RJ, Howell D, Lustberg MB, Mustian K, Koczwara B, Ng CC, Kim Y, Nápoles AM, Dixit N, Klemanski D, Ke Y, Toh YL, Fitch MI, Crichton M, Agarawal S, **Chan A**. Advances and future

directions in the use of mobile health in supportive cancer care: proceedings of the 2019 MASCC Annual Meeting Symposium. *Support Care Cancer* 2020;28:4059-67.

- Mayo SJ, Lustberg M, Dhillon HM, Nakamura ZM, Allen DH, Von Ah D, Janelins MC, **Chan A**, et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. *Support Care Cancer* 2020 Nov 24. [Epub ahead of print]
- Tan CJ, Ke Y, Ng T, Tan IMJ, Goh WL, Poon E, Farid M, Neo PSH, Srilatha B, **Chan A**. Work- and insurance-related issues among Asian adolescent and young-adult cancer survivors: a qualitative study. *Support Care Cancer* 2020;28:5901-9.
- Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, Suzuki O, Ptachcinski JR, Armistead PM, Wiltshire T, Mager DE, Weiner DL, **Crona DJ**. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. *Clin Transl Sci* 2021 Jan 27. [Epub ahead of print]
- Zhu J, Pasternak AL, **Crona DJ**. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know? *Pharmacogenomics* 2020;21:1061-4.
- Murdock JL, **Duco MR**, Reeves DJ. Tolerability of highly protein bound targeted oral oncolytic drugs in patients with hypoalbuminemia: a retrospective analysis. *Ann Pharmacother* 2021;55:165-73.
- **Economou CJP**, Ordoñez J, Wallis SC, et al. Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. *Int J Antimicrob Agents* 2020;56:106058.
- Dougherty JA, **Elder CT**. Managing multiple myeloma in the face of drug-induced adverse drug reaction. *J Pharm Pract* 2020 Dec 15. [Epub ahead of print]
- White KE, **Elder CT**. Saddle pulmonary embolism with fluorouracil: a case report. *J Oncol Pharm Pract* 2020;26:1769-73.
- Bossaer JB, **Eskens D**, Gardner A. Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics. *J Oncol Pharm Pract* 2021 Jan 12. [Epub ahead of print]
- Aebersold ML, Kraft S, **Farris KB**, et al. Evaluation of an interprofessional training program to improve cancer drug therapy safety. *JCO Oncol Pract* 2021 Feb 12. [Epub ahead of print]

- Coe AB, Adeoye-Olatunde OA, Pestka DL, Snyder ME, Zillich AJ, **Farris KB**, et al. Patterns and predictors of older adult Medicare Part D beneficiaries' receipt of medication therapy management. *Res Social Adm Pharm* 2020;16:1208-14.
- Coe AB, Choe HM, Diez HL, Rockey NG, Ashjian EJ, Dorsch MP, Kim HM, **Farris KB**. Effectiveness of four methods for preparing root canals: a scanning electron microscopic evaluation. *J Endod* 1988;14:340-5.
- Lester CA, Coe AB, Dorsch MP, **Farris KB**, et al. A learning pharmacy practice enabled by the pharmacists' patient care process. *J Am Pharm Assoc (2003)* 2020;60:e66-e72.
- Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, Syverson JG, Etz RS, Vangipuram K, Barker MR, Henry NL, **Farris KB**, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. *Support Care Cancer* 2020;28:4163-72.
- Vordenberg SE, Hayes L, Hermiz N, Iong SI, Kuhlman K, Lammers M, Linton JA, **Farris KB**. Older adults' understanding of hypothetical community pharmacy quality report cards. *J Am Pharm Assoc (2003)* 2020;60:e252-e263.
- Andrade DC, **Fatakhova M**, Fatteh S, et al. A case of successful acyclovir desensitization in a bone marrow transplant patient. *J Oncol Pharm Pract* 2020 Sep 21. [Epub ahead of print]
- Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, **Figg WD**, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. *J Clin Oncol* 2020;38:3672-84.
- Beedie SL, Huang PA, Harris EM, Strobe JD, Mahony C, Chau CH, Vargesson N, **Figg WD**. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. *FASEB J* 2020;34:11395-404.
- Chau V, Madan RA, **Figg WD**. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. *Cancer Biol Ther* 2020;21:884-7.
- Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, **Figg WD**, et al. Slow-, tight-binding inhibition of CYP17a1 by abiraterone redefines its kinetic selectivity and dosing regimen. *J Pharmacol Exp Ther* 2020;374:438-51.
- Curtis LM, Ostojic A, Venzon DJ, Holtzman NG, Pirsil F, Kuzmina ZJ, Baird K, Rose JJ, Cowen EW, Mays JW, Mitchell SA, Parsons-Wandell L, Joe GO, Comis LE, Berger A, Pusic I, Peer CJ, **Figg WD**, et al. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. *Blood* 2021;137:896-907.
- Flegel WA, Srivastava K, Sissung TM, Goldspiel BR, **Figg WD**. Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes. *Vox Sang* 2021;116:141-54.
- Fontaine SD, Ashley GW, Houghton PJ, Kurmasheva RT, Diolaiti M, Ashworth A, Peer CJ, Nguyen R, **Figg WD**, et al. A very long-acting poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models. *Cancer Res* 2020 Dec 15. [Epub ahead of print]
- Handy WF, Schmidt KT, Price DK, **Figg WD**. Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. *Cancer Biol Ther* 2020;21:782-4.
- Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, **Figg WD**, Niederfellner G, Méresse Naegelen V, Pastan I. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. *Cancer* 2020;126:4936-47.
- Heim C, Maiwald S, Steinebach C, Collins MK, Strobe J, Chau CH, **Figg WD**, et al. On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. *Biochem Biophys Res Commun* 2021;534:67-72.
- Kazandjian D, Dew A, Hill E, Ramirez EG, Morrison C, Mena E, Lindenberg L, Yuan C, Maric I, Wang HW, Calvo K, Dulau-Florea A, Roswarski J, Emanuel M, Braylan R, Turkbey B, Choyke P, Camphausen K, Stetler-Stevenson M, Steinberg SM, **Figg WD**, et al. Avelumab, a PD-L1 inhibitor, in combination with hypofractionated radiotherapy and the abscopal effect in relapsed refractory multiple myeloma. *Oncologist* 2021 Feb 8. [Epub ahead of print]
- Lester McCully CM, Rodgers LT, Garica RC, Thomas ML, Peer CJ, **Figg WD**, et al. Flow rate and apparent volume of cerebrospinal fluid in rhesus macaques (*Macaca mulatta*) based on the pharmacokinetics of intrathecally administered inulin. *Comp Med* 2020;70:526-31.
- Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee

- S, Steinberg SM, Gulley JL, **Figg WD**, et al. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. *BJU Int* 2020 Sep 24. [Epub ahead of print]
- Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, Singh H, Arlen PM, Theoret MR, Marté JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, **Figg WD**, et al. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. *J Immunother Cancer* 2021;9:e001556.
  - Peach ML, Beedie SL, Chau CH, Collins MK, Markolovic S, Luo W, Tweedie D, Steinebach C, Greig NH, Gütschow M, Vargesson N, Nicklaus MC, **Figg WD**. Antiangiogenic activity and in silico cereblon binding analysis of novel thalidomide analogs. *Molecules* 2020;25:5683.
  - Peer CJ, Goldstein DA, Goodell JC, Nguyen R, **Figg WD**, et al. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. *Br J Clin Pharmacol* 2020;86:1769-77.
  - Risdon EN, Chau CH, Price DK, Sartor O, **Figg WD**. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. *Oncologist* 2021;26:e115-e129.
  - Ross C, Szczepanek K, Lee M, Yang H, Peer CJ, Kindrick J, Shankarappa P, Lin ZW, Sanford JD, **Figg WD**, et al. Metastasis-specific gene expression in autochthonous and allograft mouse mammary tumor models: stratification and identification of targetable signatures. *Mol Cancer Res* 2020;18:1278-89.
  - Schmidt KT, Huitema ADR, Dorlo TPC, Peer CJ, Cordes LM, Sciuto L, Wroblewski S, Pommier Y, Madan RA, Thomas A, **Figg WD**. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. *Cancer Chemother Pharmacol* 2020;86:475-86.
  - Sissung TM, Cordes L, Peer CJ, Gandhi S, Redman J, Strauss J, **Figg WD**. Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in *DPYD*. *Pharmacogenomics* 2021;22:81-5.
  - Sissung TM, **Figg WD**. Facebook groups for alternative treatments for cancer: advertising masquerading as community support. *Lancet Oncol* 2021;22:25-6.
  - Strobe JD, Chau CH, **Figg WD**. Are sex discordant outcomes in COVID-19 related to sex hormones? *Semin Oncol* 2020;47:335-40.
  - Strobe JD, Lochrin SE, Sissung TM, Kem R, Chandrasekaran P, Sharon E, Price DK, Uldrick TS, Yarchoan R, **Figg WD**. Drug-drug interactions in patients with HIV and cancer in Sub-Saharan Africa. *AIDS Rev* 2020;23:13-27.
  - Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, **Figg WD**, et al. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. *Sci Transl Med* 2021;13:eabc7488.
  - Wei BR, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, Yang H, Lee M, Peat TJ, **Figg WD**, et al. Efficacy, tolerability and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma. *Mol Cancer Ther* 2020 Sep 17. [Epub ahead of print]
  - Schmidt KT, Chau CH, Strobe JD, Huitema ADR, Sissung TM, Price DK, **Figg WD**. Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models. *Mol Cancer Ther* 2021 Feb 25. [Epub ahead of print]
  - Mangan B, Culos KA, **Gatwood KS**, et al. New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide. *Eur J Haematol* 2020;1:586-80.
  - **Glode A**, May M. Immune checkpoint inhibitors: significant advancements in non-small cell lung cancer treatment. *Am J Health Syst Pharm* 2021 Feb 13. [Epub ahead of print]
  - Gamble M, Carroll E, Wright GC, **Glode AE**. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: a retrospective analysis from a large academic medical center. *J Oncol Pharm Pract* 2020;26:1964-9.
  - Lower EE, Sturdivant M, **Grate L**, Baughman RP. Use of third-line therapies in advanced sarcoidosis. *Clin Exp Rheumatol* 2020;38:834-40.
  - Green DM, Wang M, Krasin M, Srivastava D, Onder S, Jay DW, Ness KK, **Greene W**, et al. Kidney function after treatment for childhood cancer: a report from the St. Jude Lifetime Cohort Study. *J Am Soc Nephrol* 2021 Mar 2. [Epub ahead of print]
  - **Gregornik D**, Salyakina D, Brown M, et al. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium. *Pharmacogenomics J* 2021;21:8-19.

- Wake DT, Bell GC, **Gregornik DB**, et al. Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison. *Pharmacogenomics* 2021;22:165-76.
- Ragoonanan D, Khazal S, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, **Gulbis AM**, et al. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. *Nat Rev Clin Oncol* 2021 Feb 19. [Epub ahead of print]
- Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, **Gulbis AM**, et al. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. *J Immunother Cancer* 2021;9:e001818.
- Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, **Haidar CE**, et al. Clinical Pharmacogenetics Implementation Consortium guideline for *CYP2D6*, *OPRM1*, and *COMT* genotypes and select opioid therapy. *Clin Pharmacol Ther* 2021 Jan 2. [Epub ahead of print]
- Howard Sharp KM, Jurbergs N, Ouma A, Harrison L, Gerhardt E, Taylor L, Hamilton K, McGee RB, Nuccio R, Quinn E, Hines-Dowell S, Kesserwan C, Sunkara A, Gattuso JS, Pritchard M, Mandrell B, Relling MV, **Haidar CE**, et al. Factors associated with declining to participate in a pediatric oncology next generation sequencing study. *JCO Precis Oncol* 2020;4:202-11.
- Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, **Halloran M**, et al. Real-world practice patterns and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. *Future Oncol* 2021;17:411-22.
- Kachur E, Roshdy D, **Hamadeh I**, et al. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients. *Transpl Infect Dis* 2020 Nov 10. [Epub ahead of print]
- Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos J, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker LE, Fonseca G, Sitlinger A, **Hamadeh IS**, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K $\delta$  inhibitor therapy. *Blood* 2020 Dec 1. [Epub ahead of print]
- Patel JN, **Hamadeh IS**. Pharmacogenomics-guided opioid management. *BMJ Support Palliat Care* 2020;10:374-8.
- Patel JN, Voora D, Bell G, Bates J, Cipriani A, Bendz L, Frick A, **Hamadeh I**, et al. North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. *Pharmacogenomics* 2021;22:73-80.
- Paul B, **Hamadeh I**, Atrash S, et al. Daratumumab subcutaneous formulation for the treatment of multiple myeloma. *Expert Opin Biol Ther* 2020;20:1253-9.
- Ferguson MJ, Ivanovich J, Stansell P, Vik TA, **Helvie AE**, et al. Previously unreported somatic variants in two patients with pleuropulmonary blastoma with metastatic brain recurrence. *Pediatr Blood Cancer* 2021;68:e28825.
- Reece SM, **Holle L**, Mukherjee K. Survey of pharmacists' knowledge of Connecticut's medical cannabis program. *Cannabis Cannabinoid Res* 2021;6:66-73.
- **Hwang GS**, Paranjpe R, **Opsomer C**, et al. Oral endocrine therapy agent, race/ethnicity, and time on therapy predict adherence in breast cancer patients in a large academic institution. *Clin Breast Cancer* 2020;20:520-6.
- **Ice LL**, **Bartoo GT**, McCullough KB, et al. A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients. *Biol Blood Marrow Transplant* 2020;26:1627-34.
- Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, **Kloth DD**, et al. Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. *J Natl Compr Canc Netw* 2020 Sep 1. [Epub ahead of print]
- Burkeen G, Chauhan A, Agrawal R, Raiker R, **Kolesar J**, et al. Gynecologic large cell neuroendocrine carcinoma: a review. *Rare Tumors* 2020;12:2036361320968401.
- Myint ZW, Momo HD, Otto DE, Yan D, Wang P, **Kolesar JM**. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3:e2025826.
- Chilimuri S, Sun H, Alemam A, Kang KS, **Lao P**, et al. Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study. *J Clin Pharm Ther* 2021;46:440-6.
- Hassani Najafabadi A, Zhang J, Aikins ME, Najaf Abadi ZI, Liao F, Qin Y, Okeke EB, Scheetz LM, Nam J, Xu Y, Adams D, **Lester P**, et al. Cancer

- immunotherapy via targeting cancer stem cells using vaccine nanodiscs. *Nano Lett* 2020;20:7783-92.
- **Macdonald C**, Mazza D, Hickey M, et al. Motivators of inappropriate ovarian cancer screening: a survey of women and their clinicians. *JNCI Cancer Spectr* 2020;5:pkaa110.
  - **Macdonald C**, Saunders CM, Keogh LA, et al. Breast cancer chemoprevention: use and views of Australian women and their clinicians. *Cancer Prev Res (Phila)* 2020 Oct 28. [Epub ahead of print]
  - Yousefpouran S, Mostafaei S, **Manesh PV**, et al. The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV co-infection and elite controllers for determination of biomarker. *Microb Pathog* 2020;147:104355.
  - Rodriguez Llorian E, **Mann J**. Data on medical technology: a new set of variables. *Data Brief* 2020;30:105534.
  - Messinger YH, **Maxa KL**, Hennen EM, et al. Intrathecal methotrexate containing the preservative benzyl alcohol erroneously administered in pediatric leukemia patients: clinical course and preventive process. *J Pediatr Pharmacol Ther* 2020;25:328-31.
  - Mangan BL, **McAlister RK**, Balko JM, et al. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. *Br J Clin Pharmacol* 2020;86:1778-89.
  - Bednall R, White S, **Mills E**, et al. Validation of a hospital clinical pharmacy workforce calculator: a methodology for pharmacy? *Int J Clin Pract* 2020 Dec 10. [Epub ahead of print]
  - **Moore DC**, **Arnall JR**, **Thompson DL**, et al. Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab. *Clin Lymphoma Myeloma Leuk* 2020;20:e777-e781.
  - **Moore DC**, Gebru T, Plesca D. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. *J Oncol Pharm Pract* 2020 Dec 9. [Epub ahead of print]
  - **Moore DC**, Nelson V, Muslimani A. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. *Ann Hematol* 2020 Oct 1. [Epub ahead of print]
  - Hamadeh IS, **Moore DC**, Martin A, et al. Transition from intravenous to subcutaneous daratumumab in clinical practice. *Clin Lymphoma Myeloma Leuk* 2021 Mar 4. [Epub ahead of print]
  - Lee A, Larck C, **Moore DC**. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. *J Oncol Pharm Pract* 2020 Dec 26. [Epub ahead of print]
  - Kutzke JL, Leung JG, May HP, **Nedved AN**, et al. Successful continuation of clozapine in conjunction with chimeric antigen receptor T-cell (CAR-T) immunotherapy: case report. *Clin Lymphoma Myeloma Leuk* 2021;21:e194-e197.
  - Nguyen TV, **Ononogbu OJ**, Egwim OU, et al. Reducing chemotherapy administration time on an inpatient oncology unit. *J Oncol Pharm Pract* 2020 Nov 12. [Epub ahead of print]
  - Wiele A, Nguyen T, **Ononogbu O**. Reducing the wait time to initiate inpatient chemotherapy at Lyndon B. Johnson Hospital [abstract]. *J Clin Oncol* 2020;38(suppl):210.
  - **Pawloski PA**, McDermott CL, Marshall JH, et al. Descriptive analysis of first-cycle prophylactic use of G-CSF in patients with breast or lung cancer treated with high neutropenia risk chemotherapy: results from the BBCIC Distributed Research Network. *J Natl Compr Cancer Netw*. [In press]
  - Mendelsohn AB, Marshall J, McDermott CL, **Pawloski PA**, et al. Patient characteristics and utilization patterns of short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilars compared to their reference product. *Drugs Real World Outcomes* 2021 Jan 30. [Epub ahead of print]
  - Evoy KE, **Roccograndi L**, Le S, et al. National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. *J Subst Abuse Treat* 2020;119:108141.
  - Bright D, Langerveld A, DeVuyst-Miller S, **Saadeh C**, et al. Identification of a sex-stratified genetic algorithm for opioid addiction risk. *Pharmacogenomics J* 2021 Feb 15. [Epub ahead of print]
  - Bright D, **Saadeh C**, DeVuyst-Miller S, et al. Pharmacist consult reports to support pharmacogenomics report interpretation. *Pharmacogenomics Pers Med* 2020;13:719-24.
  - Alsultan MM, Hincapie AL, **Schwartz R**, et al. Healthcare services expenditures among prostate cancer patients with and without mood disorders in the United States: a propensity score-matched cross-sectional study. *J Psychosoc Oncol* 2021;39:204-18.
  - Lee BJ, Vu BN, **Seddon AN**, et al. Treatment considerations for CNS infections caused by vancomycin-resistant *Enterococcus faecium*: a focused review of linezolid and daptomycin. *Ann Pharmacother* 2020;54:1243-51.
  - Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N,

- Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, **Seddon AN**, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. *Blood* 2020;136:1134-43.
- Lee CW, Lo YT, Devi S, **Seo Y**, et al. Gender differences in preoperative opioid use in spine surgery patients: a systematic review and meta-analysis. *Pain Med* 2020;21:3292-300.
  - Lo YT, Lim-Watson M, **Seo Y**, et al. Long-term opioid prescriptions after spine surgery: a meta-analysis of prevalence and risk factors. *World Neurosurg* 2020;141:e894-e920.
  - **Sewell JH**, Williams L, McKnight E, et al. What is the role of andexanet alfa in the reversal of anticoagulant effects? *JAAPA* 2021;34:8-9.
  - **Shaghghi Z**, Alvandi M, Nosrati S, et al. Potential utility of peptides against damage induced by ionizing radiation. *Future Oncol* 2021;17:1219-35.
  - Shahsavari S, **Shaghghi Z**, Abedi SM, et al. Evaluation of  $^{99m}\text{Tc}$ -HYNIC-(ser)<sub>3</sub>-LTVPWY peptide for glioblastoma imaging. *Int J Radiat Biol* 2020;96:502-9.
  - Gregory GP, Carrington C, Cheah CY, Hawkes EA, Irving IM, **Siderov J**, et al. A consensus statement on the use of biosimilar medicines in hematology in Australia. *Asia Pac J Clin Oncol* 2020;16:211-21.
  - Weddle KJ, Kiel PJ, Crawford BS, Gass MJ, **Smith JA**. Virtually there: an innovative approach for training oncology pharmacy residents in gynecologic oncology. *J Am Pharm Assoc (2003)* 2020;60:e319-e323.
  - Szewczyk MT, **Soefje SA**. Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration. *Am J Health Syst Pharm* 2021;78:60-4.
  - Ruplin AT, **Spengler AMZ**, Montgomery RB, et al. Downstaging of muscle-invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single regimens or as switch therapy modalities. *Clin Genitourin Cancer* 2020;18:e557-e562.
  - Tran RJC, Yamzon J, **Stewart TL**, et al. Effectiveness of telepharmacy versus face-to-face anticoagulation services in the ambulatory care setting: a systematic review and meta-analysis. *Ann Pharmacother* 2020 Dec 31. [Epub ahead of print]
  - Hanna KS, Campbell M, Kolling A, Husak A, **Sturm S**, et al. Updates in the management and future landscape of urothelial carcinoma. *J Oncol Pharm Pract* 2021;27:435-44.
  - **Sugidono M**, Lo M, Young R, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults. *Transplant Cell Ther (TCT) – ASTCT*. 2021 Jan 6. [Epub ahead of print]
  - Kutzke JL, Merten JA, **Taraba JL**, et al. Risk of relapse in patients receiving azithromycin after allogeneic HSCT. *Bone Marrow Transplant* 2020 Oct 31. [Epub ahead of print]
  - **Taylor B**, Patel MP, Peters KB. When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis. *CNS Oncol* 2021 Jan 15. [Epub ahead of print]
  - Yerram P, **Thackray J**, Modelevsky L, Land J, Reiss S, Spatz KH, Levoir AC, Pak TK, Dao PH, Buege MJ, Derespiris LM, Lau C, Orozco JS, Boparai M, Koranteng LA, Reichert KE, Yan SQ, Daukshus NP, Mathew S, **Buie LW**, et al. Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City. *J Oncol Pharm Pract* 2021;27:389-94.
  - **Tossey JC**, El Boghdady Z, Reed EE, et al. Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients. *Support Care Cancer* 2021 Feb 16. [Epub ahead of print]
  - Fusco MJ, West HJ, **Walko CM**. Tumor mutation burden and cancer treatment. *JAMA Oncol* 2021;7:316.
  - Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, **Walko CM**, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: results from a phase 1 study. *Neuro Oncol* 2020 Nov 11. [Epub ahead of print]
  - Seligson ND, Knepper TC, Ragg S, **Walko CM**. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. *Clin Pharmacol Ther* 2021;109:334-42.
  - **Weddle KJ**, Kiel PJ, Crawford BS, et al. Virtually there: an innovative approach for training oncology pharmacy residents in gynecologic oncology. *J Am Pharm Assoc (2003)* 2020;60:e319-e323.
  - Dierckes SJ, Ragsdale ME, Macik MR, **Weddle KJ**. Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI). *J Oncol Pharm Pract* 2020 Dec 10. [Epub ahead of print]
  - Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, **Wojenski D**, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. *Blood* 2020;136:1134-43.

#### Presentations

- **Hwang GS**, Szabatura A, Leblebjian H, et al. Prevention of venous thromboembolism in patients

with multiple myeloma receiving immunomodulatory therapy: real-world examination of the impede study. Poster presented at: 62nd ASH Annual Meeting and Exposition; December 2020; virtual.

### Other Notable Achievements

- **Onyebuchi (Onye) Ononogbu:** Co-Founder and Chief Program Officer of the Pharmacy Initiative Leaders, Inc. (PILs).
- **Tania Stewart:** Chair of the California Society of Health-System Pharmacists (CSHP) Seminar Planning Committee for the 2021 Annual Conference.

## HIV PRN

### Awards

- **Roxane Rohani:**  
Society of Infectious Diseases Pharmacists Trainee Award.  
American College of Clinical Pharmacy Annual Meeting Resident/Fellow Travel Award.

### Publications

- Burgos RM, **Badowski ME**, Drwiega E, Ghassemi S, Griffith N, Herald F, **Johnson M**, Smith RO, **Michienzi SM**. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. *Drugs Context* 2021;10:2020-12-2.
- Rhodes NJ, Dairem A, Moore WJ, Shah A, Postelnick MJ, **Badowski ME**, **Michienzi SM**, Borkowski JL, Polisetty RS, Fong K, Spivak ES, Beardsley JR, Hale CM, **Pallotta AM**, et al. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. *Am J Health Syst Pharm* 2021 Feb 4. [Epub ahead of print]
- Keats KR, Stitt TM, **Chastain DB**, et al. Evaluating *Clostridioides difficile* infection (CDI) treatment duration in hematology/oncology patients receiving concurrent non-CDI antibiotics. *J Oncol Pharm Pract* 2021 Mar 4. [Epub ahead of print]
- Osae SP, Bradley KE, **Chastain DB**. Improving the utility of PhORCAS references: form revisions may not be enough. *Am J Health Syst Pharm* 2021;78:286-7.
- Schultz J, Hyson P, **Chastain DB**, et al. COVID-19 epidemic in the US – a gateway to screen for tuberculosis, HIV, viral hepatitis, Chagas disease, and other neglected tropical diseases among Hispanics. *PLoS Negl Trop Dis* 2020;14:e0008953.
- **Durham SH**, **Chahine EB**. Cabotegravir-rilpivirine: the first complete long-acting injectable regimen for

the treatment of HIV-1 infection. *Ann Pharmacother* 2021 Feb 16. [Epub ahead of print]

- Natali KM, **Jimenez HR**, Slim J. When coadministration cannot be avoided: real-world experience of direct acting antivirals for the treatment of hepatitis C virus infection in patients on first generation anticonvulsants. *J Pharm Pract* 2020 Dec 15. [Epub ahead of print]
- **Michienzi SM**, **Badowski ME**. Can vitamins and/or supplements provide hope against coronavirus? *Drugs Context* 2020;9:2020-5-7.
- Goldberg RN, Kania AT, **Michienzi SM**, Patel M, **Badowski ME**. Weight gain in incarcerated individuals living with HIV after switching to integrase strand inhibitor-based therapy. *J Int Assoc Provid AIDS Care* 2021 Feb 25. [Epub ahead of print]
- Matyanga CMJ, Dzingirai B, **Monera-Penduka TG**. COVID-19 related pharmacy education and workforce challenges in Zimbabwe. *Pharm Educ* 2021 Jan 15. [Epub ahead of print]
- Avedissian SN, **Rohani R**, Bradley J, et al. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: a convergence of parametric and non-parametric population approaches. *Antimicrob Agents Chemother* 2021 Feb 1. [Epub ahead of print]

### Other Notable Achievements

- **Tsitsi Monera-Penduka:** Credentialed with the American Academy of HIV Medicine (AAHIVM).

## Immunology/Transplantation PRN

### Promotions

- **Angela Maldonado:** Scientific Affairs Director, Hansa Biopharma AB.

### Awards

- **Maya Campara:** University of Illinois Health CARE Award, University of Illinois at Chicago.
- **Marie Chisholm-Burns:** 2020 ACCP Russell R. Miller Award, University of Tennessee Health Science Center College of Pharmacy.
- **Mei Jorgensen:** IMTR PRN 2020 Clinical Practice Award, University of Wisconsin-Madison.
- **Alicia Lichvar:** IMTR PRN 2020 Junior Investigator Award, University of Illinois at Chicago.
- **Christin Rogers:** IMTR PRN 2020 Mentor Award, Massachusetts General Hospital.
- **Dave Taber:** 2020 ACCP Clinical Practice Award, Medical University of South Carolina.
- **Lindsay Toman:** IMTR PRN 2020 Mentor Award, Johns Hopkins Hospital.

## Publications

- **Alghanem SS**, Soliman MM, Alibrahim AA, et al. Monitoring tacrolimus trough concentrations during the first year after kidney transplantation: a national retrospective cohort study. *Front Pharmacol* 2020;11:566638.
- **Campara M, Lourenco LM, Melaragno JI, Kaiser TE**. Implications for body weight extremes in solid organ transplantation. *Pharmacotherapy* 2021;41:44-58.
- **Lichvar AB, Patel A, Pierce D**, Petzel Gimbar R, Tzvetanov I, Benedetti E, **Campara M**. Factors influencing emergency department utilization and hospital re-admissions in a predominantly obese, racially diverse urban renal transplant population. *Prog Transplant* 2021;31:72-9.
- **Maldonado AQ, West-Thielke P, Joyal K, Rogers C**. Advances in personalized medicine and noninvasive diagnostics in solid organ transplantation. *Pharmacotherapy* 2021;41:132-43.

## Presentations

- **Sarah Alghanem**: Optimizing vancomycin PK/PD targets: new insights for the Kuwait Clinical Pharmacy Association; July 15, 2020; Kuwait via Zoom.

## New ACCP Fellows

- Lyndsey Bowman
- Christina Doligalski

## Infectious Diseases PRN

Many ACCP ID PRN members have achieved immunization certification and been active in a variety of COVID-19 vaccination efforts including, but not limited to, administering vaccines, coordinating vaccine clinics, and educating on vaccination.

## Promotions

- **Khalid Eljaaly**: First elected Chair of Infectious Disease Pharmacy Specialty Network of Saudi Society of Clinical Pharmacy.
- **Wasim El Nekidy**: Clinical Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.
- **Lauren Freeman**: OPAT/Antimicrobial Stewardship Clinical Pharmacist, WVU Medicine.

## Awards

- **Ukwen Akpoji**: 2020 Pharmacist of the Year, Ohio College of Clinical Pharmacy.
- **Sara Alosaimy**: Second-Place winner, Annual Eugene Applebaum College of Pharmacy and Health Sciences

Research Day Outstanding Research Award:  
Second Author.

American College of Clinical Pharmacy – Infectious Diseases Practice and Research Network Student/Trainee Award.

- **Alan Gross**: Outstanding Clinical Practice in Infectious Diseases, Society of Infectious Diseases Pharmacists. Outstanding reviewer, *Journal of the American College of Clinical Pharmacy*.
- **Julie Ann Justo**: Fellow of Infectious Diseases Society of America (FIDSA).
- **Roxane Rohani**: Society of Infectious Diseases Pharmacists Trainee Award. American College of Clinical Pharmacy Annual Meeting Resident/Fellow Travel Award.
- **Diandra Ruidera**: Bronze Designation on the California Department of Public Health Antimicrobial Stewardship Honor Roll.

## Grants

- **Sara Alosaimy**: Wayne State University School of Public Health Student Grant Award.
- **Madeline King**: Society of Infectious Diseases Pharmacists Residency Grant.
- **Wes Kufel**: New York State American College of Clinical Pharmacy Research Grant.
- **Michael Rybak**: Real-World Multicenter Observational Study of Imipenem-Cilastatin-Relebactam for Gram-Negative Infections. Funded by Merck & Co. Real-World, Multicenter Evaluation of T2Candida Panel in Patients with Candidemia. Funded by T2 Biosystems.

## Publications

- **Abdul-Mutakabbir JC, Alosaimy S, Morrisette T**, Kebriaei R, **Rybak MJ**. Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant gram-negative pathogens. *Pharmacotherapy* 2020;40:1228-47.
- **Abdul-Mutakabbir JC**, Kebriaei R, Stamper KC, Sheikh Z, Maassen PT, Lev KL, **Rybak MJ**. Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of *Staphylococcus aureus* in a pharmacokinetic/pharmacodynamic model. *Antibiotics (Basel)* 2020;9:696.
- Alkofide H, **Alhammad AM, Alruwaili A**, Aldemerdash A, **Almangour TA**, et al. Multidrug-resistant and extensively drug-resistant Enterobacteriaceae: prevalence, treatments, and outcomes – a retrospective cohort study. *Infect Drug Resist* 2020;13:4653-62.



- Aleanizy FS, Alqahtani FY, Eltayb EK, Alrumikan N, Almebki R, Alhossan A, **Almangour TA**, et al. Evaluating the effect of antibiotics sub-inhibitory dose on *Pseudomonas aeruginosa* quorum sensing dependent virulence and its phenotypes. Saudi J Biol Sci 2021;28:550-9.
- Alhifany AA, Almalki FA, Alatawi YM, Basindowh LA, Almajnoni SS, Elrggal ME, Alotaibi AF, Almarzoky Abuhussain SS, **Almangour TA**. Association between graduates' factors and success rate on the Saudi Pharmacist Licensure Examination: a single-institution cross-sectional study. Saudi Pharm J 2020;28:1830-3.
- Alzeer AA, Alfantoukh LA, Theneyan A, Bin Eid F, **Almangour TA**, et al. The influence of demographics on influenza vaccine awareness and hesitancy among adults visiting educational hospital in Saudi Arabia. Saudi Pharm J 2021;29:188-93.
- Badreldin HA, Thabit AK, **Almangour TA**, Alessa M, **Eljaaly K**, et al. Pursuing postgraduate pharmacy training in the United States for international pharmacy graduates: approaches, current status, challenges, and future perspectives. J Am Coll Clin Pharm 2020;4:224-33.
- Butler DA, **Biagi M**, **Gupta V**, Wieczorkiewicz S, Young L, Patel U, Naegele S, **Santarossa M**, Harrington A, Postelnick M, **Suseno M**, **Christensen A**, Giddens J, Murrey T, Hanson A, Sam S, **Pettit N**, Danziger L, **Wenzler E**. Development of a 51-hospital Chicagoland regional antibiogram and comparison to local hospital and national surveillance data. Infect Control Hosp Epidemiol 2020;41:1409-18.
- **Butterfield-Cowper JM**. A pharmacokinetic-pharmacodynamic analysis to dose optimize daptomycin in vancomycin-resistant *Enterococcus faecium*: is the answer fixed dosing or lowering breakpoints? Ann Pharmacother 2020 Nov 4. [Epub ahead of print]
- **Campanella TA**, **Gallagher JC**. A clinical review and critical evaluation of imipenem-relebactam: evidence to date. Infect Drug Resist 2020;13:4297-308.
- **Cimino C**, Allos BM, Phillips EJ. A review of  $\beta$ -lactam-associated neutropenia and implications for cross-reactivity. Ann Pharmacother 2020 Nov 20. [Epub ahead of print]
- **Cimino C**, Burnett Y, **Vyas N**, et al. Post-dialysis parenteral antimicrobial therapy in patients receiving intermittent high-flux hemodialysis. Drugs 2021 Feb 16. [Epub ahead of print]
- **Dass A**, Brown T, **Mistry B**, et al. Impact of outpatient prescribing of antibiotics for acute exacerbation of chronic obstructive pulmonary disease on 30-day re-exacerbation rates. Am J Ther 2020 Dec 29. [Epub ahead of print]
- Mandal S, Prathipati PK, Sunagawa SW, **Destache CJ**. A new combination bicittegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: a concept evaluation study. Antimicrob Agents Chemother 2021 Feb 1. [Epub ahead of print]
- Perazzolo S, Mandal S, Prathipati PK, **Destache CJ**. Bicittegravir plus tenofovir alafenamide nanoformulation as a long-acting pre-exposure prophylaxis regimen: application of modeling to design non-human primate pharmacokinetic experiments. Front Pharmacol 2020;11:603242.
- **Eljaaly K**, Bidell MR, Gandhi RG, Alshehri S, Enani MA, **Al-Jedai A**, et al. Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis 2021;8:ofab026.
- **Eljaaly K**, ElSayed N. Global Respiratory Infection Partnership, International Pharmaceutical Federation. Driving Antimicrobial Resistance Action in the Eastern Mediterranean Region: A Roadmap for AMR Action in the Eastern Mediterranean. December 2020.
- **Eljaaly K**, **Ortwine JK**, Shaikhomer M, **Almangour TA**, et al. Efficacy and safety of eravacycline: a meta-analysis. J Glob Antimicrob Resist 2021;24:424-8.
- Al-Madfaa RO, Alalawi MA, Basudan LO, Alhejaili SF, **Eljaaly K**, et al. Dual versus triple therapy for uncomplicated brucellosis: a retrospective cohort study. J Infect Dev Ctries 2020;14:1380-6.
- Alsheri S, **Eljaaly K**, Alshibani M, et al. Impact of single-dose systemic glucocorticoids on blood leukocytes in hospitalized adults. J Appl Hematol 2020;11:116-21.
- Alshibani M, Alshehri S, Bakhaider A, Atbani A, Ismail M, Jazzar B, **Eljaaly K**, et al. The impact of the first 24 h of loop diuretic on kidney function in acute decompensated heart failure. Ir J Med Sci 2020 Nov 22. [Epub ahead of print]
- Al Sulaiman KA, Al Juhani OA, **Eljaaly K**, et al. Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): a multicenter cohort study. Int J Infect Dis 2021;105:P180-187.
- Eldanasory OA, **Eljaaly K**, Memish ZA, et al. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19. Travel Med Infect Dis 2020;37:101874.
- **EI Nekidy WS**, El-Masri MM, Kadri A, et al. Efficacy of ferumoxytol versus sodium ferric gluconate in anemia management in outpatient hemodialysis patients: a prospective cohort study. Clin Nephrol 2021 Jan 12. [Epub ahead of print]

- Anouassi Z, Atallah B, Alsoud LO, **EI Nekidy W**, et al. Appropriateness of the direct oral anticoagulants dosing in the Middle East Gulf Region. *J Cardiovasc Pharmacol* 2021;77:182-8.
- Atallah B, **EI Nekidy W**, Mallah SI, et al. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers. *Thromb J* 2020;18:22.
- Atallah B, Sadik ZG, Salem N, **EI Nekidy WS**, et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. *Anaesthesia* 2021;76:327-35.
- Gupta S, Madhyastha R, Hamed F, Balkis M, **EI Nekidy W**, et al. Tocilizumab use in a chronic hemodialysis patient for the management of COVID-19-associated pneumonia and acute respiratory distress syndrome. *Case Rep Nephrol* 2020;2020:8829309.
- Salem N, Atallah B, **EI Nekidy WS**, et al. Thromboelastography findings in critically ill COVID-19 patients. *J Thromb Thrombolysis* 2020 Oct 4. [Epub ahead of print]
- **Fox AN**, Nation BE, Autry MT, et al. Possible role for acetylcysteine as a treatment for acute liver failure secondary to antitubercular medication use. *Am J Health Syst Pharm* 2020;77:1482-7.
- **Goff DA**, Ashiru-Oredope D, Cairns KA, **Eljaaly K**, **Gauthier TP**, et al. Global contributions of pharmacists during the COVID-19 pandemic. *J Am Coll Clin Pharm* 2020;3:1480-92.
- **Gross AE**, **Suda KJ**, Zhou J, et al. Serious antibiotic-related adverse effects following unnecessary dental prophylaxis in the United States. *Infect Control Hosp Epidemiol* 2021;42:110-2.
- Hubbard CC, Evans CT, Calip GS, Rowan S, Gellad WF, Campbell A, **Gross AE**, Hershow RC, McGregor JC, Sharp LK, **Suda KJ**. Community-level characteristics associated with prescribing of opioids and antibiotics by dentists; 2012 to 2017. *Am J Prev Med* 2020. [In press]
- Miles KE, Rodriguez R, **Gross AE**, et al. Strength of recommendation and quality of evidence for recommendations in current Infectious Diseases Society of America guidelines. *Open Forum Infect Dis* 2021;8:ofab033.
- Reticker A, Lichvar A, Walsh M, **Gross AE**, et al. The significance and impact of screening preservation fluid cultures in renal transplant recipients. *Prog Transplant* 2021;31:40-6.
- Weber DJ, Talbot TR, Weinmann A, Mathew T, **Heil E**, Stenehjem E, Duncan R, **Gross A**, Stinchfield P, Baliga C, **Wagner J**, et al. Policy statement from the Society for Healthcare Epidemiology of America (SHEA): only medical contraindications should be accepted as a reason for not receiving all routine immunizations as recommended by the Centers for Disease Control and Prevention. *Infect Control Hosp Epidemiol* 2021;42:1-5.
- Pop M, **Hemenway A**, Shakeel F. Probable parenteral and oral contrast-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a case report. *Am J Emerg Med* 2020 Dec 23. [Epub ahead of print]
- Luu Q, Vitale K, Shan G, **Jayakumar R**, **Viswesh V**. Evaluation of guideline recommendations for dual antipseudomonal therapy in hospitalized adults with pneumonia using combination antibiograms. *Pharmacotherapy* 2020;40:1089-98.
- Griffith NC, **Justo JA**, **Winders HR**, Al-Hasan MN, **Mediwala KN**, **Bookstaver PB**. Regulatory approval, implementation, and brief assessment of a pharmacist- and pharmacy trainee-administered penicillin allergy assessment and skin testing program. *J Am Coll Clin Pharm* 2020;3:1269-79.
- **Kufel WD**. Antibody-based strategies in HIV therapy. *Int J Antimicrob Agents* 2020;56:106186.
- Darko W, Seabury RW, Miller CD, Spinler SA, Probst LA, Cleary LM, Kelly C, **Kufel WD**. Implementation of a formal pharmacy residency research certificate program. *Am J Health Syst Pharm* 2021;78:436-46.
- Shakeraneh P, Steele JM, Seabury RW, Thomas SJ, Paolino KP, Miller CD, Probst LA, **Kufel WD**. Impact of a pharmacist-driven azithromycin de-escalation initiative for community-acquired pneumonia. *J Am Coll Clin Pharm* 2021;4:20-6.
- **Mahoney MV**, **Alexander BT**, **Rivera CG**, **Ryan KL**, **Childs-Kean LM**. A prescription for an outpatient parenteral antimicrobial therapy (OPAT) rotation for pharmacy residents. *J Am Coll Clin Pharm* 2021;4:234-44.
- **Morrisette T**, **Alosaimy S**, **Abdul-Mutakabbir JC**, Kebriaei R, **Rybak MJ**. The evolving reduction of vancomycin and daptomycin susceptibility in MRSA-salvaging the gold standards with combination therapy. *Antibiotics (Basel)* 2020;9:762.
- **Morrisette T**, **Alosaimy S**, Phillely JV, Wadle C, **Howard C**, **Webb AJ**, Veve MP, Barger ML, **Bouchard J**, Gore TW, Lagnf AM, Ansari I, Mejia-Chew C, Cohen KA, **Rybak MJ**. Preliminary, real-world, multicenter experience with omadacycline for *Mycobacterium abscessus* infections. *Open Forum Infect Dis* 2021;8:ofab002.
- **Nguyen CT**, Bethel C, **Pettit NN**, et al. From Etest to Vitek 2: impact of enterococcal linezolid susceptibility testing methodology on time to active therapy. *Antimicrob Agents Chemother* 2020;64:e00302-20.

- **Nguyen CT**, Olson G, Pho MT, Lew AK, Pitrak D, Saltzman J, Hazra A, Pursell K, **Pettit NN**. Automatic ID consultation for inpatients with COVID-19: point, counterpoint, and a single-center experience. *Open Forum Infect Dis* 2020;7:ofaa318.
- **Nguyen CT**, Petrucci K, Daily E, Brown AM, **Pettit NN**, et al. Investigating the impact of a  $\beta$ -lactam allergy label on preoperative antibiotic prophylaxis administration. *Infect Control Hosp Epidemiol* 2020 Nov 17. [Epub ahead of print]
- McCort MN, Oehler C, Enriquez M, Landon E, **Nguyen CT**, **Pettit NN**, et al. Universal molecular *Clostridioides difficile* screening and overtreatment in solid organ transplant recipients. *Transpl Infect Dis* 2020;22:e13375.
- Ridgway JP, Friedman EE, Choe J, **Nguyen CT**, Schuble T, **Pettit NN**. Impact of mail order pharmacy use and travel time to pharmacy on viral suppression among people living with HIV. *AIDS Care* 2020;32:1372-8.
- **O'Neal M**, Murray H, Dash S, Al-Hasan MN, **Justo JA**, **Bookstaver PB**. Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system. *Ther Adv Infect Dis* 2020;7:2049936120959561.
- Sheffield M, Nelson D, **O'Neal M**, **Gould AP**, **Bouchard J**, **Nicolau D**, **Justo JA**, **Hucks J**, **Bookstaver PB**. Use of continuous-infusion ceftolozane/tazobactam for resistant gram-negative bacterial infections: a retrospective analysis and brief review of the literature. *Int J Antimicrob Agents* 2020;56:106158.
- **Parsels KA**, Mastro KA, Steele JM, Thomas SJ, **Kufel WD**. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections. *J Antimicrob Chemother* 2021 Feb 3. [Epub ahead of print]
- Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavošchi L, Steele VR, Henriksen AS, Longshaw C, Manissero D, **Pecini R**, **Pogue JM**. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. *Clin Microbiol Infect* 2021 Jan 6. [Epub ahead of print]
- **Pettit NN**, **Nguyen CT**, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. *J Med Virol* 2021;93:1459-64.
- **Rebold N**, **Holger D**, **Alosaimy S**, **Morrisette T**, **Rybak M**. COVID-19: before the fall, an evidence-based narrative review of treatment options. *Infect Dis Ther* 2021 Jan 25. [Epub ahead of print]
- **Rebold N**, **Holger D**, **Rybak M**. Vancomycin dosing guidelines: where do we go from here? *Infectious Disease Special Edition*. December 2020.
- **Rhodes NJ**, Dairem A, **Moore WJ**, Shah A, Postelnick MJ, **Badowski ME**, Michienzi SM, **Borkowski JL**, **Polisetty RS**, Fong K, Spivak ES, Beardsley JR, **Hale CM**, **Pallotta AM**, et al. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. *Am J Health Syst Pharm* 2021 Feb 4. [Epub ahead of print]
- Avedissian SN, **Rohani R**, Bradley J, Le J, **Rhodes NJ**. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: a convergence of parametric and non-parametric population approaches. *Antimicrob Agents Chemother* 2021 Feb 1. [Epub ahead of print]
- Marcelin JR, Cortés-Penfield N, Del Rio C, Desai A, Echenique I, Granwehr B, Lawal F, Kuriakose K, Lee DH, Malinis M, **Ruidera D**, et al. How the field of infectious diseases can leverage digital strategy and social media use during a pandemic. *Open Forum Infect Dis* 2021;8:ofab027.
- **Rybak MJ**, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Beringer AW, Rodvold KA, **Maples HD**. Questions on vancomycin dosing. *Clin Infect Dis* 2020 Nov 26. [Epub ahead of print]
- Kebriaei R, Lev KL, Stamper KC, Lehman SM, Morales S, **Rybak MJ**. Bacteriophage AB-SA01 cocktail in combination with antibiotics against MRSA-VISA strain in an in vitro pharmacokinetic/pharmacodynamic model. *Antimicrob Agents Chemother* 2020;65:e01863-20.
- Albarillo FS, Medina RE, Joyce CS, Darji H, **Santarossa M**. Daptomycin-resistant VRE infections: a descriptive analysis at a single academic centre. *Infect Dis (Lond)* 2021 Feb 5. [Epub ahead of print]
- Vanamala K, Tatiparti K, Bhise K, Sau S, **Scheetz MH**, **Rybak MJ**, et al. Novel approaches for the treatment of methicillin-resistant *Staphylococcus aureus*: using nanoparticles to overcome multidrug resistance. *Drug Discov Today* 2021;26:31-43.
- Ciarkowski CE, **Timbrook TT**, Kukhareva PV, et al. A pathway for community-acquired pneumonia with rapid conversion to oral therapy improves health care value. *Open Forum Infect Dis* 2020;7:ofaa497.
- Oliver MB, Fong K, Certain L, Spivak ES, **Timbrook TT**. Validation of a community-acquired pneumonia score to improve empiric antibiotic selection at an academic medical center. *Antimicrob Agents Chemother* 2021;65:e01482-20.

- Sutton JD, Stevens VW, Chang NN, Khader K, **Timbrook TT**, et al. Oral  $\beta$ -lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source. *JAMA Netw Open* 2020;3:e2020166.
- **Viswesh V**. New antimicrobial agents. In: Murphy JE, Lee MW, eds. *Pharmacotherapy Self-Assessment Program, 2021 Book 1. Infectious Diseases*. Lenexa, KS: American College of Clinical Pharmacy, 2021:7-29.
- **Viswesh V**, Hassell K, Coyne L, et al. Ten tips for successful navigation of promotion and tenure. *Am J Pharm Educ* 2021;85:8414.
- Lee BJ, **Vu BN**, Seddon AN, **Hodgson HA**, **Wang SK**. Treatment considerations for CNS infections caused by vancomycin-resistant *Enterococcus faecium*: a focused review of linezolid and daptomycin. *Ann Pharmacother* 2020;54:1243-51.
- **Winders HR**, Al-Hasan MN, **Jones BM**, **Childress DT**, **Stover KR**, Britt BB, **Chahine EB**, Lau S, Andrews PD, Junco SJ, Wrenn RH, **Crane BJ**, Wong JR, Seddon MM, **Bland CM**, MacVane SH, **Gibson GM**, **Bookstaver PB**; SERGE-45 Investigators. Novel method of calculating adjusted antibiotic use by microbiological burden. *Infect Control Hosp Epidemiol* 2021 Jan 28. [Epub ahead of print]
- Younas M, Royer J, Weissman SB, **Winders HR**, Dash S, **Bookstaver PB**, **Justo JA**, et al. *Clostridioides difficile* infection and antibiotic prescription rates in the community: explaining the gender gap. *Infect Control Hosp Epidemiol* 2020 Nov 26. [Epub ahead of print]
- **Zemblem T**. Virtual antimicrobial stewardship in a hospital setting during a pandemic [blog]. The Joint Commission [homepage on the Internet]. February 2021.
- **Zemblem TN**, MacBrayne CE, Mitchell ML, et al. Lessons learned from virtual handshake stewardship during a pandemic. *Jt Comm J Qual Patient Saf* 2021;47:198-200.
- **Zemblem TN**, Schortemeyer R, Kuhn EM, et al. Extended infusion of beta-lactams is associated with improved outcomes in pediatric patients. *J Pediatr Pharmacol Ther* 2021;26:187-93.
- Thompkins A, Mitchell M, Kehl S, Kuhn E, **Zemblem T**. Vancomycin use associated with coagulase-negative *Staphylococcus* spp. blood cultures in children. *J Pharm Soc Wis* 2020;23:20-3.

#### Presentations

- **Sara Alosaimy**: Standardized treatment algorithm pathway improves mortality in adults with methicillin-resistant *Staphylococcus aureus* bacteremia:

STAPH-study. Presented at: Society of Infectious Diseases Pharmacists Annual Meeting; November 2020; virtual.

- **Monica Mahoney**: Presented at IDWeek on “OPAT in PWID” in a Meet the Professors section.

#### Board Certification in Infectious Diseases (BCIDP)

- Sumaya Ased
- Toni Campanella
- Akshith Dass
- Jaela Fredenrich
- Lauren Freeman
- Timothy Gauthier
- Alicia Hochanadel
- Nicholas Rebold
- Rania Slika
- Michele Swihart
- Axel Vazquez Deida
- Sheila Wang
- Xhilda Xhemali

#### Other Notable Achievements

- **Jacinda Abdul-Mutakabbir**: Lead Pharmacist, Loma Linda University COVID-19 Mobile Vaccination Clinics.
- **Ukwen Akpoji**: VA/AMIA 10x10 Health Informatics Certificate.
- **Khalid Eljaaly**: Member of the 2022 ACCP Global Conference on Clinical Pharmacy Program Committee. Member of the Review Panel for ASHP Foundation Literature Award for Innovation in Pharmacy Practice.
- **William Truong**: AAHIVP re-credentialed.

#### Nephrology PRN

##### Promotions

- **Calvin Meaney**: Vice Chair for Research, Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

##### Grants

- **Linda Awdishu** (Co-PI): Advancing Diverse Faculty, Curricula and Research Through a Cluster Hire at UC San Diego. University of California, Office of the President. Amount: \$496,500.
- **Soo Min Jang** (Co-PI): Association of Low Plasma Lithium Concentrations with Depressive Symptoms and Suicidal Ideation in Patients with Chronic Kidney Disease and Hemodialysis. Loma Linda University Research Affairs. Amount: \$75,000.
- **Meaney CJ**, Shah R, Occhino E: Optimizing Vancomycin Use and Clinical Outcomes in Hemodialysis Patients. New York State American

College of Clinical Pharmacy Research Grant.  
December 15, 2020.

## Publications

- **Awdishu L**, Atilano-Roque A, Tuey S, **Joy MS**. Identification of novel biomarkers for predicting kidney injury due to drugs using “omic” strategies. *Pharmacogenomics Pers Med* 2020;13:687-705.
- Dobson SR, Mauro VF, Boddu SHS, **Churchwell MD**. The physical compatibility of clinically used concentrations of diltiazem hydrochloride with heparin sodium. *J Pharm Technol* 2020;36:126-9.
- Hartman RE, Rao PSS, **Churchwell MD, Lewis SJ**. Novel therapeutic agents for the treatment of diabetic kidney disease. *Expert Opin Investig Drugs* 2020;29:1277-93.
- **EI Nekidy WS**, El-Masri MM, Kadri A, et al. Efficacy of ferumoxytol versus sodium ferric gluconate in anemia management in outpatient hemodialysis patients: a prospective cohort study. *Clin Nephrol* 2021 Jan 12. [Epub ahead of print]
- Anouassi Z, Atallah B, Alsoud LO, **EI Nekidy W**, et al. Appropriateness of the direct oral anticoagulants dosing in the Middle East Gulf Region. *J Cardiovasc Pharmacol* 2021;77:182-8.
- Atallah B, **EI Nekidy W**, Mallah SI, et al. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers. *Thromb J* 2020;18:22.
- Atallah B, Sadik ZG, Salem N, **EI Nekidy WS**, et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. *Anaesthesia* 2021;76:327-35.
- Gupta S, Madhyastha R, Hamed F, Balkis M, **EI Nekidy W**, et al. Tocilizumab use in a chronic hemodialysis patient for the management of COVID-19-associated pneumonia and acute respiratory distress syndrome. *Case Rep Nephrol* 2020;2020:8829309.
- Salem N, Atallah B, **EI Nekidy WS**, et al. Thromboelastography findings in critically ill COVID-19 patients. *J Thromb Thrombolysis* 2020 Oct 4. [Epub ahead of print]
- **Jang SM**, Bahjri K, Lee JY, et al. Use of angiotensin converting enzyme inhibitors in patients receiving therapeutic plasma exchange with centrifuge-based apheresis system. *Ther Apher Dial* 2020 Sep 29. [Epub ahead of print]
- **Jang SM, Lewis SJ, Mueller BA**. Harmonizing antibiotic regimens with renal replacement therapy. *Expert Rev Anti Infect Ther* 2020;18:887-95.
- **Jang SM**, Parker WM, **Pai AB**, Jiang R, **Cardone KE**. Assessment of literacy and numeracy skills related to medication labels in patients on chronic

in-center hemodialysis. *J Am Pharm Assoc* (2003) 2020;60:957-962.e1.

- **Lewis SJ, Mueller BA**. Evaluation and development of vancomycin dosing schemes to meet new AUC/MIC targets in intermittent hemodialysis using Monte Carlo simulation techniques. *J Clin Pharmacol* 2021;61:211-23.
- Nguyen LM, **Meaney CJ**, Rao GG, et al. Population pharmacodynamic modeling of epoetin alfa in end-stage renal disease patients receiving maintenance hemodialysis treatment using Bayesian approach. *CPT Pharmacometrics Syst Pharmacol* 2020;9:596-605.
- **Schwenk MH**. Acetazolamide intoxication in an elderly patient with diabetes and chronic renal failure after cataract surgery. *Case Rep Crit Care* 2021. [In press]

## Other Notable Achievements

- **Linda Awdishu**:  
Elected as a new ACCP Nephrology PRN Representative to Kidney Health Initiative.  
Invited to serve as Lead Scientist for development of University of California, San Diego AKI/CRRT Registry.

## Pain and Palliative Care PRN

### Grants

- **Tran TH** (PI), Swoboda H (Co-I): A Clinical Model of Bedside Delivery of Discharge Medications to Treat Opioid Use Disorder (OUD) During Hospitalization to Bridge Patients Until Their First Clinic Appointment. Portes Foundation and The Institute of Medicine of Chicago. Amount: \$30,000.

### Publications

- Bicket MC, Fu D, Swarthout MD, White E, **Nesbit SA**, et al. Effect of drug disposal kits and fact sheets on elimination of leftover prescription opioids: the DISPOSE multi-arm randomized controlled trial. *Pain Med* 2021 Feb 12. [Epub ahead of print]
- Bova SE, Krueger RM, **Nesbit SA**, et al. Perioperative methadone prescribing and association with respiratory depression. *J Opioid Manag* 2020;16:443-9.
- **Tran TH**, Ball J, Bratberg JP, et al. Report of the 2020 Special Committee on Substance Use and Pharmacy Education. *Am J Pharm Educ* 2020;84:8421.
- **Tran TH**, Swoboda H, Perticone K, et al. The substance use intervention team: a hospital-based intervention and outpatient clinic to improve care for patients with substance use disorders. *Am J Health Syst Pharm* 2021;78:345-53.

- Coon SA, Hill, LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, **Tran TH**, et al. Mobilizing pharmacists to address the opioid crisis: a joint opinion of the Ambulatory Care and Adult Medicine Practice and Research Networks of the American College of Clinical Pharmacy. *J Am Coll Clin Pharm* 2020;3:1493-513.
- Murray MM, Kolanczyk DM, Phatak A, Schmidt J, Kliethermes MA, **Tran T**, et al. Barriers to and factors influencing the pursuit of pharmacy student research. *Curr Pharm Teach Learn* 2020;12:1297-303.
- Peckham A, Ball J, Colvard M, Dadiomov D, Hill L, Nichols S, Tallian M, Ventricelli D, **Tran TH**. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. *Am J Health Syst Pharm* 2021 Jan 7. [Epub ahead of print]
- Stone RH, Griffin B, Fusco RA, Vest K, **Tran TH**, et al. Factors affecting contraception access and use in patients with opioid use disorder. *J Clin Pharmacol* 2020;60(suppl 2):S63-S73.

#### Presentations

- Reksk KS, **Hamil L**. Assessment of opioid use before and after implementation of multimodal analgesia in post-operative urology patients and the impact of pharmacy pain stewardship. Presented at: ASHP Midyear Clinical Meeting; December 2020; virtual.

#### Pediatrics PRN

The Pediatrics PRN's newest initiative is the formal creation of a Pediatrics PRN Publications Steering Committee. This committee will create a structure for identifying topics and potential authors for PRN papers and other articles on pediatrics topics. The inaugural formal chair of the committee is **Lea Eiland**, and we look forward to the future directions of this group.

#### Promotions

- **Nicholas M. Fusco**: Vice Chair of Education, Practice and Service of the Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

#### Awards

- **Renee Robinson**: 2021 Distinguished Pharmacist Award, Alaska Pharmacists Association.

#### Publications

- Hornik CD, **Bondi DS**, Green NM, **Cober MP**, **John B**. Review of fluconazole treatment and prophylaxis

for invasive candidiasis in neonates. *J Pediatr Pharmacol Ther* 2021;26:115-22.

- Patel PD, Bhagat P, Bartlett AH, **Bondi DS**. Comparison of neonatal outcomes with the use of cefotaxime versus ceftazidime in a neonatal intensive care unit. *J Pediatr Pharmacol Ther* 2020;25:117-23.
- Stranges PM, Jackevicius CA, Anderson SL, **Bondi D**, et al. ACCP white paper: Role of clinical pharmacists and pharmacy support personnel in transitions of care. *J Am Coll Clin Pharm* 2020;3:532-45.
- Szwak JA, **Bondi DS**, Knoebel R, et al. Utility of clinical-focused mini interview during post-graduate year-1 pharmacy residency interviews. *J Am Coll Clin Pharm* 2020;3:764-70.
- Weaver KL, **Bondi DS**, Shah PA, et al. Evaluation of appropriateness and cost-savings of pharmacist-driven palivizumab ordering. *J Pediatr Pharmacol Ther* 2020;25:636-41.
- Foltz-Ramos K, **Fusco NM**, Paige JB. Saving patient X: a quasi-experimental study of teamwork and performance in simulation following an interprofessional escape room. *J Interprof Care* 2021 Feb 15.
- Fox AN, Nation BE, Autry MT, **Johnson PN**. Possible role of *N*-acetylcysteine as a treatment for acute liver (ALF) secondary to anti-tubercular medications. *Am J Health Syst Pharm* 2020;77:1482-7.
- Harkin M, **Johnson PN**, Neely SB, et al. Frequency and severity of chlorothiazide-induced hyponatremia in the neonatal intensive care unit. *Am J Perinatol* 2021 Jan 6. [Epub ahead of print]
- Harkin M, Shaddix BP, Neely SB, Peek LA, Stephens K, Barker P, McMullan L, Gormley A, **Johnson PN**. Evaluation of dosing and outcomes of low-dose prophylactic warfarin in children after cardiothoracic surgery. *Am J Health Syst Pharm* 2020;77:1018-25.
- Lim S, Miller JL, Henry E, Heltsley R, Woo S, **Johnson PN**. Analysis of fentanyl pharmacokinetics, and its sedative effects and tolerance in critically ill children. *Pharmacotherapy* 2021 Feb 19. [Epub ahead of print]
- Miller JL, Lewis TV, O'Donnell A, Walling J, Neely SB, **Johnson PN**. Publication rates of pediatric-focused resident research projects presented at the Pediatric Pharmacy Association Bruce Parks Memorial Residency Showcase. *J Pediatr Pharmacol Ther* 2021;26:146-54.
- Moore E, Mayes R, Harkin M, Miller JL, Neely S, **Johnson PN**. Extended duration ketamine infusions in critically ill children: a case report and review of the literature. *J Pediatr Intensive Care* 2020 Jun 10. [Epub ahead of print]
- Nguyen TT, Bergeron E, Miller JL, Lewis TV, Hagemann TM, Neely SB, **Johnson PN**. Descriptive study of discharge

medications in pediatric patients. *SAGE Open Med* 2020;8:2050312120927945.

- Shaddix BP, Harkin M, Miller JL, **Johnson PN**. Which PGY1 pharmacy residency is right for me? Advantages and disadvantages of pediatric-focused and traditional PGY1 pharmacy programs. *J Pediatr Pharmacol Ther* 2020;25:273-7.
- Cox C, Todd T, Lubsch L, Klein K, Prescott WA, Knoderer CA, **Johnson PN**, et al. Joint statement on pediatric education at schools of pharmacy. *Am J Pharm Educ* 2020;84:ajpe7892.
- **Meyers RS, Thackray J, Matson KL**, McPherson C, Lubsch L, Hellinga RC, **Hoff DS**. Key potentially inappropriate drugs in pediatrics: the KIDs List. *J Pediatr Pharmacol Ther* 2020;25:175-91.
- **Ohler KH, Bondi DS**. Which PGY1 pharmacy residency is right for me? Advantages and disadvantages of pediatric-focused and traditional PGY1 pharmacy programs [letter]. *J Pediatr Pharmacol Ther* 2020;25:559-61.
- **Pan I**, Shah PA, Singh J, Kelly KN, **Bondi DS**. Comparison of neonatal outcomes with and without prophylaxis with indomethacin in premature neonates. *J Pediatr Pharmacol Ther*. [In press]
- **Puthoff TD**, Veneziano G, Kulaylat AN, et al. Development of a structured regional analgesia program for postoperative pain management. *Pediatrics* 2021;147:e20200138.

## Perioperative Care PRN

### Publications

- **Ali D**, Barra ME, Blunck J, et al. Stress-related gastrointestinal bleeding in patients with aneurysmal subarachnoid hemorrhage: a multicenter retrospective observational study. *Neurocrit Care* 2020 Nov 4. [Epub ahead of print]
- Carothers C, **Birrer K**, Vo M. Acetylcysteine for the treatment of suspected remdesivir-associated acute liver failure in COVID-19: a case series. *Pharmacotherapy* 2020;40:1166-71.
- Eudy JL, Pallotta A, Neuner EA, **Brummel GL**, et al. Antimicrobial stewardship practice in the ambulatory setting from a national cohort. *Open Forum Infect Dis* 2020;7:0faa513.
- **Coles LL**, Forehand CC, Quidley AM. Hydrocortisone continuous infusion versus bolus dose on glycemic control in critically ill subjects. *J Pharm Pract* 2021;34:35-9.
- Rosovsky RP, Grodzin C, Channick R, **Davis GA**, et al. Diagnosis and treatment of pulmonary embolism during the coronavirus disease 2019 pandemic: a position paper from the National PERT Consortium. *Chest* 2020;158:2590-601.
- Jackson NA, Gan T, Davenport DL, Oyler DR, **Ebbitt LM**, et al. Preoperative opioid, sedative, and antidepressant use is associated with postoperative hospital costs in colorectal surgery. *Surg Endosc* 2020 Oct 9. [Epub ahead of print]
- **Johnson EG**, Nguyen J, Oyler D, et al. Naloxone continuous infusion for spinal cord protection in endovascular aortic surgery leads to higher opioid administration and more pain. *J Cardiothorac Vasc Anesth* 2021;35:1143-8.
- Edwards AM, **Johnson EG**, Bernard AC. Intraoperative vasopressor use during emergency surgery on injured meth users. *Trauma Surg Acute Care Open* 2020;5:e000553.
- Austin K, Sweet M, **Likar E**, et al. Prospective assessment of *Clostridioides* (formerly *Clostridium*) *difficile* colonization and acquisition in hematopoietic stem cell transplant patients. *Transpl Infect Dis* 2020;22:e13438.
- Jones Tw, Jun AH, Michal JL, **Olney WJ**. High-dose daptomycin and clinical applications. *Ann Pharmacother* 2021 Feb 4. [Epub ahead of print]
- **Palm NM**, Vallabhajosyula S, Chen A, et al. Timing of resumption of beta-blockers after discontinuation of vasopressors is not associated with post-operative atrial fibrillation in critically ill patients recovering from non-cardiac surgery: a retrospective cohort analysis. *J Crit Care* 2020;60:177-82.
- **Palm NM**, Wesolowski JC, Wu JY, et al. Implementation of a leeches + antimicrobial prophylaxis order panel to optimize medicinal leech use at a tertiary care academic medical center. *J Pharm Pract* 2021 Feb 10. [Epub ahead of print]
- Sacha GL, Chen AY, **Palm NM**, et al. Evaluation of the initiation timing of hydrocortisone in adult patients with septic shock. *Shock* 2021;55:488-94.
- Roberts RJ, Miano TA, Hammond DA, **Patel GP**, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. *Crit Care Med* 2020;48:1445-53.
- Lapane KL, Dubé C, Hume AL, Tjia J, Jesdale BM, **Pawasauskas J**, et al. Priority-setting to address the geriatric pharmacoparadox for pain management: a nursing home stakeholder Delphi study. *Drugs Aging* 2021 Feb 24. [Epub ahead of print]
- **Rider TR**, Silinskie KM, Hite MS, et al. Pharmacokinetics of vancomycin in critically ill patients undergoing sustained low-efficiency dialysis. *Pharmacotherapy* 2020;40:1036-41.
- **Wolfe RC**. Intraoperative methadone: new use for an old drug. *J Perianesth Nurs* 2020;35:219-21.
- Robinson AC, **Wolfe RC**. Immune checkpoint inhibitors and perioperative considerations. *J Perianesth Nurs* 2020;35:687-91.

## Other Notable Achievements

- **Richard Parrish, Eric Johnson, and Brian Kramer:** Conducting an exploratory retrospective study that will be the first to characterize the medications used in preventing surgical site infection, venous thromboembolism, and postoperative nausea and vomiting in a cohort of patients with colorectal and gynecologic cancer participating in an Enhanced Recovery After Surgery (ERAS) program protocol. The study is part of the Enhanced Recovery Comparative Pharmacotherapy Collaborative that aims to study medication use embedded in ERAS protocols.

## Pharmaceutical Industry PRN

### Promotions

- **Cori Cooper:** US Medical Lead, UCB, Inc.
- **Evelyn Hermes-DeSantis:** Professor Emeritus, Rutgers University.
- **Maria Sheridan:** Senior Medical Science Liaison, Head of Biosimilars MSL team, Fresenius Kabi USA, LLC.
- **Catherine Sterk:** Field Director, Genentech.

### Awards

- **Catherine Sterk:** Immediate Past President, Pacific Pharmacy Alumni Association.

### Publications

- **Patil T, Hanna S, Torre W.** A rare case report of apixaban-induced lichenoid eruption. *Ther Adv Drug Saf* 2020;11:2042098620937884.
- **Patil T, Ikekwere C.** A case report of rivaroxaban-induced urticaria and angioedema with possible cross-reaction to dabigatran. *J Med Cases* 2019;10:359-63.
- **Patil T, Lebrecht M.** A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. *Thromb Res* 2020;192:124-30.
- **Patil T, Murphy K, Woodard L, et al.** Proton pump inhibitor utilization in veteran patients on combined antithrombotic therapy and validation of simplified bleeding risk score. *Pharmacotherapy* 2020;40:1219-27.
- **Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavošchi L, Steele VR, Henriksen AS, Longshaw C, Manissero D, Pecini R, et al.** Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. *Clin Microbiol Infect* 2021 Jan 6. [Epub ahead of print]

## Presentations

- **Pecini R, Nguyen S, Hackel M, et al.** In vitro antibacterial activity of cefiderocol against a multinational collection of gram-negative bacteria from urinary isolates: SIDERO-WT-2014–2018. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases; April 2020; virtual.
- **Wagenlehner F, Lucenteforte E, Pea F, Pogue J, Soriano A, Tavošchi L, Steele V, Henriksen A, Longshaw C, Manissero D, Pecini R.** Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Poster presented at: European Congress of Clinical Microbiology and Infectious Diseases; April 2020; virtual.

## Other Notable Achievements

- **Jennifer Bradford:** Vaccinated 1800 patients with their second Pfizer vaccine in a drive-up vaccination clinic, assisted by the Army and Air National Guard.
- **Marissa Johnson:** Taught high school Chemistry and English Language Learners Environmental Science. Class consisted of 28 students where 3 spoke Vietnamese, and 25 spoke Spanish at a low or emerging level. When the pandemic hit, successfully transitioned to online learning for all students. Began pharmacy school at Xavier University of Louisiana. Charter member of the student chapter for Industry Pharmacists Organization (IPhO).

## Pharmacokinetics/Pharmacodynamics/ Pharmacogenomics PRN

### Awards

- **Kelly Caudle:** Web of Science Highly Cited Researcher 2019 (highly cited papers that ranked in the top 1% in 2019 in the field of Pharmacology and Toxicology).
- **Keito Hoshitsuki:** December 2020 Highlighted Trainee Author featured in the *Journal of Pharmacology and Experimental Therapeutics* – ASPET.
- **Jason Karnes:** 2020 A. Jay Gandolfi New Investigator Award, University of Arizona College of Pharmacy.
- **Roxane Rohani:** Society of Infectious Diseases Pharmacists (SIDP) Trainee Award. American College of Clinical Pharmacy (ACCP) Annual Meeting Resident/Fellow Travel Award.
- **Lisa Varughese:** Clinical and Translational Science Award TL1, NIH.



## Publications

- **Beitelshees AL, Stevenson JM**, El Rouby N, Dillon C, **Empey PE**, Fielstein EM, **Johnson JA**, **Limdi NA**, Ong HH, Franchi F, Angiolillo DP, Peterson JF, Rosenman MB, Skaar TC, **Tuteja S**, **Cavallari LH**; IGNITE Pharmacogenetics Working Group. Evaluating the extent of reusability of *CYP2C19* genotype among patients genotyped for anti-platelet therapy selection. *Genet Med* 2020;22:1898-902.
- **Brown JT**, MacDonald D, Yapel A, et al. Integrating pharmacogenetic testing via medication therapy management in an outpatient family medicine clinic. *Pharmacogenomics* 2021 Jan 20. [Epub ahead of print]
- **Brown JT**, Ramsey LB, Vear SI, Aka I, Colace SI. Characterizing pharmacogenomic testing among children's hospitals. *Clin Transl Sci* 2020 Dec 16. [Epub ahead of print]
- Hundertmark ME, Waring S, Stenehjem DD, MacDonald D, Sperl DJ, Yapel A, **Brown JT**. Pharmacist's attitudes and knowledge of pharmacogenetics in a large, multi-state, healthcare system. *Pharm Pract (Granada)* 2020;18:2008.
- **Crews KR**, Monte AA, Huddart R, **Caudle KE**, Kharasch ED, Gaedigk A, **Dunnenberger HM**, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, **Cavallari LH**, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6*, *OPRM1*, and *COMT* genotype and select opioid therapy. *Clin Pharmacol Ther* 2021 Jan 2. [Epub ahead of print]
- Lee CR, Thomas CD, Beitelshees AL, Tuteja S, **Empey PE**, **Lee JC**, **Limdi NA**, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, **Stevenson JM**, Weck KE, Angiolillo DJ, **Johnson JA**, Stouffer GA, **Cavallari LH**; IGNITE Network Pharmacogenetics Working Group. Impact of the *CYP2C19\*17* allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Clin Pharmacol Ther* 2021;109:705-15.
- **Gammal RS**, **Caudle KE**. Pharmacogenomics resources. In: Lam JT, Gutierrez M, Shah S, eds. *Pharmacogenomics: A Primer for Clinicians*. New York: McGraw-Hill, 2020. [In press]
- **Gammal RS**, **Nguyen J**, Audi E, **Lee Y**, Petry N, **Empey PE**. Advanced pharmacy practice experiences in pharmacogenomics offered by US pharmacy programs. *Am J Pharm Educ* 2020;84:1584-8.
- **Hoshitsuki K**, Rathod S, Ramsey MJ, et al. Adalimumab immunogenicity is negatively correlated with anti-hinge antibody levels in patients with rheumatoid arthritis. *J Pharmacol Exp Ther* 2020;375:488-97.
- **Karnes JH**, Ramsey LB. Chapter 7: Pharmacogenetics and molecular testing. In: Edwards CJ, Erstad BL, eds. *Basic Skills in Interpreting Laboratory Data*, 7th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2021. [In press]
- **Karnes JH**, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Lee MTM, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, **Caudle KE**, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2C9* and *HLA-B* genotypes and phenytoin dosing: 2020 update. *Clin Pharmacol Ther* 2021;109:302-9.
- Cronin RM, Halvorson AE, Springer C, Feng X, Sulieman L, Loperena-Cortes R, Mayo K, Carroll RJ, Chen Q, Ahmedani BK, **Karnes JH**, et al. Comparison of family health history in surveys versus electronic health records in the All of Us Research Program. *J Am Med Inform Assoc* 2020. [In press]
- El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, **Karnes J**, de Lima Santos JCJ, Duconge J, **Cavallari LH**. Multi-site investigation of genetic determinants of warfarin dose variability in Latinos. *Clin Transl Sci* 2020. [In press]
- **Owusu Obeng A**, El Rouby N, Liu M, et al. Important preparatory steps and clinical considerations for pharmacogenetics adoption into practice. *J Transl Genet Genom* 2020 Dec 24. [Epub ahead of print]
- **Reed RC**, Rosenfeld WE, Lippmann SM, et al. Rapidity of CNS effect on photoparoxysmal response for brivaracetam vs. levetiracetam: a randomized, double-blind, crossover trial in photosensitive epilepsy patients. *CNS Drugs* 2020;34:1075-86.
- **Reed RC**, Rosenfeld WE, Lippmann SM, et al. Creative use of the conventional "human photosensitivity model in epilepsy." In: Kasteleijn-Nolst Trenite D, ed. *The Importance of Photosensitivity for Epilepsy*. Springer Nature, 2021:305-21.
- Kasteleijn-Nolst Trenite DG, **Reed RC**. Summary of current knowledge and the path forward for new research into photosensitivity and epilepsy. In: Kasteleijn-Nolst Trenite D, ed. *The Importance of Photosensitivity for Epilepsy*. Springer Nature, 2021:413-27.
- Avedissian SN, **Rohani R**, Bradley J, et al. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance:

a convergence of parametric and non-parametric population approaches. Antimicrob Agents Chemother 2021 Feb 1. [Epub ahead of print]

- Claudio-Campos K, Padrón A, Jerkins G, Nainapampil J, Nelson R, Martin A, Wiisanen K, **Smith DM**, Strekalova Y, Marsiske M, **Cicali EJ**, **Cavallari LH**, et al. Acceptability, feasibility, and utility of integrating pharmacogenetic testing into a child psychiatry clinic. Clin Transl Sci 2021;14:589-98.
- **Stevenson JM**, Alexander GC, Palamuttam N, et al. Projected utility of pharmacogenomic testing among individuals hospitalized with COVID-19: a retrospective multicenter study in the United States. Clin Transl Sci 2021;14:153-62.
- **Varughese LA**, Lau-Min KS, Cambareri C, et al. DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation. Pharmacotherapy 2020;40:1108-29.
- Lau-Min KS, Asher SB, Chen J, Domchek SM, Feldman M, Joffe S, Landgraf J, Speare V, **Varughese LA**, et al. Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genet Med 2020 Dec 10. [Epub ahead of print]
- Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, **Varughese LA**, et al. SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy. medRxiv 2021 Jan 16. [Epub ahead of print]

### Presentations

- **Burruss R**, Arikian V, Oleru K, et al. Association of COVID-19 on adherence to oral neurology medications and quality of life of USA neurology patients on the service of a specialty pharmacy. Presented at: AMCP Spring Meeting; April 2021; San Francisco, CA.
- **Burruss R**, Cranston B, Arikian V, et al. Impact of COVID-19 pandemic on adherence to oral oncology medications and quality of life of cancer patients on the service of a specialty pharmacy. Presented at: AMCP Spring Meeting; April 2021; San Francisco, CA.
- Steiner HE, Giles JB, Knight H, Fox K, Stanaway IB, Heise W, **Karnes JH**. Association of the ABO O blood group with increased warfarin stable dose. Presented at: Pharmacogenomics Research Network Annual Meeting; October 2020; virtual.

### Other Notable Achievements

- **Royce A. Burruss**: Received ACCP Certification in Applied Pharmacogenomics.
- **Jason Karnes**:  
Adjunct Assistant Professor, Department of Biomedical Informatics, Vanderbilt University School of Medicine.  
Editorial Board, *Clinical Pharmacology and Therapeutics*.  
Chair, Early Career Committee, Pharmacogenomics Research Network.  
Vice Chair, Research Affairs Committee, American College of Clinical Pharmacy.

### Pulmonary PRN

The Pulmonary PRN continues to thrive, especially as pulmonary topics such as COVID-19 remain prevalent. The PRN continues to foster networking and research collaborations among members, and at least three projects are in progress.

### Grants

- **Brittany Bissell**: Early Career Pilot Award: Pilot Study to Evaluate the Influence of Opioid Exposure on Immune Cell Profiles in Sepsis. University of Kentucky Center for Clinical and Translational Science. Amount: \$25,000.

### Publications

- **Bissell BD**, Donaldson JC, Morris PE, et al. A narrative review of pharmacologic de-resuscitation in the critically ill. J Crit Care 2020;59:156-62.
- Gonzalez LE, **Boylan PM**. Netarsudil for the treatment of open-angle glaucoma and ocular hypertension: a literature review. Ann Pharmacother 2020 Nov 4. [Epub ahead of print]
- Kenny M, Clarke MM, **Pogue KT**. Overview of riociguat and its role in the treatment of pulmonary hypertension. J Pharm Pract 2020 Oct 21. [Epub ahead of print]
- Condemi MS, Basting A, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Magee CA, McLean B, Reichert M, **Santibañez M**, et al. Major publications in the critical care pharmacotherapy literature: 2019. J Crit Care 2021;62:197-205.
- Fernandez D, Maldonado A, Williams L, Rogers B, **Santibañez M**. 617: Correlation between thromboelastography and standard coagulation tests at a community hospital. Crit Care Med 2021;49:302.
- Moore PQ, Cheema N, Celmins LE, Patel A, Follman S, Soni H, **Szwak JA**, et al. Point-of-care naloxone distribution in the emergency department: a pilot study. Am J Health Syst Pharm 2021;78:360-6.

## Promotions and Job Updates

- **Hanna Phan:**  
New position as Clinical Associate Professor at the University of Michigan College of Pharmacy.  
Clinical Pharmacist Specialist in Pediatric Pulmonary/Cystic Fibrosis at Michigan Medicine (Ann Arbor, Michigan).
- **Kristen Pogue:** Promoted to Clinical Associate Professor, University of Michigan College of Pharmacy (Ann Arbor, Michigan).
- **Melissa Santibañez:** New position as Assistant Professor of Critical Care, Nova Southeastern University College of Pharmacy (Fort Lauderdale, Florida).

## Awards

- **Brittany Bissell:** 2020 Kentucky Society of Health-System Pharmacists Innovative Health-System Pharmacy Practice Award.

## Other Notable Achievements

- **Jennifer Austin Szwak:** Elected as Chair of the Vizient Pharmacy Network Research Committee.
- **Pamela Moye-Dickerson:** Appointed as a Standing Member of the AHRQ Healthcare Information Technology Research Study Section.
- **Kristen Pogue:** Appointed as Vice Chair of the Board of Pharmacy Specialties Cardiology Specialty Council.

## Women's Health PRN

### Promotions

- **Lauren Lakdawala:** Clinical Coordinator, Level 2, Johns Hopkins Home Care Group, Outpatient Pharmacy Specialty Services.

### Publications

- Barrett C, Scoular S, **Borgelt LM.** Knowledge, perceptions, and uptake of the human papillomavirus vaccine in a sample of U.S. high school adolescents. *J Pediatr Pharmacol Ther* 2020;25:697-704.
- Jones JF, Reisdorph N, Armstrong M, Doenges K, Stamm C, **Borgelt LM.** Comparison of reported versus measured content of over-the-counter and prescription prenatal multivitamins and minerals. *J Am Pharm Assoc* 2021. [In press]
- **Mospan CM,** Balenger SB, Gillette C. Student pharmacists' perceptions regarding pharmacist-prescribed hormonal contraceptives and their professional responsibility. *J Am Pharm Assoc.* [In press]

- Katz M, Newmark RL, Aronstam A, O'Grady N, Strome S, **Rafie S,** et al. An implementation project to expand access to self-administered depot medroxyprogesterone acetate. *Contraception* 2020;102:392-5.
- Luli A, Tran N, Ataya A, **Rafie S.** Patient screenings for preconception health interventions at a community pharmacy. *Pharmacy* 2020;8:181.
- Nikpour G, Allen A, **Rafie S,** et al. Pharmacy implementation of a new law allowing year-long hormonal contraception supplies. *Pharmacy* 2020;8:165.
- Pfaff A, **Rafie S.** Expanding pharmacy capacity for patient-centered reproductive health services. *Pharmacy* 2020;8:236.
- **Stone RH,** Abousaud M, Abousaud A, et al. A systematic review of intravaginal diazepam for the treatment of pelvic floor hypertonic disorder. *Clin Pharmacol* 2020;60(suppl 2):S110-S120.
- **Stone RH, Griffin B,** Fusco RA, **Vest K,** et al. Factors affecting contraception access and use in patients with opioid use disorder. *Clin Pharmacol* 2020;60(suppl 2):S63-S73.
- Beal J, Ades R, **Vernon V,** Wilkinson T, **Meredith A.** Pharmacists' perceptions, barriers, and potential solutions to implementing a direct pharmacy access policy in Indiana. *Med Care Res Rev* 2020 Oct 5. [Epub ahead of print]
- Mitchell M, Stauffenberg C, **Vernon V, Mospan CM,** Shipman AJ, **Rafie S.** Opposition to pharmacist contraception services: evidence for rebuttal. *Pharmacy* 2020;8:176.

## Other Notable Achievements

- **Lauren Lakdawala:** Chair, Pharmacist Contraceptive Prescribing Workgroup, Maryland Pharmacists Association.

## ACCP FOUNDATION UPDATE



### 2021 Futures Grants: Mentored Research Funding Opportunity

The 2021 ACCP Foundation Futures Grants program invites *student, trainee, and early-career ACCP members* to apply for developmental research grants. The amount of Futures Grants awards ranges from **\$5000 to \$40,000**, depending on applicant eligibility and budget approval. Up to \$100,000 in mentored, developmental research awards will be distributed through the 2021 Futures Grants program. To access detailed instructions about this grant award program, visit [www.accpfoundation.org/futures](http://www.accpfoundation.org/futures).

The grant application portal will open May 15, 2021, and completed applications will be due no later than September 1, 2021. Grants will be reviewed and scored by the translational category of the research in addition to the applicant's eligibility level.

All applicants are required to complete a set of online eligibility questions before submitting an application. Applicant responses will provide an immediate determination of eligibility for the student/resident or junior investigator awards as well as access to the appropriate online application form. Responses to the eligibility questions and partly completed applications can be saved and completed later by retaining the return access code provided.

For questions, please contact:

**Jessie Culley, Project Coordinator**

**ACCP Foundation**

**(913) 492-3311**

**E-mail: [jculley@accp.com](mailto:jculley@accp.com)**

*Supported by the ACCP Foundation Frontiers Fund.*

## WASHINGTON REPORT

### **National Center for Health Statistics: Supporting Research to Address Health Disparities**

At least in theory, the mission of ACCP's Washington office is fairly simple. Consistent with ACCP's core values and [strategic plan](#), the Government and Professional Affairs team is focused on developing, positioning, and advancing clinical pharmacists within evolving payment and care delivery structures to help patients achieve medication optimization. Put simply, ACCP is committed to securing coverage – and payment – for pharmacists' clinical services under Medicare and by other major health plans. However, although the team's stated mission may be concise, the tactics and strategies employed to advance the College's goals are far more complex and nuanced. This is because ACCP understands that Medicare's mission is not to grant status to certain health professions as providers, but to ensure access to quality health care for the rapidly growing population of individuals over 65. ACCP's advocacy efforts are thus entirely focused on establishing coverage for the comprehensive medication management service ("the what") rather than seeking provider status for pharmacists ("the who").

[The Quadruple Aim](#) is often considered central to the core principles of quality management in health care: improve the patient care experience, improve the health of a population, reduce per capita health care costs, and enhance clinical experience. As value-based care becomes more prevalent, coverage and payment are increasingly tied to quality and outcomes, all of which begin with patient care teams. ACCP believes that by integrating services that achieve medication optimization

## Call for Abstracts

### **[2021 ACCP Annual Meeting – October 16–19 – Phoenix, Arizona](#)**

#### **Important Dates:**

##### Submission Deadline

- June 15, 2021: Submission deadline for Original Research, Systematic Reviews/Meta-Analyses, Case Reports, Clinical Pharmacy Forum, and Advances in International Clinical Pharmacy Practice, Education, or Training abstracts
- July 15, 2021: Submission deadline for Research-in-Progress abstracts (Students and Residents and Fellows)

##### Notification of Acceptance

- August 15, 2021: Authors will be notified of acceptance or declination no later than this date.

To review the complete submission instructions, guidelines, and review criteria, or to submit an abstract, visit [www.accp.com/abstracts/2021abstracts/](http://www.accp.com/abstracts/2021abstracts/).

All abstracts accepted and presented by the designated presenting author, except for "Encore" and "Research-in-Progress" presentations, will have full-text abstracts published online in *JACCP*, an official journal of ACCP. Only the abstract title, authors, and original citation will be published for "Encore" presentations.

as part of this larger transition toward team-based care, the entire profession will achieve its long-term goals of payment for services.

The Centers for Medicare & Medicaid Services has initiated a [quality strategy](#) vision focused on tying payment incentives to value through new payment models to improve care and integrating care teams through health information technology. Eliminating racial and ethnic disparities is considered foundational to implementing this strategy.

### **CDC Coalition**

In keeping with ACCP's commitment to promote the generation of innovative science, develop successful practice models, and disseminate new knowledge to advance pharmacotherapy and patient care, ACCP is a proud member of the [CDC Coalition](#) – a nonpartisan group of organizations committed to strengthening our nation's public health infrastructure and prevention programs. The CDC Coalition's mission is to ensure that health promotion and disease prevention are given top priority in federal funding, to support a funding level for the [Centers for Disease Control and Prevention \(CDC\)](#) that enables

it to carry out its prevention mission, and to assure an adequate translation of new research into effective state and local programs. Coalition member groups represent millions of public health workers, researchers, clinicians, educators, and citizens served by CDC programs.

### Friends of AHRQ

The COVID-19 pandemic revealed that our nation's goal to have a system that ensures access to high-quality health care for all is falling far short of its potential. We are seeing the deep racial and ethnic inequities both within and beyond health care as people of color are disproportionately contracting COVID-19, suffering worse outcomes, having less access to diagnostics, vaccinations, and treatments, and are dying at higher rates. At the same time, the federal government, states, localities, and health providers are taking dramatic actions to respond to the pandemic and other existing health care challenges, and they are being forced to take action without sufficient research and evaluations on the impacts of their decisions.

The [Agency for Healthcare Research and Quality \(AHRQ\)](#) supports research to improve health care quality, reduce costs, advance patient safety, decrease medical errors, and broaden access to essential services. As the lead federal agency for funding health services research (HSR) and primary care research (PCR), AHRQ is the bridge between cures and care and ensures that Americans get the best health care at the best value. The RAND Corporation, in its report titled "[Health Services and Primary Care Research Study](#)," identified AHRQ as "the only agency that has statutory authorizations to generate HSR and be the home for federal PCR, and the unique focus of its research portfolio on systems-based outcomes (e.g., making health care safer, higher quality, more accessible, equitable, and affordable) and approaches to implementing improvement across health care settings and populations in the United States."

The [Friends of AHRQ](#) is a diverse coalition of more than 250 organizations that support AHRQ. These groups are either the producers or end users of the health services research developed by AHRQ.

ACCP is proud to support the Friends of AHRQ, advocating on behalf of the agency to Congress. Activities include:

- Sending joint letters to key members of Congress
- Making joint visits to members of Congress and their staff
- Holding briefings to demonstrate the importance of AHRQ research

### Friends of NCHS

The COVID-19 pandemic serves as an important reminder of the extent to which the United States relies on the flow

of objective, credible statistics to support the decisions of governments, businesses, households, and other organizations. Any loss of trust in the integrity of the federal statistical system and its products can foster uncertainty about the validity of measures the nation uses to monitor and assess performance and progress.

The [National Center for Health Statistics \(NCHS\)](#) is the nation's principal health statistics agency, providing data to identify and address health issues. NCHS compiles statistical information to help guide public health and health policy decisions. These health statistics allow NCHS to:

- Document the health status of the U.S. population and selected subgroups
- Document access to and use of the health care system
- Identify disparities in health status and use of health care by race and ethnicity, socioeconomic status, other population characteristics, and geographic region
- Track the impact of major policy initiatives
- Monitor trends in health indicators
- Support biomedical and health services research
- Provide data to support public policies and programs, including recent data on opioid overdose deaths

NCHS collects data on chronic disease prevalence, health disparities, teen pregnancy, infant mortality, disproportionate maternal mortality among African American women, ED use, causes of death, and rates of insurance, to name a few. These data sets are used across the federal government and play an essential role in making up the nation's statistical and public health infrastructure.

ACCP is a longstanding member of the [Friends of NCHS](#) – a coalition of more than 250 organizations that advocate and support appropriate federal funding for NCHS. The Friends of NCHS advocate on behalf of NCHS to Congress. Its activities include:

- Sending joint letters to key members of Congress
- Making joint visits to members of Congress and their staff
- Coordinating briefings to demonstrate the importance of NCHS and the research it supports

NCHS health data are critical to helping officials better understand and confront some of the nation's most pressing health concerns, including the opioid crisis and the spread of infectious diseases like COVID-19. Common stakeholders that use these data include the U.S. Census Bureau in informing its population estimates and projections, the Department of Agriculture in developing nutrition policies that guide multibillion-dollar federal food assistance programs, state and local governments, and public health officials, federal policy-makers, and health services researchers.

Looking to the future, ACCP supports additional funding that will allow NCHS to use its expertise to create a true 21st-century statistical agency and reaffirm its status as the world's gold-standard producer of health statistics. With additional funding, NCHS will be able to link and integrate electronic health records with other data collection systems into its own data production processes.

## ACCP Outlook for the Biden Administration and 117th Congress

### 117th Congress

With the 117th Congress now under way, beyond the partisan fallout over the last days of the previous administration, work is beginning on a series of hearings into key nominations for Biden's proposed cabinet.

ACCP has already begun outreach to incoming congressional leaders as we assess the health priorities set out by the key committees of jurisdiction and how these align with our long-standing commitment to integrating clinical pharmacists' services into evolving team-based payment and delivery structures.

### Inside the Department of Health and Human Services

With a proposed [FY 2021 budget authority](#) of \$1.4 trillion, the U.S. Department of Health and Human Services (HHS) is a sprawling bureaucracy that directly affects the lives of almost every American. Yet the budget number alone does not fully capture the department's complexity. Mandatory spending programs (primarily paying for health coverage for Medicare and Medicaid through the Centers for Medicare & Medicaid Services) account for \$1.3 trillion of that annual spending. This leaves a comparatively slim discretionary budget of \$100 billion spread across 11 separate operating divisions, including:

- Agency for Healthcare Research and Quality (AHRQ)
- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration (FDA)
- Indian Health Service (IHS)
- National Institutes of Health (NIH)
- Substance Abuse & Mental Health Services Administration (SAMHSA)

### Where Does ACCP Expect to Be Most Active?

Drilling deep into the Centers for Medicare & Medicaid Services (CMS), the Center for Medicare and Medicaid Innovation (the Innovation Center or CMMI) was established under the Affordable Care Act (ACA) to test the development of innovative health care payment and service delivery models.

ACCP is already working closely with partners within CPC+, a national advanced primary care medical home model launched through CMMI, that aims to strengthen primary care through regionally based multi-payer

payment reform and care delivery transformation. Certain CPC+ primary care practice tracks require comprehensive medication management (CMM) as a required service. Throughout 2021 ACCP will be working to support this initiative and help build on this important work through targeted expansion in key regions.

### Grassroots Action Alert: Share Your Pandemic Experience with Elected Officials in Congress!

Since the onset of the COVID-19 pandemic, ACCP members have shared stories about caring for patients, generating new science, and teaching the next generation of pharmacists amid uniquely challenging circumstances. As we enter the next phase of the pandemic, clinical pharmacists continue to serve their communities, working to optimize medications for patients as part of integrated health care teams.

At this critical time, it is important that policy-makers hear firsthand from clinical pharmacists describing their contributions to COVID-related patient care, research, education, or leadership. In addition, as the pandemic response shifts to vaccine distribution, we want to hear about your involvement in helping patients navigate through vaccine administration and management.

With the availability of COVID vaccines continuing to dominate the work of the profession, now is a perfect time to tell your elected officials about the vital work clinical pharmacists are already doing and how policy changes at the federal level could quickly expand opportunities for patients to access these services.

Contacting the offices of your elected officials is simple. On our revamped Legislative Action Center, we have prepared a letter for you to review and edit. Simply follow the instructions to send this message to Capitol Hill. But take the time to personalize the letter by providing additional information about your practice and the patients you care for, and remember to let ACCP know about any responses you receive from your elected officials.

Thank you for participating in this important advocacy effort. [Click here to take action now!](#)

### ACCP/VCU/ASHP Congressional Health Policy Fellow Program

Recruitment is now open for the 2022–2023 ACCP/VCU/ASHP Congressional Health Policy Fellow Program. The current Fellow, [Nimit Jindal, Pharm.D.](#), is serving on the Majority Staff of the Senate Committee on Health, Education, Labor, and Pensions (HELP). The previous Fellow, Kyle Robb, BCPS, also served in this office, under the Minority Staff.

Launch of the Fellow Program is one of the proudest accomplishments of ACCP's Washington office, and the College is grateful to Jindal, Robb, and all who served before them for their leadership on behalf of the profession.

For more information and details on how to apply for this prestigious opportunity, [click here](#).

### **GTMRx Institute Unites Stakeholders to Advance Optimization of Medication and Gene Therapies**

The [Get the Medications Right \(GTMRx\) Institute](#) is a multi-stakeholder collaboration formed to ensure the appropriate and personalized use of medication and gene therapies by advancing to a scientific, evidence-based, and cost-effective decision-making process and a team-based, systematic approach to medication use. Since its inception, over 950 individuals and organizations, including professional organizations, provider groups, patient advocacy and consumer groups, and pharmaceutical, diagnostics, and IT companies – together with employers and payers – have joined GTMRx in this work.

Released in July 2020, the [GTMRx Blueprint for Change](#) outlines steps for medication optimization, including adoption of an evidence-based process of care, implementation of CMM, and application of a personalized approach that leads to better care, reduced costs, and improved patient satisfaction and provider worklife. The Blueprint is based on 8 months of multi-stakeholder input and guidance to facilitate, engage, and promote medication optimization. The Blueprint Launch Resource Center contains several other useful items, including an evidence document summarizing key papers, case examples, FAQs, and social media tools.

### **Get Involved with GTMRx!**

ACCP members are encouraged sign up as members of GTMRx to receive updates and access to exclusive programming. [Click here](#) to join this exciting effort today.

### **Contribute to ACCP-PAC!**

Political Action Committee (PAC) contributions are a constitutionally protected part of the U.S. political system under the First Amendment's guarantee of free speech.

ACCP-PAC is the only means through which the College can provide financial support for candidates for Congress. With its 20,000 ACCP members, ACCP is in a position to become one of the most prominent pharmacy PACs in Washington. To do this, the College needs the widespread support of its membership. If each ACCP member contributed just \$30, ACCP-PAC would raise over \$500,000. All ACCP members should consider donating at least \$30 to ACCP-PAC.

[Click here](#) to support your PAC today!

## **STUDENT INITIATIVES UPDATE**

### **2021 ACCP Student Chapter Awards – Applications Due June 30**

ACCP presents two Student Chapter awards annually: the Outstanding Student Chapter and the Outstanding Student Chapter Member. Application for each award is submitted as part of the required Annual Chapter Report and is due June 30, 2021. A description of each award follows.

#### **Outstanding Student Chapter Award**

This award recognizes the ACCP student chapter that has exemplified strength in leadership, dedication in patient care, and passion for professional development through its activities and membership. The chapter's activities should address ACCP's core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education. A key component of all the core values is the clinical pharmacist's ability to work collaboratively within the health care environment. Each chapter must demonstrate its ability to work with other health disciplines.

An announcement will be featured on the ACCP website, and an article highlighting the winning chapter's accomplishments will be published in *StuNews* and the *ACCP Report*. A commemorative plaque and \$1000 cash will be awarded to the winning chapter. The faculty liaison/adviser and one appointed student liaison from the winning chapter will receive complimentary full Annual Meeting registrations, and each will receive a \$250 travel stipend to attend.

Members of student chapters who wish to apply for the award must complete an application form as part of their end-of-the-year report, due June 30. As part of the application process, each chapter is required to submit a rationale (250 words or less) outlining the plan for using the \$1000 award funds, should this chapter be selected as the winner.

#### **Outstanding Student Chapter Member**

This award recognizes a student who has enhanced student involvement from his or her ACCP chapter at the local, state, or national level and who has expanded the presence of ACCP through community engagement, education promotion, research opportunities, and/or professional stewardship. The activities of the selected student should address ACCP's core values of extending the frontiers of clinical pharmacy and promoting dedication to excellence in patient care, research, and education.

Each chapter award recipient will receive a certificate suitable for framing and recognition in an *ACCP Report* article, a *StuNews* article, and the *Annual Meeting News*. In addition, student award winners in attendance at the award-year Annual Meeting will be recognized during the Clinical Pharmacy Challenge semifinal round of competition.

Each recognized student chapter will select its recipient for Outstanding Student Chapter annually and submit the winner's name to the ACCP national office as part of its year-end report, due June 30.

## ACCP SNAC NOW ACCEPTING APPLICATIONS FOR 2020–2021

Begun as a working group in 2006, the National Student Network Advisory (SNAC) group became a standing committee of the College in 2007 whose members are appointed by the ACCP president-elect. The present committee serves in an advisory capacity to the ACCP Board of Regents and staff, providing feedback and assistance in developing new programs and services for students. Student members who are interested in serving on the ACCP SNAC, either as a member-at-large or in a leadership role, may apply for appointment. All applicants must submit a CV, a personal essay, and a letter of recommendation from a professor, preceptor, or academic dean or his or her designee. Application for appointment to the 2020–2021 SNAC is [available online](#). Applications are due June 15, 2021.

## RESIDENTS, FELLOWS, AND GRADUATE STUDENTS

All resident, fellow, and graduate student members of ACCP currently receive the monthly electronic newsletter *Experts in Training*. The 2021 Resident Advisory Committee (RAC) has been in communication with the PRNs to encourage its resident and fellow members to contribute regularly to the newsletter. The response has been very positive, and RAC hopes to maintain these ongoing relationships with the PRNs. You may view archives through the link above. For topics you'd like to see covered in future editions, submit your ideas to [ksims@accp.com](mailto:ksims@accp.com).

PRNs can also engage resident, fellow, and graduate students through [Twitter](#) and [Instagram](#). Follow or tag @ACCPpostgrads to engage in dialogue on professional development and clinical topics.

ACCP resident and fellow members continue to benefit from the mentoring program. This year, 36 residents were matched with a mentor. Mentor/mentee pairs are encouraged to correspond at least monthly and are provided with timely topics of discussion. A call for mentors goes out each year in August.

RAC is a working group of residents, fellows, and graduate student members of ACCP. The current RAC is developing newsletter and social media content, Annual Meeting programming, and case studies for managing harassment in professional settings. Committee members are also focused on improving ACCP mentoring and career advancement programs. Applications for chair, vice chair, and member-at-large positions are due by June 15, 2021.



## PRN MEMBERSHIP TOTALS

PRACTICE AND RESEARCH NETWORKS	TOTAL
Adult Medicine PRN	871
Ambulatory Care PRN	1888
Cardiology PRN	1085
Central Nervous System PRN	207
Clinical Administration PRN	383
Critical Care PRN	2018
Drug Information PRN	230
Education and Training PRN	535
Emergency Medicine PRN	975
Endocrine and Metabolism PRN	271
Geriatrics PRN	258
GI/Liver/Nutrition PRN	148
Global Health PRN	151
Health Outcomes PRN	162
Hematology/Oncology PRN	673
HIV PRN	227
Immunology/Transplantation PRN	488
Infectious Disease PRN	1940
Nephrology PRN	166
Pain and Palliative Care PRN	250
Pediatrics PRN	767
Perioperative Care PRN	94
Pharmaceutical Industry PRN	215
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics PRN	277
Pulmonary PRN	75
Women's Health PRN	231
<b>TOTAL:</b>	<b>14,585</b>

## PRN CHAIRS CONTACT INFORMATION

For more information about a specific PRN, please contact the PRN's chair identified as follows.

PRACTICE AND RESEARCH NETWORKS	PRN CONTACT
Adult Medicine	<a href="#"><u>Carmen Smith</u></a>
Ambulatory Care	<a href="#"><u>Ashley Meredith</u></a>
Cardiology	<a href="#"><u>Dave Dixon</u></a>
Central Nervous System	<a href="#"><u>Alyssa M. Peckham</u></a>
Clinical Administration	<a href="#"><u>Jennifer Twilla</u></a>
Critical Care	<a href="#"><u>Alex Flannery</u></a>
Drug Information	<a href="#"><u>Steven Johnson</u></a>
Education and Training	<a href="#"><u>Taylor Steuber</u></a>
Emergency Medicine	<a href="#"><u>Abby Bailey</u></a>
Endocrine and Metabolism	<a href="#"><u>Krystal Riccio</u></a>
Geriatrics	<a href="#"><u>Julianna Fernandez</u></a>
GI/Liver/Nutrition	<a href="#"><u>Kyle Hampson</u></a>
Global Health	<a href="#"><u>Chelsea Pekny</u></a>
Health Outcomes	<a href="#"><u>Shubha Bhat</u></a>
Hematology/Oncology	<a href="#"><u>Katie Gatwood</u></a>
HIV	<a href="#"><u>Sarah Pérez</u></a>
Immunology/Transplantation	<a href="#"><u>Alicia Lichvar</u></a>
Infectious Diseases	<a href="#"><u>Monica Mahoney</u></a>
Nephrology	<a href="#"><u>Susan Lewis</u></a>
Pain and Palliative Care	<a href="#"><u>Tran H. Tran</u></a>
Pediatrics	<a href="#"><u>Deborah Bondi</u></a>
Perioperative Care	<a href="#"><u>Gourang Patel</u></a>
Pharmaceutical Industry	<a href="#"><u>Cori Cooper</u></a>
Pharmacokinetics/Pharmacodynamics/Pharmacogenetics	<a href="#"><u>James M. Stevenson</u></a>
Pulmonary	<a href="#"><u>Brittany D. Bissell</u></a>
Women's Health	<a href="#"><u>Nicole Cieri-Hutcherson</u></a>